E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007
DateTitle 
07/25/17Quest Diagnostics Reports Second Quarter 2017 Financial Results, Raises 2017 Financial Outlook
- Second quarter revenues of $1.94 billion, up 1.9% on a reported basis and up 2.3% on an equivalent basis versus 2016. - Second quarter diluted EPS of $1.37, flat on a reported basis from 2016; and $1.55 on an adjusted basis excluding amortization, up 15.7% from 2016. Excess tax benefit associated with stock-based compensation benefited diluted EPS by $0.10 in the quarter and increased $0.08 compared to 2016. - Raises outlook for full year 2017 revenues, diluted EPS and cash provided by o... 
Printer Friendly Version
07/19/17Quest Diagnostics Launches QHerit™, a Pan-Ethnic Genetic Screening Panel Aligned with New Medical Guidelines
QHerit Expanded Carrier Screen helps both women and men across multiple ethnicities identify risk of passing 22 genetic diseases to their children MADISON, N.J., July 19, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the launch of QHerit™, a new genetic screening service that provides women and men with insight into their genetic risk of passing on heritable disorders to their offspring. ... 
Printer Friendly Version
07/18/17Quest Diagnostics Completes Acquisition of Med Fusion and Clear Point in Texas, Forming National Precision Oncology Center of Excellence
MADISON, N.J., July 18, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) today announced that it has completed its previously announced acquisition of the laboratory businesses Med Fusion and Clear Point. Operating from a nearly 200,000 square foot facility in Lewisville, Texas, the two businesses form the basis for the company's first national center of excellence in precision diagnostics for oncology. In connection with the transaction, Quest is now a pr... 
Printer Friendly Version
07/06/17Quest Diagnostics To Release Second Quarter 2017 Financial Results On July 25
MADISON, N.J., July 6, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2017 results on Tuesday, July 25, 2017, before the market opens.  It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.  The conference call can be accessed in listen-only mode by dialing 773-799-3475, p... 
Printer Friendly Version
06/27/17Quest Diagnostics Announces Intent to Acquire Cape Cod Healthcare Outreach Laboratory Business in Massachusetts
Acquisition to Enhance Access to Innovative, High-value Diagnostic Information Services for People on Cape Cod MADISON, N.J. and HYANNIS, Mass., June 27, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has signed a nonbinding letter of intent to acquire the outreach laboratory services business of Cape Cod Healthcare (CCHC).  The acquisition is subject to review by the Massachusetts Health Policy Commiss... 
Printer Friendly Version
06/26/17Quest Diagnostics and Walmart Team Up to Expand Access to Healthcare Services
MADISON, N.J. and BENTONVILLE, Ark. , June 26, 2017-- Quest Diagnostics (NYSE: DGX) and Wal-Mart Stores, Inc. (NYSE: WMT), announced they will be working together to help improve access to care and, over time, help lower costs for basic healthcare services. The collaboration will initially launch with a select number of locations (approximately 15) in Walmart stores in Florida and Texas by the end of 2017. These co-branded sites will initially provide laboratory... 
Printer Friendly Version
06/22/17Quest Diagnostics Adds Custom Coaching, At-Home Collection to Expand Blueprint for Athletes™ Service
Fitness enthusiasts can customize biometric testing service to fit their lifestyle with redesigned packages, one-on-one coaching and goal setting as well as at-home phlebotomy and microsampling MADISON, N.J., June 22, 2017 /PRNewswire/ -- Fitness devotees and amateur and competitive athletes can now access sports biomarker testing from their home with a suite of expanded capabilities from Blueprint for Athletes, the biomarker testing service from Quest Diagnostics (NYSE: DGX) th... 
Printer Friendly Version
06/12/17Quest Diagnostics to Form Precision Oncology Center of Excellence Through Acquisition of Two Texas Laboratory Businesses to Serve Oncologists Nationwide
- Quest to acquire Lewisville, Texas-based Med Fusion and Clear Point to create a base in the southwestern United States for providing precision medicine diagnostics to aid cancer treatment and care - Transaction involves preferred provider relationships for Quest with Baylor Scott & White Health, McKesson's The US Oncology Network, Texas Oncology, and Pathologists Bio-Medical Laboratories - Once completed, the transaction will bring Quest's services to 12 hospitals in North Texas and ... 
Printer Friendly Version
06/08/17Data Diagnostics Wins 2017 MedTech Breakthrough Award
Healthcare analytics technology from Quest Diagnostics and Inovalon extends value of electronic health records to close patient gaps in real time Eighth industry award given to Data Diagnostics solution since it was formally launched in early 2016 MADISON, N.J., June 8, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) announced that their point-of-care health analytics technology Data Diagnostics® won a MedTech Breakthrough Award for Best Overall... 
Printer Friendly Version
06/06/17New Study: Physicians Lack the Right Tools to Close Costly Gaps in Healthcare
Health plan executives say co-investment in HIT with providers may bridge remaining gaps and accelerate value-based care adoption MADISON, N.J., June 6, 2017 /PRNewswire/ -- 2017 QUEST DIAGNOSTICS/INOVALON STUDY FINDS: Tools still lacking to support value-based care: Fifty-three percent of health plan executives said physicians have the tools they need, but only 43 percent of physicians agreed. EHRs are not giving physicians all th... 
Printer Friendly Version
05/16/17Increases in Illicit Drugs, Including Cocaine, Drive Workforce Drug Positivity to Highest Rate in 12 Years, Quest Diagnostics Analysis Finds
Cocaine, marijuana and methamphetamine use up broadly among United States workforce across multiple specimen types and testing populations Marijuana positivity increases significantly in three years MADISON, N.J., May 16, 2017 /PRNewswire/ -- Drug use in the American workforce, fueled by illicit drugs, reached the highest positivity rate in 12 years, according to an analysis of more than ten million workforce drug test results released today by Quest Diagnostics (NYSE: DGX), the world's ... 
Printer Friendly Version
05/16/17Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 16, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.45 per share, payable on July 24, 2017 to shareholders of record of Quest Diagnostics common stock on July 10, 2017. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the w... 
Printer Friendly Version
05/12/17Quest Diagnostics To Speak At The UBS Global Healthcare Conference
MADISON, N.J., May 12, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the UBS Global Healthcare Conference in New York City.  Mark Guinan, Executive Vice President and CFO, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Tuesday, May 23, 2017 at 2:30 p.m. Eastern Time.... 
Printer Friendly Version
05/02/17Quest Diagnostics To Speak At The Deutsche Bank 42nd Annual Health Care Conference
MADISON, N.J., May 2, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Deutsche Bank 42nd Annual Health Care Conference in Boston. Mark Guinan, Executive Vice President and CFO, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Wednesday, May 3, 2017 at 9:20 a.m. Easte... 
Printer Friendly Version
05/01/17Quest Diagnostics and PeaceHealth Complete Transaction to Increase Access to Innovative, High-value Diagnostic Information Services in the Pacific Northwest
Quest completes acquisition of PeaceHealth Laboratories' outreach lab services operation Quest also begins to manage laboratories located within PeaceHealth's medical centers in three states MADISON, N.J. and VANCOUVER, Wash., May 1, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and PeaceHealth, a mission-based not-for-profit healthcare system, today announced that they have completed a previously announced two-part a... 
Printer Friendly Version
05/01/17Quest Diagnostics CIO Lidia Fonseca Wins 2017 Forbes CIO Innovation Award
Award recognizes the innovation of the QuestQuanum™ portfolio of data analytics and information technology solutions MADISON, N.J., May 1, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its senior vice president and chief information officer Lidia L. Fonseca has received a 2017 Forbes CIO Innovation Award. The award, presented during the Forbes Innovation Summit on April 24, recognizes CIOs of multibi... 
Printer Friendly Version
04/24/17Quest Diagnostics 50th Anniversary: Celebrating a Half Century of Life-Changing Results
To mark the milestone, Quest provides charitable grants of $50,000 each to the American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks MADISON, N.J., April 24, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalit... 
Printer Friendly Version
04/24/17Data Diagnostics Wins Gold at the 30th Annual Edison Awards
Healthcare analytics technology from Quest Diagnostics and Inovalon enables patient data to be turned into actionable insights that inform quality, reimbursement and care outcomes MADISON, N.J., April 24, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) announced that Data Diagnostics®, a point-of-care health analytics technology, won a gold award in the Health and Wellness—Patient Care category at the 2017 Edison Awards, which honor the best innovations and in... 
Printer Friendly Version
04/20/17Quest Diagnostics Reports First Quarter 2017 Financial Results, Raises 2017 Financial Outlook
- First quarter revenues of $1.90 billion, up 1.9% on a reported basis and up 3.0% on an equivalent basis versus 2016 - First quarter diluted EPS of $1.16 on a reported basis, up 63.4% from 2016; and $1.33 on an adjusted basis excluding amortization, up 17.7% from 2016. Excess tax benefit associated with stock-based compensation increased diluted earnings per share by $0.11 in the quarter. - Raises outlook for full year 2017 diluted EPS. Reported diluted EPS now expected to be between $4.7... 
Printer Friendly Version
04/07/17Quest Diagnostics To Release First Quarter 2017 Financial Results On April 20
MADISON, N.J., April 7, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2017 results on Thursday, April 20, 2017, before the market opens.  It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.  The conference call can be accessed in listen-only mode by dialing 888-300-0211 ... 
Printer Friendly Version
04/06/17Quest Diagnostics Presents Supplier Excellence Awards to Five Partners
MADISON, N.J., April 6, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today awarded Supplier Excellence Awards to five companies at its 2017 Supplier Forum. Supplier Excellence awards recognize world class products, systems, or services that provide consistent and reliable performance; companies that develop and implement novel solutions to move the business forward; individuals who step u... 
Printer Friendly Version
03/07/17Quest Diagnostics To Speak At The Barclays Global Healthcare Conference
MADISON, N.J., March 7, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami. Stephen Rusckowski, Chairman, President and CEO, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Wednesday, March 15, 2017 at 8:30 a.m. Eastern Ti... 
Printer Friendly Version
03/06/17Quest Diagnostics and American Diabetes Association® to Help Identify People at Risk for Type 2 Diabetes
Quest Diagnostics will donate up to $200,000 to American Diabetes Association -- $1 for every employee biometric wellness screening it completes between March 28 and April 27 MADISON, N.J., March 6, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, including employer health and wellness screening and health improvement services, announced a unique collaboration with the American Diabetes Association aimed at helping more peo... 
Printer Friendly Version
02/21/17Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb.  21, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.45 per share, payable on April 19, 2017 to shareholders of record of Quest Diagnostics common stock on April 5, 2017. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from th... 
Printer Friendly Version
02/16/17Quest Diagnostics: Harvard Pilgrim Health Care Partners with Physicians to Close Costly Gaps in Care
Physicians to use health analytics technology Data Diagnostics® from Quest Diagnostics and Inovalon to help improve patient care and financial performance MADISON, N.J., Feb. 16, 2017 /PRNewswire/ -- Harvard Pilgrim Health Care now offers physicians Data Diagnostics®, a point-of-care health analytics technology from Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) that is designed to help close costly gaps in care and improve health outcomes. Ac... 
Printer Friendly Version
02/16/17Quest Diagnostics Named One of 2017 "World's Most Admired Companies" by Fortune Magazine
MADISON, N.J., Feb. 16, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" for 2017 by Fortune.  The annual survey designated Quest Diagnostics as one of only six companies in the "Health Care: Pharmacy and Other Services" industry to attain Most Admired status, and the only diagnostic information services compan... 
Printer Friendly Version
02/15/17Quest Diagnostics and PeaceHealth to Increase Access to Innovative, High-Value Laboratory Services in the Pacific Northwest
Quest to acquire PeaceHealth Laboratories' outreach lab services and assume management of labs located within PeaceHealth's medical centers in three states MADISON, N.J. and VANCOUVER, Wash., Feb. 15, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and PeaceHealth, a mission-based not-for-profit healthcare system, have formed a two-part arrangement to enhance the delivery of laboratory services to communities in Oregon, Wa... 
Printer Friendly Version
02/08/17Veracyte To Expand Patient Access To The Afirma® Gene Expression Classifier In Thyroid Cancer Diagnosis Through Agreement With Quest Diagnostics
SOUTH SAN FRANCISCO, Calif., Feb. 8, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT), a genomic diagnostics company focused on reducing unnecessary surgeries and healthcare costs by resolving diagnostic uncertainty, will extend access to its Afirma Gene Expression Classifier (GEC) through an agreement with Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. The agreement is intended to meet growing physician demand for innovative genomic testing ser... 
Printer Friendly Version
01/26/17Quest Diagnostics Reports Fourth Quarter And Full Year 2016 Financial Results; Provides Guidance For Full Year 2017
-- Fourth quarter revenues of $1.86 billion, up 0.7% on a reported basis and up 1.9% on an equivalent basis versus 2015 -- Fourth quarter diluted EPS of $1.09 on a reported basis, down 15.5% from 2015; fourth quarter diluted EPS of $1.31 on an adjusted basis excluding amortization, up 10.1% from 2015 -- Full year revenues of $7.52 billion, up 0.3% on a reported basis and up 2.6% on an equivalent basis versus 2015 -- Full year diluted EPS of $4.51 on a reported basis, down 7.4% from 2015... 
Printer Friendly Version
01/26/17Quest Diagnostics Partners With Montefiore Health System to Deliver High-Value, Innovative Laboratory Services
MADISON, N.J. and NEW YORK, Jan. 26, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, is working with  Montefiore Health System (MHS) to provide diagnostic laboratory services. This partnership will enhance the quality and efficiency of laboratory services at Montefiore. "We are pleased to partner with Montefiore, a premiere academic health system recognized for personalized, accountable car... 
Printer Friendly Version
01/18/17Quest Diagnostics Launches Nation's First Hepatitis B Virus Quantitative Test to Help Assess Response to Antiviral Therapy
Company expands hepatitis testing capabilities with new HBV surface antigen (sAg) quantitative testing MADISON, N.J., Jan. 18, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the launch of a new test service that helps physicians evaluate a patient's response to drug therapies used to treat infection with the hepatitis B virus (HBV). The first test of its kind available in the United States, the test is sig... 
Printer Friendly Version
01/11/17Quest Diagnostics To Release Fourth Quarter And Full Year 2016 Financial Results On January 26
MADISON, N.J., Jan. 11, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2016 results on Thursday, January 26, 2017, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.  The conference call can be accessed in listen-only mode by diali... 
Printer Friendly Version
01/06/17Quest Diagnostics Achieves Perfect Score On 2017 Human Rights Campaign Corporate Equality Index
MADISON, N.J., Jan. 6, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, received a rating of 100 from the Human Rights Campaign Foundation on the 2017 Corporate Equality Index, earning the distinction of being a "Best Place to Work for LGBT Equality."  The Corporate Equality Index (CEI) is a national benchmarking survey and report on corporate policies and practices related to L... 
Printer Friendly Version
01/05/17Quest Diagnostics To Speak At The 35th Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 5, 2017 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, Chairman, President and CEO, will discuss the company's vision, goals and two-point strategy to accelerate growth and drive operational excellence. The presentation is scheduled for Wednesday, January 11, 2017 at 5:30 ... 
Printer Friendly Version
12/15/16Quest Diagnostics Board of Directors Elects Stephen H. Rusckowski Chairman of the Board
Daniel C. Stanzione Named Lead Independent Director MADISON, N.J., Dec. 15, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostics information services, today announced that its Board of Directors elected Stephen H. Rusckowski, the company's President and Chief Executive Officer, to serve in the additional position of Chairman of the Board of Directors.  The company's independent directors also designated Dr. Dan... 
Printer Friendly Version
12/12/16Quest Diagnostics Provides Notice of Data Security Incident
MADISON, N.J., Dec. 12, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) announced today that it is investigating an unauthorized third-party intrusion into an internet application on its network.  The company provided notice to individuals whose accounts have been affected.  On November 26, 2016 an unauthorized third party accessed the MyQuest by Care360® internet application and obtained Protected Health Information (PHI) of approximately 34... 
Printer Friendly Version
12/07/16Data Diagnostics Named Most Innovative Healthcare Product of the Year by 2016 Best in Biz Awards
Point-of-care healthcare analytics technology from Quest Diagnostics and Inovalon facilitates better care quality and value-based financial performance MADISON, N.J., Dec. 7, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics™, a point-of-care healthcare analytics technology, has been named the Most Innovative Product of the Year for Healthcare in the Best in Biz Award annual competition, the only independent business awards ... 
Printer Friendly Version
11/21/16Quest Diagnostics to Expand Consumer Offering Through Patient-Initiated Testing Services in Colorado and Missouri
Service provides patients autonomy over their own health by allowing them to choose from diagnostic tests without a physician's order MADISON, N.J., Nov. 21, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, has launched QuestDirect, a new Patient-Initiated Testing service which will empower consumers who live in Colorado and Missouri to manage their health by ordering certain lab tests directly without a physician's order. ... 
Printer Friendly Version
11/11/16Quest Diagnostics Raises Revenue Growth Outlook, Increases Dividend at 2016 Investor Day
- Revenue growth beyond 2016 to be between 3-5%, earnings to grow faster than revenues in mid-to-high single digit range - Raises dividend by 12.5% to annual rate of $1.80 per share - Reaffirms Invigorate target of $1.3 billion run rate cost savings by end of 2017 - Quest to expand retail presence in Safeway stores to more than 50 by end of 2016, 200 by end of 2017 MADISON, N.J., Nov. 11, 2016 /PRNewswire/ -- At a meeting with analysts and investors at its Investor Day today, membe... 
Printer Friendly Version
10/20/16Quest Diagnostics Reports Third Quarter 2016 Financial Results
- Revenues of $1.89 billion, up 0.3% on a reported basis and up 2.1% on an equivalent basis versus 2015 - Reported diluted EPS of $1.34, down 43.0% from 2015 due to the gain on contribution to Q2 Solutions last year - Adjusted diluted EPS excluding amortization of $1.37, up 7% from 2015 - Cash provided by operations of $301 million, up 41.7% from 2015 - Full year EPS outlook narrowed MADISON, N.J., Oct. 20, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the wor... 
Printer Friendly Version
10/18/16IBM and Quest Diagnostics Launch Watson-Powered Genomic Sequencing Service to Help Physicians Bring Precision Cancer Treatments to Patients Nationwide
Memorial Sloan Kettering Cancer Center to Provide Deep Knowledge Base to Augment Watson's Data Sources and Quest's Medical Reporting New Service Extends Reach to Community Oncologists Who Provide 70 Percent of Cancer Care CAMBRIDGE, MA, MADISON, NJ, and NEW YORK, NY - 18 Oct 2016: IBM Wa... 
Printer Friendly Version
10/18/16IBM and Quest Diagnostics Launch Watson-Powered Genomic Sequencing Service to Help Physicians Bring Precision Cancer Treatments to Patients Nationwide
Memorial Sloan Kettering Cancer Center to Provide Deep Knowledge Base to Augment Watson's Data Sources and Quest's Medical Reporting New Service Extends Reach to Community Oncologists Who Provide 70 Percent of Cancer Care CAMBRIDGE, Mass., MADISON, N.J. and NEW YORK, Oct. 18, 2016 /PRNewswire/ -- IBM Watson Health (NYSE: IBM) and Quest Diagnostics (NYSE: DGX) today announced the launch of IBM Watson Genomics from Quest Diagnostics, a new service that helps advance precision medicine by c... 
Printer Friendly Version
10/06/16Quest Diagnostics' Women in Leadership Initiative recognized by Healthcare Businesswomen's Association with ACE award
FAIRFIELD, N.J., Oct. 6, 2016 /PRNewswire-USNewswire/ -- The Healthcare Businesswomen's Association (HBA) has named Quest Diagnostics' Women in Leadership (WIL) Employee Business Network as the winner of the 2016 HBA ACE award. ACE (Advancement, Commitment, Engagement) recognizes internal leadership programs that perform by advancing and enhancing the careers of women in their respective organizations. The award will be presented to Quest Diagnostics on November 3 at the 2016 HBA Annual... 
Printer Friendly Version
10/06/16Quest Diagnostics To Release Third Quarter 2016 Financial Results On October 20
MADISON, N.J., Oct. 6, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2016 results on Thursday, October 20, 2016, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 773-681-5898, passcode 3214469. The company sug... 
Printer Friendly Version
09/27/16Quest Diagnostics To Host Investor Day On November 11, 2016
MADISON, N.J., Sept. 27, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Friday, November 11, 2016 at The Intercontinental New York Barclay Hotel, 111 East 48th St, New York, NY.  During the event, President and Chief Executive Officer Steve Rusckowski, Chief Financial Officer Mark Guinan, and other senior executives will shar... 
Printer Friendly Version
09/21/16Quest Diagnostics Launches Zika Antibody Test Service Based on the CDC MAC-ELISA Antibody Test
Company also introduces molecular Zika testing for serum and paired urine MADISON, N.J., Sept. 21, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of a new antibody test service that aids the diagnosis of infection with the Zika virus. The service is based on the Zika Immunoglobulin M (IgM) Antibody Capture Enzyme-Linked Immunosorbent Assay (Zika MAC-ELISA), developed by the Centers for Dis... 
Printer Friendly Version
09/16/16Quest Diagnostics Sustainability Efforts Earn Place on DJSI World and National Indices for Over Twelve Years
MADISON, N.J., Sept. 16, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, was named for the twelfth consecutive year in the North America Dow Jones Sustainability Index (DJSI) and for a thirteenth year in the World DJSI. The Dow Jones Sustainability Index provides an integrated assessment of companies based on economic, environmental and social criteria with a strong focus on long-term shareholder value. To be included or r... 
Printer Friendly Version
09/15/16Drug Positivity in U.S. Workforce Rises to Nearly Highest Level in a Decade, Quest Diagnostics Analysis Finds
Annual Drug Testing Index Reveals Fifth Straight Year of Increases in Detection Rate of Amphetamine and Heroin; Marijuana Positivity Increases 47 Percent Since 2013 in Oral Fluid Testing MADISON, N.J., Sept. 15, 2016 /PRNewswire/ -- Following years of declines, the percentage of employees in the combined U.S. workforce testing positive for drugs has steadily increased over the last three years to a 10-year high, according to an analysis of nearly 11 million workforce drug test results relea... 
Printer Friendly Version
09/13/16Optum and Quest Diagnostics Partner to Help Make the Health System Work Better for Patients, Physicians, Health Plans and Employers
... 
Printer Friendly Version
09/12/16Quest Diagnostics To Speak At The Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 12, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. Steve Rusckowski, the company's President and CEO, and Mark Guinan, Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, September 13, 2016 at 2:05 p... 
Printer Friendly Version
08/18/16Quest Diagnostics Approved to Use Electronic Drug Test Process for Federally-Mandated Workforce by U.S. Health and Human Services
eCCF dramatically improves efficiency and time savings in workplace drug testing MADISON, N.J., Aug. 18, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic services, announced today that the U.S. Department of Health and Human Services (HHS) has authorized the company to perform drug testing using electronic Custody and Control Forms (eCCF) for federally-mandated, safety-sensitive workers. With the approval, Quest becomes the largest workplace dru... 
Printer Friendly Version
08/17/16Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 17, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share, payable on October 19, 2016 to shareholders of record of Quest Diagnostics common stock on October 4, 2016. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of... 
Printer Friendly Version
08/05/16Quest Diagnostics To Speak At The 18th Annual Pacific Crest Global Technology Leadership Forum
MADISON, N.J., Aug. 5, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 18th Annual Pacific Crest Global Technology Leadership Forum in Vail, Colorado. Lidia Fonseca, the company's Senior Vice President and CIO, will discuss the company's technology solutions and the role of technology within the organization. The presentation is scheduled for Tuesday, August 9th, 2016 ... 
Printer Friendly Version
08/05/16Quest Diagnostics To Speak At The Canaccord Genuity 36th Annual Growth Conference
MADISON, N.J., Aug. 5, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Canaccord Genuity 36th Annual Growth Conference in Boston, Massachusetts. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, August 10, 2016 at 10:00 a.m. Eastern Time. The pres... 
Printer Friendly Version
08/04/16Quest Diagnostics Launches New Digital Dementia Assessment Test to Aid Physicians' Assessment of Individuals with Cognitive Dysfunction
First digital testing technology from diagnostics leader is designed to help primary care physicians and ACOs improve the detection and monitoring of patients with dementias such as Alzheimer's disease MADISON, N.J., Aug. 4, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced CogniSense™, a digital cognitive assessment tool that aids in a physician's assessment, diagnosis and care management of individuals with... 
Printer Friendly Version
08/03/16Quest Diagnostics and AncestryDNA Collaborate to Expand Consumer DNA Testing
World leaders in consumer genomics and diagnostic information services team up Driven by rapidly growing global consumer demand for self-discovery through genomics MADISON, N.J., and LEHI, Utah, Aug. 3, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and AncestryDNA, the leader in family history and consumer genomics, are teaming up to help meet the rapidly growing consumer demand for genetic tests that provide insights... 
Printer Friendly Version
07/27/16Data Diagnostics Healthcare Technology Wins Two Gold Honors for Innovation in the 2016 Golden Bridge Awards
Healthcare analytics technology from Quest Diagnostics and Inovalon supports adoption of value-based care MADISON, N.J., July 27, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics™, a point-of-care health analytics technology, has won two gold medals at the 2016 Golden Bridge Awards. The solution earned gold in the categories of New Product, Service, Upgrade, or Innovation of the Year and Innovations in Technology. The annua... 
Printer Friendly Version
07/26/16One in Two American Adults Misuse Their Prescription Drugs, Finds Analysis of More Than Three Million Lab Tests from Quest Diagnostics
Study Finds Sharp Increase in Patients Who Combine Prescribed Medications with Other Drugs; Two in Three Users of Heroin Take it with Benzodiazepines, a Potentially Lethal Combination MADISON, N.J., July 26, 2016 /PRNewswire/ -- The majority of American adults taking opioids and other commonly prescribed medications use them in ways that put their health at risk, including potentially dangerous combinations with other drugs, according to a new study from Quest Diagnostics (NYSE: DGX), the w... 
Printer Friendly Version
07/21/16Quest Diagnostics Reports Second Quarter 2016 Financial Results
- Q2 2016 revenues of $1.91 billion, lower by 1% on a reported basis and higher by 2.4% on an equivalent basis versus 2015 - Reported diluted EPS of $1.37, up 69.1% from 2015 - Adjusted diluted EPS excluding amortization of $1.34, up 7.2% from 2015 - Updates full year reported EPS guidance and maintains full year adjusted outlook MADISON, N.J., July 21, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, ... 
Printer Friendly Version
06/30/16Quest Diagnostics To Release Second Quarter 2016 Financial Results On July 21
MADISON, N.J., June 30, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2016 financial results on Thursday, July 21, 2016, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 773-681-5898, passcode 3214469. The co... 
Printer Friendly Version
06/15/16Unsafe Lead Levels in Children Found in Numerous Regions of the United States, Finds New Study in Journal of Pediatrics
Largest percentage of children with very high blood lead levels concentrated in six regions, including in New York, Pennsylvania and Ohio MADISON, N.J., June 15, 2016 /PRNewswire/ -- Despite four decades of public health efforts to minimize children's exposure to lead, high percentages of unsafe blood lead levels are still found in children in numerous regions of the United States, according to a new study by researchers at Quest Diagnostics (NYSE: DGX), the world's leading provider of diag... 
Printer Friendly Version
06/15/16Quest Diagnostics and Safeway Team to Offer Convenient Diagnostic Testing to Customers in More States
MADISON, N.J., June 15, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Safeway, one of the largest food and drug retailers in the U.S., are teaming up to offer diagnostic testing in 12 Safeway locations, in addition to the two locations currently operating in Arizona through Quest's Sonora Quest Laboratories joint venture with Banner Health.   Quest Diagnostics will provide diagnostic testing services offered in comp... 
Printer Friendly Version
06/14/16New Study of Physicians and Health Plan Executives Reveals Actions Needed to Accelerate Value-Based Care
HIGHLIGHTS FROM THE QUEST DIAGNOSTICS/INOVALON STUDY INCLUDE: - Seventy-four percent of physicians and health plan executives said that quality measures are too complex, making it difficult for physicians to achieve them. - About two-thirds (65 percent) of physicians said they do not have all the healthcare information they need about their patients. - Sixty-four percent of physicians and health plan executives said that physicians do not have the tools needed to succeed in a value-base... 
Printer Friendly Version
06/09/16Data Diagnostics Healthcare Technology Wins Two 2016 IT World Awards
Healthcare analytics technology from Quest Diagnostics and Inovalon connects with nearly 600 EHR platforms to provide actionable patient insights at the point of care MADISON, N.J., June 9, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and Inovalon (NASDAQ: INOV) today announced that Data Diagnostics™, a point-of-care health analytics technology, has won two IT World Awards®. The solution earned a gold medal in the IT Products and Services for Healthcare category and a bronze medal for... 
Printer Friendly Version
06/06/16Quest Diagnostics to Relocate Corporate Headquarters, Consolidate Office Facilities, in New Jersey
MADISON, N.J., June 6, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will relocate its corporate headquarters from Madison, N.J. to Secaucus, N.J. when its lease expires in September 2017.  The company also will consolidate its corporate support functions in Lyndhurst, N.J. with the new headquarters in Secaucus upon expiration of its current lease of that facility, also in September 2017. The new office loc... 
Printer Friendly Version
06/02/16Quest Diagnostics To Speak At The Goldman Sachs 37th Annual Global Healthcare Conference
MADISON, N.J., June 2, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 2016 Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, June 7, 2016 at 11:40 a.m. Eastern Time. The... 
Printer Friendly Version
06/02/16Fit Female College Athletes More Prone to Overreaching than Less Fit Ones, Putting Performance at Risk, Finds New Research Presented at American College of Sports Medicine Annual Meeting
Biomarker monitoring may help identify athletes at risk for overtraining BOSTON and MADISON, N.J., June 2, 2016 /PRNewswire/ -- Female college athletes at their highest pre-season fitness levels may be more susceptible to overreach in a team sport environment than less fit ones, according to original research being presented at the American College of Sports Medicine Annual (ACSM) Meeting. Researchers at Rutgers, The State University of New Jersey, reported that biomarker testing of fe... 
Printer Friendly Version
06/01/16One Year After Launch, BRCA Share™ Open Data Initiative Reveals New Findings on BRCA Gene Mutations Linked to Hereditary Breast and Ovarian Cancer Risk
Co-Founded by Quest Diagnostics and Inserm, with LabCorp as First Member, BRCA Share is now the Largest Open BRCA Datashare of Curated BRCA Variants Clinically Suitable for Patient Management MADISON, N.J. and PARIS and BURLINGTON, N.C., June 1, 2016 /PRNewswire/ -- BRCA Share, a public-private BRCA gene datashare initiative, today announced the public release of a large collection of new data on genetic variants in the BRCA1 and BRCA2 genes. Mutations of these genes raise the risk of breas... 
Printer Friendly Version
05/31/16Quest Diagnostics and HCA's HealthONE System Partner to Deliver High-Value and Innovative Laboratory Services at Six Denver-Area HealthONE Hospitals
MADISON, N.J. and DENVER, May 31, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the HealthONE System of HCA Healthcare (NYSE: HCA) are teaming up to enhance the quality and value of diagnostic services to patients and their doctors through an agreement for Quest to manage in-patient laboratory operations for six Denver-area hospitals in the HealthONE system.  Under the agreement, Quest Diagnostics will manage Health... 
Printer Friendly Version
05/26/16Quest Diagnostics Launches Three Genetic Test Panels for Predicting Hereditary Cancer Risk
34-gene panel for assessing risk of 15 inherited cancers among new Quest Vantage™ test services to be highlighted during the 2016 ASCO Annual Meeting MADISON, N.J., May 26, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of three new cancer test services designed to provide clinically actionable insight into an individual's risk of developing hereditary forms of cancer.  Part of the company... 
Printer Friendly Version
05/23/16Quest Diagnostics Announces Proposed Senior Notes Offering
MADISON, N.J., May 23, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $500,000,000 aggregate principal amount of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The issuance of the notes will be subject to customary closing conditions. The company int... 
Printer Friendly Version
05/18/16Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 18, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.40 per share, payable on July 20, 2016 to shareholders of record of Quest Diagnostics common stock on July 6, 2016. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clinic... 
Printer Friendly Version
05/18/16Quest Diagnostics Completes Effort to Refocus on Diagnostic Information Services; Updates 2016 Revenue Outlook
- Strategy to refocus business portfolio completed with sale of Focus Diagnostics products business for $300 million - Full Year 2016 revenue now expected to be between $7.47 billion and $7.54 billion, reflecting sale - Full year 2016 EPS outlook remains unchanged MADISON, N.J., May 18, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed efforts to refocus its business on diagnostic ... 
Printer Friendly Version
05/13/16DiaSorin S.p.A. Completes Acquisition of the Focus Diagnostics' Molecular and Immunoassay Product Business from Quest Diagnostics
SALUGGIA, Italy, May 13, 2016 /PRNewswire/ -- DiaSorin S.p.A. (FTSE Italy: DIA) today announced the completion of the transaction to acquire the Focus Diagnostics' immunodiagnostic and molecular diagnostic products business ("Focus") from Quest Diagnostics (NYSE: DGX), initiated with a binding purchase agreement signed on March 29, 2016. DiaSorin paid to Quest Diagnostics $300 million in cash for all the tangible and intangible assets of Focus used by the latter to develop, manufacture and... 
Printer Friendly Version
04/28/16Zika Test from Quest Diagnostics Authorized by the FDA for Emergency Use
First Test from a Commercial Lab to Receive Emergency Use Authorization for Testing Patients in the United States, including Puerto Rico, for Zika Infection MADISON, N.J., April 28, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The te... 
Printer Friendly Version
04/21/16Quest Diagnostics Reports First Quarter 2016 Financial Results
- Q1 2016 revenues of $1.86 billion grew 3.6% on an equivalent basis and 1.3% on a reported basis - Diagnostic Information Services revenues increased 3.8% from a year ago - Adjusted diluted EPS excluding amortization of $1.12, up 6.7% from 2015 - Reported diluted EPS of $0.70, up 67% from 2015 MADISON, N.J., April 21, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the first ... 
Printer Friendly Version
04/15/16New Diagnostic Pathways Could Improve Dementia Diagnosis, According to Consensus Statements to Be Presented at the American Academy of Neurology Annual Meeting
Quest Diagnostics and UCSF will also present novel research on improving the quality and reducing the costs of dementia care MADISON, N.J., April 15, 2016 /PRNewswire/ -- A tiered diagnostic approach that incorporates clinical, imaging and laboratory data may help physicians more efficiently screen for neurodegenerative disorders such as dementia, according to the consensus of a multi-disciplinary panel of experts. The consensus statement is among eight presentations developed with the part... 
Printer Friendly Version
04/14/16Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies
MADISON, N.J., April 14, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has expanded its chronic hepatitis C virus (HCV) test services to include new capabilities to help physicians identify or predict resistance to several HCV therapies, including the recently FDA-approved Zepatier™, from Merck, and Daklinza™, from Bristol-Myers Squibb. The new services enhance the ability of physicians to determ... 
Printer Friendly Version
04/07/16Quest Diagnostics To Release First Quarter 2016 Financial Results On April 21
MADISON, N.J., April 7, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2016 results on Thursday, April 21, 2016, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 773-681-5898, passcode 3214469. The company sugg... 
Printer Friendly Version
03/30/16DiaSorin To Acquire Focus Diagnostics' Molecular And Immunoassay Product Business From Quest Diagnostics, Significantly Advancing Its Presence In The Molecular Diagnostic Market
- Focus Diagnostics' unique Simplexa™ platform and products to allow DiaSorin to quickly enter the molecular segment; - DiaSorin will strengthen its offering in the US market accessing approximately 200 hospitals served today by Focus, and will leverage its commercial presence worldwide to distribute the Focus products in markets today under served in Europe and Asia; - The cash transaction, valued at $300 million, is expected to be immediately accretive to DiaSorin's ongoing earnings per ... 
Printer Friendly Version
03/29/16Quest Diagnostics Marlborough Lab Earns LEED Green Building Certification
MADISON, N.J., March 29, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that its state of the art clinical laboratory in Marlborough, Mass., has achieved Leadership in Energy and Environmental Design (LEED) certification from  the U.S. Green Building Council. The 209,000 square foot lab serves as the hub for the New England area and hosts more than 1,000 employees. Environmentally friendly features ... 
Printer Friendly Version
03/29/16Quest Diagnostics Announces Early Tender Date Results of Cash Tender Offers for Up to $200 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 29, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the early tender results of its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $200 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and... 
Printer Friendly Version
03/28/16Quest Diagnostics Announces Pricing of Cash Tender Offers for Up to $200 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 28, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the determination of the pricing for its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $200 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 N... 
Printer Friendly Version
03/15/16Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 15, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has commenced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $200 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 and 5.750% Senior Notes due 2040 (collectively, the "Notes"). The terms and conditions of the Offers are... 
Printer Friendly Version
03/09/16Quest Diagnostics To Speak At The Barclays Global Healthcare Conference
MADISON, N.J., March 9, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Thursday, March 17, 2016 at 10:45 a.m. Eastern Time. The presentation will be webcast l... 
Printer Friendly Version
02/29/16Quest Diagnostics Completes Acquisition of Clinical Laboratory Partners' Outreach Laboratory Service Business in Connecticut
MADISON, N.J. and HARTFORD, Conn., Feb. 29, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the outreach laboratory service business of Clinical Laboratory Partners (CLP), a wholly-owned subsidiary of Hartford HealthCare (HHC). HHC is an integrated health care system with five hospitals in Connecticut. Financial terms were not disclosed. With the acq... 
Printer Friendly Version
02/24/16Quest Diagnostics and Inovalon Bring Real-Time, Point-of-Care Analytics to HIMSS16 with Data Diagnostics™
Integrated with nearly 600 EHR platforms to align clinical management with quality, utilization and financial performance goals MADISON, N.J. and BOWIE, M.D., February 24, 2016 – Quest Diagnostics (NYSE: DGX) and Inovalon (Nasdaq: INOV) today announced they will showcase Data Diagnostics™, real-time analytics at the point of care, at HIMSS16, furthering the national roll-out of the solution. Based on one of healthcare’s largest datasets and integrated with nearly 600 electronic h... 
Printer Friendly Version
02/22/16Quest Diagnostics to Showcase Its Advanced Healthcare Information Technology Solutions at HIMSS16 Under its New Quanum™ Brand
The Quanum suite of healthcare information and technology solutions, based on Quest's industry leading dataset of 20 billion test results and national connectivity, help deliver better care and outcomes at lower costs MADISON, N.J., Feb. 22, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it will showcase its Quanum™ suite of healthcare information technology (HIT) solutions, including Data Diagnostics with... 
Printer Friendly Version
02/19/16Quest Diagnostics Named One of 2016 "World's Most Admired Companies" by Fortune Magazine
MADISON, N.J., Feb. 19, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" for 2016 by Fortune.  The annual Fortune "World's Most Admired Companies" survey ranked Quest Diagnostics third among 10 companies in the "Health Care: Pharmacy and Other Services" industry, a jump of two places from last year. Quest ranked in the top three in all of th... 
Printer Friendly Version
01/28/16Quest Diagnostics Reports Fourth Quarter And Full Year 2015 Financial Results; Provides Guidance For Full Year 2016; Increases Dividend 5% To $0.40 Per Quarter
-- Full year revenues grew 2% on an equivalent basis and 0.8% on a reported basis -- Full year adjusted diluted EPS excluding amortization of $4.77, up 6% versus prior year -- Full year reported diluted EPS of $4.87, up 29% versus prior year -- Fourth quarter revenues grew 0.6% on an equivalent basis versus 2014; down 1.8% on a reported basis versus 2014 -- Fourth quarter adjusted diluted EPS excluding amortization of $1.19, up 0.8% versus prior year -- Fourth quarter reported dil... 
Printer Friendly Version
01/25/16Quest Diagnostics Expands Dako's PD-L1 IHC 28-8 Complementary Test to Include Melanoma
Third offering in Quest's precision medicine menu for oncology immunotherapies MADISON, N.J., Jan. 25, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company. Earlier today, Dako announced the U.S. Food and Drug Administration (FDA) approved the complementary in vitro diagnostic te... 
Printer Friendly Version
01/15/16Quest Diagnostics To Release Fourth Quarter And Full Year 2015 Financial Results On January 28
MADISON, N.J., Jan. 15, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2015 results on Thursday, January 28, 2016, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469.... 
Printer Friendly Version
01/04/16Quest Diagnostics To Speak At The 34th Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 4, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, January 12, 2016 at 7:30 p.m. Eastern Time. The presentation will be we... 
Printer Friendly Version
12/23/15New York Giants Incorporate Sports Science from Quest Diagnostics into Training
Quest Diagnostics Blueprint for Athletes™ provides new laboratory diagnostics for professional and amateur athletes EAST RUTHERFORD, N.J., Dec. 23, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and the New York Football Giants today made it official: Giants' players are now using Quest's baseline athletic performance testing service "Blueprint for Athletes," which has been a major factor for the Giants' training and preparation for NFL games this season.  The Blueprint for Athlet... 
Printer Friendly Version
12/10/15Quest Diagnostics, Barnabas Health Enter Into Strategic Laboratory Partnership To Deliver High-value And Innovative Diagnostic Information Services
MADISON, N.J. and WEST ORANGE, N.J., Dec. 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Barnabas Health, New Jersey's largest not-for-profit integrated health care delivery system, are teaming up to enhance quality and value of diagnostic services to patients and their doctors through an agreement for Quest to manage laboratory operations for Barnabas Health hospitals. Under the agreement, Quest Diagnostics will... 
Printer Friendly Version
12/04/15Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec. 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on Jan. 27, 2016 to shareholders of record of Quest Diagnostics common stock on Jan. 12, 2016. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest data... 
Printer Friendly Version
12/04/15Quest Diagnostics Increases Share Repurchase Authority by $500 Million
MADISON, N.J., Dec. 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has increased the company's share repurchase authorization by $500 million. The $500 million authorization announced today is an increase to the $522 million that was available as of Sept. 30, 2015 under the company's share repurchase authorization program.  Fourth quarter repurchases will be repor... 
Printer Friendly Version
12/03/15Quest Diagnostics Streamlines Hepatitis C Virus Lab Testing by Performing Molecular Testing for all Positive Antibody Test Results
MADISON, N.J., December 3, 2015 – In its commitment to provide diagnostic insights that enhance patient care and outcomes, Quest Diagnostics (NYSE: DGX) will automatically perform molecular testing on all patient specimens whose antibody screening results indicate hepatitis C virus infection, and remove standalone positive antibody screening as a test option. The change to the company’s service menu eliminates the prospect a patient may receive a positive screening result but fail to unde... 
Printer Friendly Version
11/10/15Quest Diagnostics to Acquire Clinical Laboratory Partners' Outreach Laboratory Service Business in Connecticut
Acquisition to Enhance Access to Innovative, High-value Diagnostic Information Services for People in Connecticut MADISON, N.J. and HARTFORD, Conn., Nov. 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has entered into a definitive agreement to acquire the outreach laboratory service business of Clinical Laboratory Partners (CLP), a wholly-owned subsidiary of Hartford HealthCare (HHC). HHC is an inte... 
Printer Friendly Version
10/22/15Quest Diagnostics Reports Third Quarter 2015 Financial Results
- Revenues of $1.88 billion, up 0.9% on an equivalent basis vs. 2014; down 1.3% on a reported basis vs. 2014 - Adjusted diluted EPS excluding amortization of $1.28, up 6.7% vs. 2014 - Reported diluted EPS of $2.35, up 167% vs. 2014 including gain on contribution to clinical trials joint venture - Full year adjusted diluted EPS outlook narrowed to $4.75 - $4.80 MADISON, N.J., Oct. 22, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of di... 
Printer Friendly Version
10/21/15Quest Diagnostics' ExamOne Life Insurance Testing Business to Acquire Superior Mobile Medics
Transaction to Expand Paramedical Services Offering for Insurers, Brokerages and Life Insurance Applicants MADISON, N.J., Oct. 21, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that its ExamOne business, the leader in helping insurers meet their underwriting needs, has agreed to acquire the business assets of Superior Mobile Medics. Based in San Diego, Calif., Superior Mobile Medics is a national pro... 
Printer Friendly Version
10/09/15Quest Diagnostics Introduces Dako's PD-L1 Complementary Diagnostic Test to Support Bristol-Myers Squibb's OPDIVO® Anti-PD-1 Therapy for Non-squamous Non-small Cell Lung Cancer
The new Quest test service is based on the first FDA-approved complementary diagnostic MADISON, N.J., Oct. 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it now provides clinical laboratory testing using the  PD-L1 IHC 28-8 pharmDx immunohistochemistry test, available through Dako, an Agilent Technologies company.  Today, the U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squi... 
Printer Friendly Version
10/08/15Testing for More Cystic Fibrosis Mutations than Recommended by Current Medical Guidelines May Identify A Greater Number of Potential Carriers, Finds Study Presented at 2015 ASHG Annual Meeting
Scientists from Quest Diagnostics also provide an oral presentation on the novel "molecular combing" technique's ability to identify gene mutations to aid diagnosis of a form of muscular dystrophy MADISON, N.J., Oct. 8, 2015 /PRNewswire/ -- Genetic testing for mutations beyond those currently recommended in medical guidelines may aid the identification of more couples at risk of having a child with cystic fibrosis, according to a study presented today at the 2015 American Society of Human G... 
Printer Friendly Version
10/06/15FDA Clears the Focus Diagnostics Simplexa™ Flu A/B & RSV Direct Test to Include 53 New Virus Strains for the 2015-2016 Flu Season
Molecular test from Quest Diagnostics' products business is cleared to identify 92 influenza and respiratory syncytial virus strains, more than any other FDA-cleared molecular test CYPRESS, Calif. and MADISON, N.J., Oct. 6, 2015 /PRNewswire/ -- In advance of the 2015-2016 flu season, Focus Diagnostics, the products business of Quest Diagnostics (NYSE: DGX), today announced that its Simplexa™ Flu A/B & RSV Direct Kit has received 510(k) clearance from the U.S. Food and Drug Administratio... 
Printer Friendly Version
10/05/15Quest Diagnostics To Release Third Quarter 2015 Financial Results On October 22
MADISON, N.J., Oct. 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2015 results on Thursday, October 22, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company sug... 
Printer Friendly Version
10/02/15Quest Diagnostics Introduces Dako's PD-L1 Companion Diagnostic for KEYTRUDA®, Merck's Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
Testing by Quest will advance precision medicine by helping to identify patients who may benefit from new oncology immunotherapy MADISON, N.J., Oct. 2, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx™ immunohistochemistry companion diagnostic. Earlier today, the U.S. Food and Drug Administration (FDA) approved Merck's KEY... 
Printer Friendly Version
09/29/15Quest Diagnostics and Inovalon Advance Value-Based Healthcare with Industry-First Real-Time Analytics at the Point of Care
"Data Diagnostics™" provides valuable on-demand insights to align clinical management with quality, utilization and financial performance goals MADISON, N.J., Sept. 29, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inovalon (Nasdaq: INOV), a leading technology company providing advanced, cloud-based data analytics and data-driven intervention platforms to the healthcare industry, today announced the national launch o... 
Printer Friendly Version
09/14/15Quest Diagnostics Sustainability Efforts Earn Continued Place on 2015 DJSI World and National Indices
MADISON, N.J., Sept. 14, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, was named for the eleventh consecutive year in the North America Dow Jones Sustainability Index (DJSI) and for a twelfth year in the World DJSI. The Dow Jones Sustainability Index provides an integrated assessment of companies based on economic, environmental and social criteria with a strong focus on long-term shareholder value. To be included or rem... 
Printer Friendly Version
09/11/15Quest Diagnostics To Speak At The Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 11, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Thursday, September 17, 2015 at 11:10 a.m. Eastern Time. The presentation will b... 
Printer Friendly Version
09/10/15Quest Diagnostics To Speak At The 10th Annual Wells Fargo Healthcare Conference
MADISON, N.J., Sept. 10, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 10th Annual Wells Fargo Healthcare Conference in New York City.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for today, Thursday, September 10, 2015 at 9:10 a.m. Eastern Time. The pre... 
Printer Friendly Version
09/10/15One in Two Adolescents Misuse Their Prescription Drugs, Study Shows
Analysis by Quest Diagnostics of 2.5 million de-identified test results finds about half of patients of all ages are still taking opioids and other potentially addictive medications inappropriately MADISON, N.J., Sept. 10, 2015 /PRNewswire/ -- Although prescription drug misuse is on the decline among adolescents, one in two patients tested between the ages of 10 and 17 years are not using their medications appropriately, potentially putting their health at risk, according to an analysis by ... 
Printer Friendly Version
09/03/15Focus Diagnostics Receives FDA Clearance to Add Genital Swab Claim to Moderate Complexity Simplexa™ HSV 1 & 2 Direct Molecular Test
System from Quest Diagnostics' products business is first FDA-cleared Herpes Simplex Virus 1 and 2 test that uses genital swab or cerebrospinal fluid (CSF) specimen collection MADISON, N.J. and CYPRESS, Calif., Sept. 3, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Dir... 
Printer Friendly Version
08/18/15Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 18, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on October 21, 2015 to shareholders of record of Quest Diagnostics common stock on October 6, 2015. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of... 
Printer Friendly Version
08/04/15Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California
MADISON, N.J. and LOS ANGELES, Aug. 4, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed the previously announced acquisition of MemorialCare Health System's laboratory outreach service business. As a result of the transaction, patients and physicians now have access to Quest's extensive range of innovative services and network of nearly 200 patient service centers in southern Californi... 
Printer Friendly Version
07/29/15Quest Diagnostics Collaborates with Perinatal Quality Foundation on National Initiative to Advance Clinically Appropriate Noninvasive Prenatal Screening
Educational campaign and patient registry to provide new insights and clarification on use of advanced screening tests to assess fetal health while promoting outcomes research on tests' predictive accuracy WASHINGTON, July 29, 2015 /PRNewswire/ -- The Perinatal Quality Foundation (PQF) today announced a nationwide campaign to improve understanding of the advantages, limitations and clinically appropriate interpretation of results of noninvasive prenatal screening and other diagnostic tests ... 
Printer Friendly Version
07/23/15Quest Diagnostics Reports Second Quarter 2015 Financial Results
- Revenues of $1.93 billion, up 1.2% from 2014 - Adjusted diluted EPS excluding amortization of $1.25, up 5.0% from 2014 - Reported diluted EPS of $0.81 was negatively impacted by debt refinancing and other charges - Revenue outlook updated to reflect recently completed joint venture with Quintiles - Full year 2015 outlook for adjusted diluted EPS excluding amortization of $4.70 to $4.85, unchanged MADISON, N.J., July 23, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE... 
Printer Friendly Version
07/07/15Quest Diagnostics To Release Second Quarter 2015 Financial Results On July 23
MADISON, N.J., July 7, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2015 results on Thursday, July 23, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company ... 
Printer Friendly Version
07/02/15Quintiles and Quest Diagnostics Launch Q2 Solutions
Closes previously announced clinical trials laboratory services joint venture transaction RESEARCH TRIANGLE PARK, N.C. & MADISON, N.J.--(BUSINESS WIRE)-- Quintiles and Quest Diagnostics today announced the launch of Q2 Solutions, their new combined clinical trials laboratory services organization. Q2 Solutions brings together the clinical trials laboratory operations of the two parent organizations to provide biopharmaceutical customers with the diverse capabilitie... 
Printer Friendly Version
06/30/15Quest Diagnostics to Acquire MemorialCare Health System's Laboratory Outreach Service Business
Transaction to Extend Laboratory Partnership Serving Patients and Physicians in Southern California while Bolstering Quest's Growth Strategy in the Region MADISON, N.J. and LOS ANGELES, June 30, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and MemorialCare Health System, a nationally recognized nonprofit health system in Los Angeles and Orange counties, today announced they have entered into a definitive agreement for Q... 
Printer Friendly Version
06/16/15Physicians Rank Quest Diagnostics Care360 Top EHR for Small Group Practices in 2015 Black Book Survey
MADISON, N.J., June 16, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Care360 cloud-based electronic health record (EHR) has ranked number one among physician practices and groups with two to five practicing physicians. The ranking is based on a poll of 5,700 small and solo medical practices surveyed by Black Book™ in 2015. Physicians across all specialties in these small-sized practices ranked C... 
Printer Friendly Version
06/09/15Quest Diagnostics to Comment on 2015 Revenue Outlook in Light of Joint Venture Progress at Goldman Sachs 36th Annual Global Healthcare Conference
MADISON, N.J., June 9, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that, in light of recent progress in finalizing its clinical trials joint venture, Mark Guinan, the company's Senior Vice President and CFO, will provide commentary on its revenue outlook when he presents at the Goldman Sachs 2015 Global Healthcare Conference in Rancho Palos Verdes, California on June 10. On March 31, 2015, Quest... 
Printer Friendly Version
06/09/15Illicit Drug Positivity Rate Increases Sharply in Workplace Testing, Finds Quest Diagnostics Drug Testing Index™ Analysis
Upsurge in marijuana, cocaine and methamphetamine drive second consecutive year of increases in the positivity rate for drug tests, suggesting a potential reversal in a decades' long decline in workforce drug use MADISON, N.J., June 9, 2015 /PRNewswire/ -- The percentage of American workers testing positive for illicit drugs such as marijuana, cocaine and methamphetamine has increased for the second consecutive year in the general U.S. workforce, according to insights from more than 10 mill... 
Printer Friendly Version
06/05/15Quest Diagnostics to Speak at the Goldman Sachs 36th Annual Global Healthcare Conference
MADISON, N.J., June 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 2015 Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Wednesday, June 10, 2015 at 2:20 p.m. Eastern Daylight Ti... 
Printer Friendly Version
05/28/15Quest Diagnostics to Speak at the Jefferies 2015 Global Healthcare Conference
MADISON, N.J., May 28, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies 2015 Global Healthcare Conference in New York.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Tuesday, June 2, 2015 at 8:00 a.m. Eastern Time. The presentation will be webcast liv... 
Printer Friendly Version
05/15/15Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 15, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.38 per share, payable on July 22, 2015 to shareholders of record of Quest Diagnostics common stock on July 8, 2015. About Quest Diagnostics Quest Diagnostics empowers people to take action to improve health outcomes.  Derived from the world's largest database of clin... 
Printer Friendly Version
05/12/15Quest Diagnostics to Enhance Quality of Noninvasive Prenatal Screening with QNatal Advanced™
New prenatal screening service provides actionable information for women with high-risk pregnancies MADISON, N.J., May 12, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services and a leader in women's health and genomic testing, today launched QNatal Advanced, a noninvasive prenatal screening service for detecting chromosomal abnormalities in high-risk pregnancies. QNatal Advanced analyzes ... 
Printer Friendly Version
05/04/15Quest Diagnostics Announces LeukoVantage™, Advancing Precision Medicine for Hematologic Malignancies
Genomic service detects 30 gene mutations to aid in the diagnosis, prognosis, monitoring and treatment selection for several myeloid neoplasms MADISON, N.J., May 4, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced LeukoVantage™, an evidence-based genomic test service that aids in the diagnosis, prognosis, monitoring and selection of treatment for myeloid neoplasms, a group of hematologic malignancies that in... 
Printer Friendly Version
04/23/15Quest Diagnostics Reports First Quarter 2015 Financial Results
-- Revenues of $1.84 billion, up 5.3% from 2014 -- Adjusted diluted EPS excluding amortization of $1.05, up 13% from 2014 -- Reported diluted EPS of $0.42 was negatively impacted by recent debt refinancing charges -- Guidance unchanged for full year revenue and adjusted diluted EPS excluding amortization MADISON, N.J., April 23, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for ... 
Printer Friendly Version
04/21/15Quest Diagnostics and Inserm Launch Multinational BRCA Gene Datashare Initiative, with LabCorp as First Participant, to Improve the Detection of Inherited Risk of Breast and Ovarian Cancers
BRCA Share™ is a novel public-private initiative designed to enhance the clarity and quality of patient testing MADISON, N.J. and PARIS and BURLINGTON, N.C., April 21, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Inserm, the French National Institute of Health and Medical Research institution, today launched BRCA Share™, a novel datashare initiative they co-founded to provide scientists and laboratory organizations ... 
Printer Friendly Version
04/15/15FDA Clears the Simplexa™ Group A Strep Direct Test from Focus Diagnostics, a Quest Diagnostics Business
CYPRESS, Calif. and MADISON, N.J., April 15, 2015 /PRNewswire/ -- Focus Diagnostics, the clinical-laboratory products business of Quest Diagnostics (NYSE: DGX), today announced the FDA 510(k) clearance and CLIA moderate-complexity categorization for its Simplexa Group A Strep Direct Kit.  Simplexa Group A Strep Direct is a real-time polymerase chain reaction assay for the detection of Group A Streptococcus bacteria directly from throat swabs.  The most prevalent form of Group A Streptococcus... 
Printer Friendly Version
04/14/15HPV-Only Screening Misses More Cervical Cancers in Women 30 and Older Than Pap-Only or Pap-HPV Co-testing, Finds National Study
As many as 19% of women received false negatives for cervical cancer when HPV-only tested, finds Quest Diagnostics Health Trends™ study published in Cancer Cytopathology of 256,648 women, one of the largest of different screening tests for cervical cancer MADISON, N.J., April 14, 2015 /PRNewswire/ -- HPV-only screening is less likely to accurately detect cervical pre-cancer and cancer than testing that includes a Pap test in women 30-65 years of age, according to a new study published onlin... 
Printer Friendly Version
04/13/15Quest Diagnostics To Release First Quarter 2015 Financial Results On April 23
MADISON, N.J., April 13, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2015 results on Thursday, April 23, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The compan... 
Printer Friendly Version
04/09/15Quest Diagnostics to Launch Interactive Insights and IntelliTest Interactive Reports and Health Data Analytics Tools at HIMSS 2015
Company's HIT solutions turn health information into actionable insights to help ACOs, health systems, hospitals and physicians improve health care quality, outcomes and efficiencies MADISON, N.J., April 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will unveil a suite of new technology solutions during the HIMSS 2015 Annual Conference & Exhibition, the industry's largest health IT educational program and exhibiti... 
Printer Friendly Version
04/02/15Quest Diagnostics Recognizes Five Strategic Partners with Supplier Excellence Awards
MADISON, N.J., April 2, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today awarded Supplier Excellence Awards to five companies at its 2015 Supplier Forum. Supplier Excellence awards recognize world class products, systems, or services that provide consistent and reliable performance; companies that develop and implement novel solutions to move the business forward; individuals who step up to the challenge and excel in ... 
Printer Friendly Version
03/31/15Quintiles and Quest Diagnostics to Form Joint Venture to Provide Global Clinical Trials Laboratory Services
Combines the complementary strengths and scale of leading biopharmaceutical services and diagnostic information services providers New entity creates superior value proposition through the depth and scale of its capabilities, services and expertise Business to help biopharmaceutical customers bring new drug therapies to market and support precision medicine Joint venture would have generated approximately $575 million in revenues in 2014 Quintiles will own 60% and Quest D... 
Printer Friendly Version
03/23/15Diabetes Diagnoses Surge in States that Expanded Medicaid Under the Affordable Care Act
Quest Diagnostics Health Trends™ study in Diabetes Care suggests health care reform has increased access to preventive health services, but only in states that expanded Medicaid MADISON, N.J., March 23, 2015 /PRNewswire/ -- People in states that expanded Medicaid under the Affordable Care Act (ACA) are far more likely to be newly identified with diabetes than in states that elected not to expand the public health care program, finds a new study by researchers at Quest Diagnostics (NYSE: DGX... 
Printer Friendly Version
03/19/15Quest Diagnostics Announces Early Tender Date Results of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 19, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the early tender results of its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and... 
Printer Friendly Version
03/18/15Quest Diagnostics Announces Pricing of Cash Tender Offers for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 18, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the determination of the pricing for its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 N... 
Printer Friendly Version
03/10/15Quest Diagnostics to Enhance Diagnosis of Pediatric Neurological Disorders with Exclusive Whole Exome Sequencing from Personalis
Proprietary Neurome™ service provides insight into the genetic causes of neurological disorders so parents and health care providers can develop personalized care strategies MADISON, N.J., March 10, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of Neurome™, a whole exome sequencing service designed to aid the diagnosis of rare neurological disorders in pediatric populations. Personalis, I... 
Printer Friendly Version
03/05/15Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $1,200,000,000 in aggregate principal amount of three series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The issuance of the notes will be subject to customary closing condi... 
Printer Friendly Version
03/05/15Quest Diagnostics Commences Cash Tender Offer for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has commenced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 and 5.750% Senior Notes due 2040 (collectively, the "Notes"). The terms and conditions of the Offers are ... 
Printer Friendly Version
03/05/15Quest Diagnostics Announces Amendments to the Prices Offered in its Previously Announced Cash Tender Offer for Up to $250 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it is amending the terms of its cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $250 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and, together with t... 
Printer Friendly Version
03/04/15Quest Diagnostics To Speak At The Barclays Global Healthcare Conference
MADISON, N.J., March 4, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, March 11, 2015 at 1:05 p.m. Eastern Time. The presentation will be webcast l... 
Printer Friendly Version
02/20/15Quest Diagnostics Earns Fortune Magazine 2015 "World's Most Admired Companies" Designation
MADISON, N.J., Feb. 20, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named a "Most Admired Company" by Fortune Magazine in the "Health Care: Pharmacy and Other Services" category. "We are proud that Quest Diagnostics is included on FORTUNE's 2015 World's Most Admired Companies list in our category," said Steve Rusckowski, President and CEO. "The honor is a true team accomplishment, and ... 
Printer Friendly Version
02/09/15Quest Diagnostics and Myriad Genetics End BRCA Patent Litigation
Agreement ensures continuing broad patient access to Quest's BRCAvantage™ services for evaluating genetic risk of developing breast, ovarian and other cancers MADISON, N.J., Feb. 9, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it and Myriad Genetics Inc. have reached an agreement that ends their BRCA gene-patent litigation.  Under the agreement, Quest Diagnostics and Myriad Genetics and its co-... 
Printer Friendly Version
01/29/15Quest Diagnostics Reports Fourth Quarter and Full Year 2014 Financial Results; Provides Guidance For Full Year 2015; Increases Dividend 15%
MADISON, N.J., Jan. 29, 2015 /PRNewswire/ -- Fourth quarter revenues from continuing operations of $1.9 billion, up 7.2% versus prior year Adjusted diluted EPS from continuing operations of $1.08, up 4.9% versus prior year Reported diluted EPS from continuing operations of $1.26, up 30% versus prior year Dividend increased 15% to $0.38 per quarter Full year 2015 revenues to grow 2% to 3% Full year 2015 adjusted diluted EPS excluding amortization expense expected to be between $4.... 
Printer Friendly Version
01/28/15Quest Diagnostics and CDC Expand Public Health Collaboration to Improve Hepatitis Diagnosis and Treatment
Multi-year fee-based contract for Quest's test data and analytics expertise aims to reveal insights from national testing trends to promote guideline-based care and better outcomes for 4.4 million Americans with viral hepatitis MADISON, N.J. and ATLANTA, Jan. 28, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it will collaborate with the Centers for Disease Control and Prevention (CDC) to identify tre... 
Printer Friendly Version
01/13/15Quest Diagnostics To Release Fourth Quarter And Full Year 2014 Financial Results On January 29
MADISON, N.J., Jan. 13, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2014 results on Thursday, January 29, 2015, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 321... 
Printer Friendly Version
01/08/15Quest Diagnostics Names New Health Plan Leader
MADISON, N.J., Jan. 8, 2015 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the appointment of veteran health plan executive Michael Cole as vice president of health plans for Quest Diagnostics.  "We are very focused on strengthening our relationships with health plan customers," said Steve Rusckowski, president and chief executive officer, Quest Diagnostics.  "Mike has the experience and leadership to build an... 
Printer Friendly Version
01/06/15Quest Diagnostics To Speak At The 33rd Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 6, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Wednesday, January 14, 2015 at 2:30 p.m. Eastern Time. The presentation will be... 
Printer Friendly Version
01/05/15Quest Diagnostics to Speak at the Goldman Sachs Healthcare CEOs Unscripted Conference
MADISON, N.J., Jan. 5, 2015 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs Healthcare CEOs Unscripted Conference in Boston.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, January 6, 2015 at 11:00 a.m. Eastern Time. The presentation will be we... 
Printer Friendly Version
12/09/14FDA Clears the Focus Diagnostics Simplexa™ Flu A/B & RSV Direct Test to Include Eight Circulating Influenza Viruses
CYPRESS, Calif. and MADISON, N.J., Dec. 9, 2014 /PRNewswire/ -- As the 2014-2015 flu season begins, Focus Diagnostics, the products business of Quest Diagnostics (NYSE: DGX), today announced that its Simplexa™ Flu A/B & RSV Direct Kit has received FDA clearance for eight additional influenza strains. These strains may pose significant potential health risks and may be circulating this winter. The FDA, which granted 510(k) clearance to the test kit originally in July 2012, cleared additional ... 
Printer Friendly Version
12/04/14Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec. 4, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.33 per share, payable on January 28, 2015 to shareholders of record of Quest Diagnostics common stock on January 13, 2015. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to ma... 
Printer Friendly Version
12/01/14Quest Diagnostics To Speak At The Piper Jaffray 26th Annual Healthcare Conference
MADISON, N.J., Dec. 1, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Piper Jaffray 26th Annual Healthcare Conference in New York City.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Tuesday, December 2, 2014 at 9:30 a.m. Eastern Time. The presentation... 
Printer Friendly Version
11/05/14Quest Diagnostics Discusses Progress in Executing Strategy to Drive Shareholder Value and Presents Outlook at Investor Day
- Company Expects to Generate 2% to 5% Revenue Growth and Adjusted Diluted EPS Growth of 8% to 10% on Average Over Next Three Years - - New Target of $600 Million in Additional Run-Rate Savings Over Next Three Years Will Bring Total Run-Rate Savings Expected by End of 2017 to $1.3 billion - NEW YORK, Nov. 5, 2014 /PRNewswire/ -- At a meeting with analysts and investors at its Investor Day here today, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the... 
Printer Friendly Version
11/04/14Quest Diagnostics Introduces BRCAvantage Plus™, Providing New Choices in Genetic Breast Cancer Risk Testing
First major service extension to the company's BRCAvantage™ BRCA1 and BRCA2 mutation test menu offers screening for five new non-BRCA genes shown to increase risk of inherited breast cancer MADISON, N.J., Nov. 4, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced BRCAvantage Plus, the company's first suite of lab-developed test services for assessing genetic breast cancer risk based on clinically validated non... 
Printer Friendly Version
10/23/14Quest Diagnostics Reports Third Quarter 2014 Financial Results
MADISON, N.J., Oct. 23, 2014 /PRNewswire/ -- Revenues from continuing operations of $1.9 billion, up 6.5% versus prior year Adjusted diluted EPS from continuing operations of $1.10, up 7.8% versus prior year Reported diluted EPS from continuing operations of $0.88, compared to $2.66 in 2013, which included a net gain of $1.80 per diluted share from asset sales Full year 2014 revenues now expected to grow approximately 3.5%, versus 2.5% to 3.5% previously Full year 2014 adjusted dilu... 
Printer Friendly Version
10/22/14Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors
MADISON, N.J., Oct. 22, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Jeffrey M. Leiden, M.D., Ph.D., to serve as a director, effective December 1, 2014. Including Dr. Leiden, the Board has 11 members. Dr. Leiden is the Chairman, President and CEO of Vertex Pharmaceuticals.   Dr. Leiden has more than 20 years of scientific and commercial experience in the pharmaceut... 
Printer Friendly Version
10/07/14Quest Diagnostics To Release Third Quarter 2014 Financial Results On October 23
MADISON, N.J., Oct. 7, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2014 results on Thursday, October 23, 2014, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests pa... 
Printer Friendly Version
10/02/14Quest Diagnostics Unveils New State-of-the-Art Clinical Laboratory in Marlborough, Massachusetts
Congresswoman Niki Tsongas, Representative Danielle Gregoire and Marlborough Mayor Arthur Vigeant join community event to open 200,000 square-foot "lab of the future" designed to deliver innovative, efficient diagnostic information services to New England Medical experts from UMass Memorial Medical Group and the University of Massachusetts to provide scientific leadership for testing onsite MARLBOROUGH, Mass., Oct. 2, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leadin... 
Printer Friendly Version
10/01/14Quest Diagnostics Names Mayo Clinic Executive Franklin R. Cockerill, M.D., Vice President and Chief Laboratory Officer
Former president and CEO of Mayo Medical Laboratories and chair of lab medicine and pathology for Mayo Clinic to oversee Quest's clinical testing operations MADISON, N.J., Oct. 1, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Franklin R. Cockerill, III, M.D., has joined the company as vice president and chief laboratory officer, effective October 1, 2014. Dr. Cockerill w... 
Printer Friendly Version
10/01/14Quest Diagnostics To Host Investor Day On November 5, 2014
MADISON, N.J., Oct. 1, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the  world's leading provider of diagnostic testing, information and services, will host Investor Day for institutional investors and financial analysts in New York City on Wednesday, November 5, 2014 at The Hudson Theatre at the Millennium Broadway, 145 West 44th Street, New York, NY.  During the event, Quest Diagnostics executives will discuss the company's strategy, performance and plans to drive s... 
Printer Friendly Version
09/12/14Quest Diagnostics Marks 10 Years on the Dow Jones Sustainability Index
MADISON, N.J., Sept. 12, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today celebrates a decade on the North America Dow Jones Sustainability Index (DJSI) and 11 consecutive years on the World DJSI. The Dow Jones Sustainability Index family ranks companies for corporate sustainability according to economic, environmental and social criteria. To be included or remain in the index, companies must continually intensify th... 
Printer Friendly Version
09/11/14Workforce Drug Test Positivity Rate Increases for the First Time in 10 Years, Driven by Marijuana and Amphetamines, Finds Quest Diagnostics Drug Testing Index™ Analysis of Employment Drug Tests
Colorado and Washington experience surges in marijuana tests positivity rate, but data suggests state legalization of recreational marijuana may not be sole driver of increases MADISON, N.J., Sept. 11, 2014 /PRNewswire/ -- The percentage of positive drug tests among American workers has increased for the first time in more than a decade, fueled by a rise in marijuana and amphetamines, according to an analysis of 8.5 million urine, oral fluid and hair workplace drug test results released tod... 
Printer Friendly Version
09/08/14More People Testing Positive for Chikungunya Virus in the U.S., Finds Study at ICAAC 2014
Clinical testing volume and positivity rate both grew after the first case of the infectious disease spread to Western Hemisphere this year MADISON, N.J., Sept. 8, 2014 /PRNewswire/ -- A growing number of patients in the United States are being tested – and testing positive – for the mosquito-borne chikungunya virus, according to a study presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Washington, D.C. The study, by scientists from Quest Diagnosti... 
Printer Friendly Version
09/04/14Quest Diagnostics To Speak At The Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 4, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Monday, September 8, 2014 at 10:30 a.m. Eastern Time. The presentation will be w... 
Printer Friendly Version
08/27/14Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study
Testing for the protein 14-3-3eta may improve the diagnosis of RA, including in early stages when treatment is most likely to improve outcomes MADISON, N.J., Aug. 27, 2014 /PRNewswire/ -- A novel biomarker for rheumatoid arthritis (RA) has significant potential to help physicians better identify early-stage disease, when treatment can often arrest further disease progression and disability, according to a new study in The Journal of Rheumatology. Researchers from Quest Diagnostics (NYS... 
Printer Friendly Version
08/15/14Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 15, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.33 per share, payable on October 22, 2014 to shareholders of record of Quest Diagnostics common stock on October 7, 2014. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic information services needed to make better healthcare de... 
Printer Friendly Version
07/24/14Quest Diagnostics Reports Second Quarter 2014 Financial Results
MADISON, N.J., July 24, 2014 /PRNewswire/ -- Revenues from continuing operations of $1.9 billion, up 4.8% versus prior year Adjusted diluted EPS from continuing operations of $1.08, up 1.9% versus  prior year Reported diluted EPS from continuing operations of $0.92, 7% below prior year Cash from operations of $280 million, up 34% versus prior year Full year 2014 revenues now expected to be up 2.5% to 3.5%, versus up 2% to 4% previously Full year 2014 adjusted diluted EPS range na... 
Printer Friendly Version
07/23/14Quest Diagnostics Adds Vicky Gregg to Board of Directors
MADISON, N.J., July 23, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Vicky Gregg to serve as a director, effective immediately, expanding the Board to 10 members. Ms. Gregg served as the Chief Executive Officer of Chattanooga-based Blue Cross Blue Shield of Tennessee from 2003 through December 2012. Prior to being elected CEO, she served in a number of other leaders... 
Printer Friendly Version
07/16/14Decline in Prescription Drug Misuse More than Twice as High in States with Broad Drug Abuse Prevention Programs, New Quest Diagnostics Health Trends Study Finds
Three-year analysis of more than 1.4 million test results also shows majority of Americans continue to put health at risk through dangerous drug combinations and skipping doses MADISON, N.J., July 16, 2014 /PRNewswire/ -- Five states that have implemented multi-faceted prescription drug abuse prevention programs in recent years showed the highest rate of decline in prescription drug misuse rates nationwide, according to a new study issued today by Quest Diagnostics (NYSE: DGX), the world's ... 
Printer Friendly Version
07/07/14Quest Diagnostics To Release Second Quarter 2014 Financial Results On July 24
MADISON, N.J., July 7, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2014 results on Thursday, July 24, 2014, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests part... 
Printer Friendly Version
06/10/14Quest Diagnostics Introduces bioMerieux THxID®-BRAF Companion Diagnostic to Advance Precision Medicine for Melanoma
MADISON, N.J., June 10, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today introduced a new cancer test service based on the FDA-approved THxID®-BRAF test from bioMerieux, a world leader in the field of in vitro diagnostics. The THxID®-BRAF test is a companion diagnostic for two treatments for melanoma. The test is intended to be used as an aid in selecting patients with melanoma whose tumors carry the BRAF V600E mutation fo... 
Printer Friendly Version
06/04/14Quest Diagnostics To Speak At The Goldman Sachs 35th Annual Global Healthcare Conference
MADISON, N.J., June 4, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Goldman Sachs 35th Annual Global Healthcare Conference in Rancho Palos Verdes, California. Mark Guinan, the company's Senior Vice President and Chief Financial Officer and Jay Wohlgemuth, M.D., Senior Vice President, Medical, Science and Innovation, will discuss the company's vision, goals and five-... 
Printer Friendly Version
06/01/14Memorial Sloan Kettering Cancer Center and Quest Diagnostics Partner to Advance Precision Medicine in Cancer Diagnosis and Treatment
Diagnostic insights into gene mutations in solid tumor cancers will aid therapy selection and prognosis for patients and advance research NEW YORK and MADISON, N.J., June 1, 2014 /PRNewswire/ -- Memorial Sloan Kettering Cancer Center, the world's oldest and largest private cancer center, and Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a joint collaboration that will utilize MSK's clinical and research insights i... 
Printer Friendly Version
05/21/14Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 21, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.33 per share, payable on July 23, 2014 to shareholders of record of Quest Diagnostics common stock on July 9, 2014. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make bett... 
Printer Friendly Version
05/05/14Quest Diagnostics To Speak At The Deutsche Bank 39th Annual Health Care Conference
MADISON, N.J., May 5, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Deutsche Bank 39th Annual Heath Care Conference in Boston.  Stephen Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five-point strategy.  The presentation is scheduled for Thursday, May 8, 2014 at 10:00 a.m. Eastern Time. The presentation will be webcast... 
Printer Friendly Version
04/28/14Athena Diagnostics to Present Original Research on Neurogenetics at American Academy of Neurology's 2014 Annual Meeting
Company scientists advance understanding of role of genetics in seizure disorders, Charcot-Marie-Tooth disease and other conditions at top neurology industry conference MADISON, N.J., April 28, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that several scientists from its Athena Diagnostics specialty neurology business will present research during ... 
Printer Friendly Version
04/24/14Quest Diagnostics Reports First Quarter 2014 Financial Results
MADISON, N.J., April 24, 2014 /PRNewswire/ -- Full year revenue and adjusted earnings per diluted share guidance unchanged First quarter adjusted diluted EPS from continuing operations of $0.84, vs. $0.89 in 2013 First quarter adjusted diluted EPS was reduced by approximately $0.11 due to unseasonably harsh winter First quarter reported diluted EPS from continuing operations of $0.71, vs. $0.72 in 2013 First quarter revenues $1.75 billion, 2.3% below prior year Quest Diagnosti... 
Printer Friendly Version
04/23/14Quest Diagnostics Extends Partnership with Steward Health Care System
MADISON, N.J. and BOSTON, April 23, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Steward Health Care System LLC (Steward), New England's largest community-based accountable care organization and one of the nation's largest Pioneer ACOs, today announced that Quest has acquired the remainder of Steward's outreach laboratory service operations. Under the arrangement, Quest will provide outreach laboratory testing services t... 
Printer Friendly Version
04/23/14Next-Generation Gene Sequencing from Athena Diagnostics Streamlines Epilepsy Diagnosis
Quest Diagnostics' specialty neurology business unveils 10 new epilepsy diagnostic services, including industry's first clinical multi-analyte test for autoimmune epilepsy Test services to be unveiled at the AAN Annual Meeting, April 26 - May 4 in Philadelphia MADISON, N.J., April 23, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a suite of new testing services from its Athena Diagnostics specialty neu... 
Printer Friendly Version
04/21/14Quest Diagnostics Completes Acquisition of Summit Health
MADISON, N.J., April 21, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, has completed the previously announced acquisition of Summit Health,  a leading provider of on-site prevention and wellness services. Financial terms were not disclosed. Health and wellness is a large and fast growing segment within the healthcare industry. A report by RAND Corp based on 2012 data found that 85% of employers with over 1,000 employees... 
Printer Friendly Version
04/07/14Patients Nationwide Now Have Direct Access to Lab Test Results through Quest Diagnostics
Company launches new website to enable patients to access lab data under federal rule that takes effect today Physicians who use Quest's Care360 EHR may qualify for Meaningful Use incentives MADISON, N.J., April 7, 2014 /PRNewswire/ -- For the first time, Americans nationwide can directly access their personal laboratory data through Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. Quest Diagnostics provides diagnostic information services t... 
Printer Friendly Version
04/03/14Quest Diagnostics To Release First Quarter 2014 Financial Results On April 24
MADISON, N.J., April 3, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2014 results on Thursday, April 24, 2014, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests par... 
Printer Friendly Version
03/24/14Focus Diagnostics Receives FDA Clearance for Moderate Complexity Simplexa® HSV 1 & 2 Direct Molecular Test for Aiding the Diagnosis of Encephalitis
Quest Diagnostics business launches first HSV PCR for CSF in United States. Test provides results in about 60 minutes. MADISON, N.J. and CYPRESS, Calif., March 24, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information and services, today announced that its Focus Diagnostics products business has received expedited FDA 510(k) clearance and CLIA moderate complexity categorization for its new Simplexa HSV 1 & 2 Direct molecular test on t... 
Printer Friendly Version
03/12/14Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., March 12, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it intends to offer $600,000,000 in aggregate principal amount of two series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The issuance of the notes will be subject to customary closing conditio... 
Printer Friendly Version
03/11/14Quest Diagnostics to Acquire Summit Health
Combined Offering to Accelerate Growth from Prevention and Wellness Programs MADISON, N.J., March 11, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into a definitive purchase agreement under which Quest will acquire Summit Health. Terms of the transaction were not disclosed. Summit Health is a leading provider of on-site prevention and wellness programs primarily for employers. Fo... 
Printer Friendly Version
03/10/14Quest Diagnostics Completes Acquisition of Solstas Lab Partners and Raises 2014 Financial Guidance
- Full Year 2014 Revenues expected to grow 2% - 4% compared to 2013 - Full Year Adjusted Earnings Per Diluted Share to be between $3.95 and $4.15 MADISON, N.J., March 10, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the previously announced acquisition of Solstas Lab Partners Group and its subsidiaries (Solstas), a full-service commercial laboratory company based in Greensboro, N... 
Printer Friendly Version
02/26/14Quest Diagnostics Expands Hereditary Cancer Screening Offering with Lynch Syndrome Blood and Biopsy Testing for Colorectal Cancer
Company Supports March's Colorectal Cancer Awareness Month by Participating in the One Million Strong Screening Event in New York City on March 3 MADISON, N.J., Feb. 26, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced new pathology and blood test offerings to help identify and assess an individual's risk of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC), an inherited genetic... 
Printer Friendly Version
02/24/14Quest Diagnostics to Present Interoperability Solutions for Health Systems at HIMSS 2014
Retired New York Giants Player Stephen Baker to Join Quest as it Provides 100 Complimentary Blueprint for Wellness® Profiles at Booth 3064 on February 25 MADISON, N.J., Feb. 24, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, will exhibit at booth 3064 and host a series of "Tech Talks" and other programs during the HIMSS 2014 Annual Conference & Exhibition, the industry's largest health IT educational program and exhib... 
Printer Friendly Version
02/17/14Quest Diagnostics Announces Senior Leadership Appointments
-- John B. Haydon transitions to Vice President, Joint Ventures and Strategic Programs -- James E. Davis named Senior Vice President, Operations -- Lidia L. Fonseca named Senior Vice President and Chief Information Officer MADISON, N.J., Feb. 17, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced a series of senior leadership appointments designed to strengthen the management team as it executes t... 
Printer Friendly Version
02/14/14Quest Diagnostics To Speak At The 2014 RBC Capital Markets Global Healthcare Conference
MADISON, N.J., Feb. 14, 2014 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the RBC Capital Markets 2014 Global Healthcare Conference in New York.  Mark Guinan, the company's Senior Vice President and Chief Financial Officer, will discuss the company's vision, goals and five-point strategy.  The presentation is scheduled for Tuesday, February 25, 2014 at 8:30 a.m. Eastern Time... 
Printer Friendly Version
02/12/14ChartMaxx® from Quest Diagnostics Achieves Meaningful Use 2014 Certification from ICSA Labs
Enabling Health Systems to Qualify for CMS Financial Incentives MADISON, N.J. and CINCINNATI, Feb. 12, 2014 /PRNewswire/ -- ChartMaxx, the enterprise content management (ECM) solution from Quest Diagnostics (NYSE:DGX), has achieved 2014 Edition Modular EHR* ONC Health IT Certification which supports both Stages 1 and 2 of the Meaningful Use (MU) program. With the certification, health system providers who use the product may qualify for government financial incentives awarded to physicians ... 
Printer Friendly Version
02/05/14ChartMaxx® from Quest Diagnostics Earns 2013 'Best in KLAS' for Healthcare Document Management and Imaging Software Products
ChartMaxx Enterprise Content Management System Honored with Top Ranking for the Ninth Time MADISON, N.J., Feb. 5, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that its ChartMaxx® enterprise content management technology (ECM) solution was ranked the top healthcare Document Management and Imaging (DMI) software product, according to the 2013 Best in KLAS: Software & Services report, an independent ran... 
Printer Friendly Version
02/04/14Suboptimal Anticoagulant Treatment to Prevent Stroke Prevalent in Patients with Atrial Fibrillation, Finds Study in Circulation
The Quest Diagnostics Health Trends™ study of 2.7 million test results is the largest to examine warfarin treatment in patients with atrial fibrillation (Afib) treated in primary care and other non-hospital care settings in the United States Findings raise prospect that new oral anticoagulants may be more appropriate for some patients MADISON, N.J., Feb. 4, 2014 /PRNewswire/ -- Approximately one in two patients with atrial fibrillation (Afib) do not optimally reduce their risk of stroke ... 
Printer Friendly Version
02/03/14New Rules Opening Access to Lab Test Results Will Empower Patients to Take Control of Their Health
MADISON, N.J., Feb. 3, 2014 /PRNewswire/ -- A final rule issued today by the U.S. Department of Health and Human Services (HHS) giving Americans increased access to their personal health information will empower patients to exercise greater control over their health, according to Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) "Patient engagement is essential to creating a health... 
Printer Friendly Version
01/30/14Quest Diagnostics Reports Fourth Quarter 2013 Financial Results; Provides Guidance For Full-Year 2014; Increases Dividend 10%
MADISON, N.J., Jan 30, 2014 /PRNewswire/ -- Fourth quarter adjusted diluted EPS from continuing operations of $1.03, 2% above prior year Fourth quarter reported diluted EPS from continuing operations of $0.97, 12% above prior year Fourth quarter revenues $1.76 billion, 1% below the prior year Full year 2014 revenues expected to be flat to 2% below the prior year, excluding Solstas acquisition Full year 2014 adjusted diluted EPS from continuing operations expected to be between $3.90... 
Printer Friendly Version
01/22/14Quest Diagnostics to Acquire Solstas Lab Partners
Transaction to give patients and healthcare providers in the Southeastern United States greater access to innovative and cost-effective diagnostic information services MADISON, N.J., Jan. 22, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has entered into a definitive agreement under which Quest will acquire Solstas Lab Partners Group and its subsidiaries (Solstas) for a total transaction value of ... 
Printer Friendly Version
01/17/14Quest Diagnostics To Release Fourth Quarter And Full Year 2013 Financial Results On January 30
MADISON, N.J., Jan. 17, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2013 results on Thursday, January 30, 2014, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) The conference call can also be accessed in li... 
Printer Friendly Version
01/13/14Quest Diagnostics Adds Timothy L. Main to Board of Directors
MADISON, N.J., Jan. 13, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has elected Timothy L. Main to serve as a director, effective immediately. Including Mr. Main, the Board has 10 members. (Photo: http://photos.prnewswire.com/prnh/20140113/NY45552 ) (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) Tim Main currently serves as Chairman of the Board of Director... 
Printer Friendly Version
01/09/14UC San Francisco and Quest Diagnostics Launch Collaboration to Advance the Field of Precision Medicine
MADISON, N.J. and SAN FRANCISCO, Jan. 9, 2014 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and the University of California, San Francisco (UCSF), the nation's leading university focused exclusively on health, have formed a collaboration to accelerate the translation of biomedical research into advanced diagnostics in the field of precision medicine, for improved patient care, treatment and outcomes. Initial clinical areas of foc... 
Printer Friendly Version
12/12/13Quest Diagnostics Updates Revenue and Adjusted Diluted EPS Guidance for Full-Year 2013
MADISON, N.J., Dec. 12, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today updated its estimates for full-year 2013 revenues and adjusted diluted earnings per share, on a continuing operations basis and before special items.  The company previously updated its full-year 2013 guidance on October 17, 2013.   For the full-year 2013, the company expects: Revenues to be approximately 3.5% below the prior year, which is u... 
Printer Friendly Version
12/09/13BRCAvantage™ from Quest Diagnostics to Make Medical Congress Debut at the 2013 San Antonio Breast Cancer Symposium
Quest and Alamo Breast Cancer Foundation also Co-Hosting Panel on "Cancer and BRCA Testing in the News, the Arts and Popular Culture," Joined by Director of Upcoming Film "Decoding Annie Parker" MADISON, N.J., Dec. 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that BRCAvantage™, a service-rich oncology offering designed to increase access to BRCA testing for at-risk patients and maximize the value of diagnos... 
Printer Friendly Version
12/06/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec. 6, 2013 /PRNewswire/-- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on January 22, 2014 to shareholders of record of Quest Diagnostics common stock on January 7, 2014. (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagn... 
Printer Friendly Version
11/26/13Quest Diagnostics To Speak At The Piper Jaffray 25th Annual Healthcare Conference
MADISON, N.J., Nov. 26, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Piper Jaffray 25th Annual Healthcare Conference in New York City.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Tuesday, December 3, 2013 at 9:30 a.m. Eastern Time. (Logo:  http://photos.pr... 
Printer Friendly Version
11/18/13Drug Use Among American Workers Declined 74% Over Past 25 Years, Finds Unprecedented Analysis of More Than 125 Million Workplace Urine Drug Tests
Landmark Drug Testing Index™ analysis from Quest Diagnostics coincides with passage of the Drug-Free Workplace Act 25 years ago today MADISON, N.J., Nov. 18, 2013 /PRNewswire/ -- Drug use among American workers declined dramatically over the past 25 years, although the rate of positive test results for certain drugs, including amphetamine and opiates, continues to climb, according to a landmark analysis of workplace drug test results released today by Quest Diagnostics (NYSE: DGX), the worl... 
Printer Friendly Version
11/08/13Quest Diagnostics to Speak at the Credit Suisse 2013 Annual Healthcare Conference
MADISON, N.J., Nov. 8, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Credit Suisse 2013 Annual Healthcare Conference in Arizona.  Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Tuesday, November 12, 2013 at 1:00 p.m. Eastern Time. (Logo:  http://photos.prnewswi... 
Printer Friendly Version
10/17/13Quest Diagnostics Reports Third Quarter 2013 Financial Results; Updates Guidance for Full-Year 2013
MADISON, N.J., Oct. 17, 2013 /PRNewswire/ -- Adjusted diluted EPS from continuing operations of $1.02, vs. $1.15 in 2012 Reported diluted EPS from continuing operations of $2.66, vs. $0.98 in 2012 Revenues from continuing operations of $1.79 billion, 1.9% below prior year Full year 2013 revenues now expected to be approximately 3.5% below prior year Full year 2013 adjusted diluted EPS from continuing operations expected to be $3.85 to $3.95 Quest Diagnostics Incorporated (NYSE:... 
Printer Friendly Version
10/15/13National Survey Reveals Low Public Awareness and Understanding of BRCA Testing for Risk of Inherited Breast and Ovarian Cancers Among American Women
Seventy-two Percent (72 percent) of Adult Women in the U.S. Have Never Heard of BRCA Testing, yet 58 Percent Would Want to Know if They Carried High-Risk Gene Mutations MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- According to the results of a recent Quest Diagnostics (NYSE: DGX)  survey, seventy-two percent (72 percent) of American women age 18 and older have never heard of the BRCA test, a genetic test that can identify mutations in BRCA1 and BRCA2 genes associated with increased risk of ... 
Printer Friendly Version
10/15/13Quest Diagnostics Introduces BRCAvantage™, Broadly Expanding Patient Access to BRCA Genetic Testing for Inherited Breast and Ovarian Cancers
Also Releases Results from National Harris Survey Revealing Widespread Confusion about BRCA Testing MADISON, N.J., Oct. 15, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of BRCAvantage™, a suite of four new lab-developed genetic tests (LDT) that identify mutations in BRCA1 and BRCA2 genes, which are associated with increased risk of inherited breast and ovarian cancers. Serving an estimat... 
Printer Friendly Version
10/10/13Quest Diagnostics Provides Preview of Third Quarter 2013 Financial Performance
MADISON, N.J., Oct. 10, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today provided a preview of revenues and earnings per share for its third quarter ended September 30, 2013. The company has not yet finalized its financial results and intends to provide a full report on third quarter 2013 results, including updated 2013 guidance, and conduct a conference call with investors on October 17, 2013. (Logo: http://photos.prne... 
Printer Friendly Version
10/07/13Quest Diagnostics Acquires ConVerge Diagnostic Services
Transaction to expand patient access to innovative diagnostic information services and bolster Quest's growth strategy in New England MADISON, N.J. and PEABODY, Mass., Oct. 7, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has acquired ConVerge Diagnostic Services, LLC from Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. ConVerge is a leading ... 
Printer Friendly Version
10/03/13Quest Diagnostics Again Listed on Dow Jones Sustainability World and North America Indices
MADISON, N.J., Oct. 3, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, has again been named to the Dow Jones Sustainability Indices (DJSI) for both World and North America. This marks Quest Diagnostics' tenth consecutive year on the World Index (since 2004) and its ninth consecutive year on the North America Index (since 2005). (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) "Quest Diagnostics is committed... 
Printer Friendly Version
10/02/13Quest Diagnostics To Release Third Quarter 2013 Financial Results On October 17
MADISON, N.J., Oct. 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report third quarter 2013 results on Thursday, October 17, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO) The conference call can also be accessed in listen-only mode by... 
Printer Friendly Version
10/01/13Quest Diagnostics Completes Sale of Enterix Business to Clinical Genomics of Australia
MADISON, N.J. and SYDNEY, Oct. 1, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that on September 30, 2013 it completed the sale of its Enterix colorectal cancer screening test business to Clinical Genomics Technologies Pty Ltd., an Australian life sciences company. Terms of the transaction were not disclosed. (Logo: http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) At its Investor Day presentatio... 
Printer Friendly Version
09/06/13Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 6, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy.  The presentation is scheduled for Monday, September 9, 2013 at 10:00 a.m. Eastern Time. (Logo: http://photos.prnewsw... 
Printer Friendly Version
08/20/13Quest Diagnostics Increases Share Repurchase Authority by $1 Billion
Increase brings total current authorization to approximately $1.3 billion MADISON, N.J., Aug. 20, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors has increased the company's share repurchase authorization by $1 billion, bringing the total authorization to approximately $1.3 billion. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO) "The increase i... 
Printer Friendly Version
08/20/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 20, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on October 16, 2013 to shareholders of record of Quest Diagnostics common stock on October 1, 2013. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO) About Quest Diagnostics Quest Diagnostics is the world's leading provider of dia... 
Printer Friendly Version
08/14/13Quest Diagnostics Care360 is Top EHR, as Ranked by Doctors in 2013 Black Book Survey
Quest's electronic health record ranked number one for overall satisfaction across all physician categories; also ranked number one for mobile innovation and access MADISON, N.J., Aug. 14, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Care360 cloud-based electronic health record (EHR) has ranked number one in several categories in the Black Book 2013 Rankings of EHRs in the replacement market. Th... 
Printer Friendly Version
08/08/13Quest Diagnostics Introduces Comprehensive Opioid Therapy Genetic Test Based on CYP450 Biomarker License with Transgenomic
Believed to be first clinical test to identify variants of four enzymes that mediate drug metabolism, providing greater insights for guiding treatment for the more than 100 million Americans with chronic pain MADISON, N.J., Aug. 8, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of a new lab-developed genetic test to aid the delivery of personalized opioid pain-relieving treatment. It is be... 
Printer Friendly Version
07/26/13Harvard, MIT and Brown Students, MAP for Health and Quest Diagnostics Employees Again Rally Boston to Set "See No Evil, Hear No Evil, Speak No Evil" Guinness World Record, Drawing Attention to World Hepatitis Day
Volunteer Team Urges City Residents and Visitors to Come Out, Be Counted, and Paint at Hepatitis Awareness Event, Chinatown Park, 10:00 a.m. on July 28th. BOSTON, July 26, 2013 /PRNewswire/ -- Students at Harvard, Massachusetts Institute of Technology and Brown University, Massachusetts Asian & Pacific Islanders (MAP) for Health and local employee volunteers of Quest Diagnostics will join elected officials, community and healthcare leaders and Boston residents to once again rally the ci... 
Printer Friendly Version
07/25/13Quest Diagnostics and New York Giants Team Up in a Partnership to Enhance Athletes' Health and Performance
Giants Training Facility and Headquarters Renamed Quest Diagnostics Training Center EAST RUTHERFORD, N.J., July 25, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) and the New York Giants are teaming up to find new ways to use laboratory diagnostic information services to improve the health and performance of athletes of all ages and abilities through a new collaboration. (Logo:  http://photos.prnewswire.com/prnh/20130717/NY48934LOGO ) The partnership was announced today at the Gi... 
Printer Friendly Version
07/18/13Quest Diagnostics Reports Second Quarter 2013 Financial Results
MADISON, N.J., July 18, 2013 /PRNewswire/ -- Adjusted diluted EPS from continuing operations of $1.06, vs. $1.15 in 2012 Reported diluted EPS from continuing operations of $0.99, vs. $1.09 in 2012 Revenues from continuing operations of $1.8 billion, 3.3% below prior year Full year 2013 revenues now expected to be 1% to 2% below prior year Full year 2013 EPS range narrowed to  $4.35 to $4.50 Sales of HemoCue and ibrutinib royalty rights for approximately $800 million provide fl... 
Printer Friendly Version
07/18/13Quest Diagnostics Sells Ibrutinib Royalty Rights To Royalty Pharma For $485 Million In Cash
Retains royalty rights to odanacatib and other Celera drug assets MADISON, N.J. and NEW YORK, July 18, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the sale of its rights to royalties from commercialization of the drug candidate ibrutinib to Royalty Pharma, the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, for $485... 
Printer Friendly Version
07/17/13Quest Diagnostics Names Mark J. Guinan as New CFO
MADISON, N.J., July 17, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that Mark J. Guinan will join the company on July 29 as its next Senior Vice President and Chief Financial Officer.    Since 2010, Mr. Guinan has served as Chief Financial Officer for Hill-Rom Holdings Inc. (NYSE: HRC), a manufacturer and provider of medical technologies and related services for the health care industry. Previously, he had served in a number of finance and operations roles ... 
Printer Friendly Version
07/10/13Quest Diagnostics Partners with CDC to Improve Hepatitis C Public Health Research to Promote Early Detection and Medical Intervention
Collaboration aims to improve health outcomes for the estimated 3.2 million Americans infected with hepatitis C MADISON, N.J., July 10, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced a collaboration with the U.S. Centers for Disease Control and Prevention (CDC) to improve public health analysis of hepatitis C screening, diagnosis and treatment, based on analysis of the company's national hepatitis C virus ... 
Printer Friendly Version
07/02/13Quest Diagnostics To Release Second Quarter 2013 Financial Results On July 18
MADISON, N.J., July 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report second quarter 2013 results on Thursday, July 18, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests partici... 
Printer Friendly Version
06/26/13Quest Diagnostics Care360 EHR and Other Services Offered Through AT&T Healthcare Community Online
Goal to facilitate greater provider access to secure health data, promoting greater care coordination and improved cost efficiencies MADISON, N.J., June 26, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced an agreement with AT&T* to provide the Quest Diagnostics Care360® Solution Suite, including the Care360 electronic health record (EHR) and eprescribing and laboratory order/results services, through AT&... 
Printer Friendly Version
06/24/13Quest Diagnostics Completes Acquisition of Lab-Related Clinical Outreach Operations of Dignity Health
Acquisition consistent with strategy to drive one to two percent in growth per year through strategically aligned fold-in acquisitions MADISON, N.J. and SAN FRANCISCO, June 24, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has completed the previously announced acquisition of lab-related clinical outreach service operations of Dignity Health, a hospital system based in California. Quest Diagno... 
Printer Friendly Version
06/06/13Quest Diagnostics CEO Steve Rusckowski Reaffirms Full-Year 2013 Guidance At The Jefferies 2013 Global Healthcare Conference
MADISON, N.J., June 6, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Steve Rusckowski, President and CEO, presented at the Jefferies 2013 Global Healthcare Conference in New York City today. During the presentation, Mr. Rusckowski reaffirmed the company's guidance for its results from continuing operations, before special items, for the full-year 2013:   Revenues are expected to approximate th... 
Printer Friendly Version
06/06/13Quest Diagnostics and Hologic Form Strategic Alliance to Improve Women's Health
Collaboration features national availability of the APTIMA HPV mRNA-based cervical cancer screening test as well as a focus on developing and expanding access to diagnostic solutions for women's health MADISON, N.J. and BEDFORD, Mass., June 6, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading diagnostic information services company, and Hologic, Inc. (Hologic) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imagin... 
Printer Friendly Version
06/05/13Quest Diagnostics To Speak At The Jefferies 2013 Global Healthcare Conference
MADISON, N.J., June 5, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that Steve Rusckowski, President and CEO, is scheduled to speak at the Jefferies 2013 Global Healthcare Conference in New York City on Thursday, June 6, 2013 at 1:00 p.m. Eastern Time. During the conference, Mr. Rusckowski will reaffirm the company's full-year 2013 guidance.  Revenues are expected to approximate the prior-year level... 
Printer Friendly Version
05/21/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 21, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on July 17, 2013, to shareholders of record of Quest Diagnostics common stock on July 2, 2013. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make bette... 
Printer Friendly Version
05/16/13Quest Diagnostics Acquires Concentra's Laboratory Business, Enters into Services Agreement
Patients, physicians and employers to benefit from greater access to broader menu of innovative diagnostic information services MADISON, N.J., May 16, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has acquired the toxicology and clinical laboratory business of medical center operator Concentra, a subsidiary of Humana Inc. (NYSE: HUM).  In addition, Quest Diagnostics has entered into a long-term ag... 
Printer Friendly Version
05/13/13Decades of Improving Cholesterol Levels Abruptly Ended in 2008, PLOS ONE Study Finds
Largest study of LDL blood levels, based on tests of nearly 105 million Americans, suggests improvements in cardiovascular health may have stalled in recent years MADISON, N.J., May 13, 2013 /PRNewswire/ -- Decades of declines in LDL cholesterol blood levels, a key marker of death risk from heart disease, abruptly ended in 2008, and may have stalled since, according to a multi-year, national study published in PLOS ONE. The study, by researchers at Quest Diagnostics (NYSE: DGX), examine... 
Printer Friendly Version
05/07/13Quest Diagnostics to Speak at the Bank of America Merrill Lynch 2013 Health Care Conference
MADISON, N.J., May 7, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas. The presentation is scheduled for Wednesday, May 15, 2013 at 11:40 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site:  http://www... 
Printer Friendly Version
04/17/13Quest Diagnostics Reports First Quarter 2013 Financial Results
MADISON, N.J., April 17, 2013 /PRNewswire/ -- Adjusted diluted EPS from continuing operations of $0.89, vs. $1.05 in 2012 Reported diluted EPS from continuing operations of $0.72, vs. $0.97 in 2012 Revenues from continuing operations of $1.8 billion, 6.4% below prior year Full year 2013 adjusted EPS and cash flow guidance unchanged Full year 2013 revenues now expected to approximate the prior year level Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider o... 
Printer Friendly Version
04/17/13Quest Diagnostics to Acquire Lab-Related Clinical Outreach Operations of Dignity Health in California and Nevada
Transaction expected to deliver innovative and high-quality diagnostic information services at lower costs to patients MADISON, N.J. and SAN FRANCISCO, April 17, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has entered into a definitive agreement to acquire lab-related clinical outreach service operations of Dignity Health, a hospital system based in California. Under the agreement, Quest Dia... 
Printer Friendly Version
04/16/13Quest Diagnostics Names Jim Davis, Senior Vice President, Diagnostic Solutions
MADISON, N.J., April 16, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, announced today that Jim Davis, a former vice president for three GE healthcare businesses, has joined Quest Diagnostics as Senior Vice President, Diagnostic Solutions. In this role, Mr. Davis will lead the company's Diagnostic Solutions business. In this role, he will oversee Diagnostic Products, Insurer Services, Clinical Trials and Healthcare Informat... 
Printer Friendly Version
04/09/13Quest Diagnostics Completes Sale of HemoCue Business to Radiometer Medical ApS
MADISON, N.J., April 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has completed the sale of its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances. HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide. In February 2013, Quest Diagnos... 
Printer Friendly Version
04/09/13Quest Diagnostics Launches Novel Rheumatoid Arthritis Tests
Based on 14-3-3eta protein biomarker for aiding early RA diagnosis through an exclusive license with Augurex Life Sciences MADISON, N.J., April 9, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of two new blood tests for aiding the early diagnosis of rheumatoid arthritis (RA), an autoimmune disorder that can cause debilitating joint damage. The lab-developed tests are based on the prop... 
Printer Friendly Version
04/08/13Recreational Marijuana Users More Likely To Misuse Prescription Drugs, According to National Study by Quest Diagnostics
Quest Diagnostics Health Trends™ analysis also finds marijuana is the most commonly abused drug in the United States, but medical marijuana users are not more likely to misuse other drugs MADISON, N.J., April 8, 2013 /PRNewswire/ -- Individuals who use marijuana recreationally are more likely to misuse other drugs, including pain-controlling, but potentially addictive narcotics, sedatives and other prescription medications, than individuals who do not use marijuana, according to a new natio... 
Printer Friendly Version
04/05/13Quest Diagnostics To Release First Quarter 2013 Financial Results On April 17
MADISON, N.J., April 5, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2013 results on Wednesday, April 17, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469. The company suggests parti... 
Printer Friendly Version
04/03/13Prescription Drug Misuse Remains at Alarming Levels, According to National Study by Quest Diagnostics
Quest Diagnostics Health Trends™ analysis of a quarter million test results finds three out of five Americans tested misused their prescription medications, including through potentially dangerous drug combinations MADISON, N.J., April 3, 2013 /PRNewswire/ -- Despite increased public attention on the epidemic of prescription medication abuse, about three in five Americans tested misused their prescription drugs in 2012, virtually the same as in 2011, according to a national study issued tod... 
Printer Friendly Version
04/02/13Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
MADISON, N.J., April 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that Sukumar Nagendran, M.D., has joined Quest Diagnostics as vice president, medical affairs, a new position. In this role, Dr. Nagendran will provide medical oversight for the company's diagnostic information services. He reports to Jon R. Cohen, M.D., senior vice president and chief medical officer, and will be based at the company's h... 
Printer Friendly Version
03/27/13Federal Guidelines Recommend New HIV Testing Method
U.S. Department of Health and Human Services issues medical guidelines recommending genotypic testing to aid HIV therapy selection MADISON, N.J., March 27, 2013 /PRNewswire/ -- A new test based on gene sequencing may be used to assess a patient's suitability for treatment with CCR5 antagonists, a class of HIV antiretroviral therapies, under new medical guidelines issued by the U.S. Department of Health and Human Services (DHHS). The new genotypic test performs comparably to the standard... 
Printer Friendly Version
03/18/13Quest Diagnostics Launches Dementia Diagnostic Panel, First in Industry for Treatable Forms of Cognitive Impairment Based on Medical Guidelines
Test to be unveiled at the American Academy of Neurology Annual Meeting in San Diego, March 16-23, 2013 MADISON, N.J. and WORCESTER, Mass., March 18, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the availability of the first clinical test panel for aiding the diagnosis of suspected dementia due to treatable forms of cognitive impairment. The test panel is believed to be the first commercial service from ... 
Printer Friendly Version
03/14/13Quest Diagnostics Announces Chief Financial Officer Transition Plan
MADISON, N.J., March 14, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that Robert A. Hagemann, Senior Vice President and Chief Financial Officer, plans to leave the company at the end of May 2013.  The company is launching a search for a new CFO that will consider both internal and external candidates, and Mr. Hagemann will assist in identifying his successor.  Mr. Hagemann will continue in his capacity as... 
Printer Friendly Version
03/14/13Quest Diagnostics Supports New Chronic Kidney Disease Guideline Focused on Predicting and Managing Risk
Public Encouraged to Learn About Their Kidneys and Understand Their Risks on World Kidney Day, March 14, 2013 MADISON, N.J., March 14, 2013 /PRNewswire/ -- On World Kidney Day, Quest Diagnostics, the world's leading provider of diagnostic information services, today announced its support of the updated global version of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) Chronic Kidney Disease (CKD) guideline recently released by Kidney Disease: Improving G... 
Printer Friendly Version
03/07/13Pre-Employment Drug Test Positives Increase More Than 5%, According to New Data from Quest Diagnostics Drug Testing Index™
Marijuana Remains Most Commonly Detected; Oral Fluid Finding More Positives MADISON, N.J., March 7, 2013 /PRNewswire/ -- Job candidates subject to pre-employment drug screening tested positive for illicit drugs at a greater rate in the first six months of 2012 than in all of 2011, according to Drug Testing Index™ (DTI) data released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services. The positivity rate from pre-employment urine drug s... 
Printer Friendly Version
03/05/13Quest Diagnostics to Showcase Its Award-Winning Healthcare IT Connectivity Solutions at HIMSS13
IT solutions enable physicians, hospitals, patients, ACOs and payers to be smart, synchronized and connected NEW ORLEANS, March 5, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, is presenting its award-winning healthcare information technology (HIT) connectivity solutions at HIMSS13.  Quest Diagnostics offers the broadest access to diagnostic information services through its network of laboratories and through it... 
Printer Friendly Version
03/04/13Quest Diagnostics Ranks No. 1 in Industry Category on FORTUNE's World's Most Admired Companies List
MADISON, N.J., March 4, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that that it has been recognized in FORTUNE magazine's "World's Most Admired Companies" list as the No. 1 company in the Health Care industry category of "Pharmacy and Other Services."  "We are proud that Quest Diagnostics has rejoined FORTUNE's World's Most Admired Companies as the leader in our category," said Steve Rusckowski, Pres... 
Printer Friendly Version
02/28/13ChartMaxx® and Appian Announce Partnership to Bring Next Generation Business Process Management to the Healthcare Industry at HIMSS13
Upgrade in functionality solves critical IT priorities, enables better patient experience, improves efficiency and provides greater return on investment for hospitals MASON, Ohio, Feb. 28, 2013 /PRNewswire/ -- In line with its reputation for being on the forefront of tools that provide insights for better healthcare, Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced a partnership between ChartMaxx®, its leading Document Management... 
Printer Friendly Version
02/26/13Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb. 26, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend of $0.30 per share, payable on April 16, 2013, to shareholders of record of Quest Diagnostics common stock on April 2, 2013. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to mak... 
Printer Friendly Version
02/25/13Quest Diagnostics to Sell HemoCue Business to Radiometer Medical ApS
MADISON, N.J., Feb. 25, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has signed a definitive agreement to sell its HemoCue diagnostic products business to Radiometer Medical ApS for a purchase price of approximately $300 million plus customary adjustments for cash balances. HemoCue develops, produces and markets hemoglobin, glucose and other point-of-care testing systems worldwide. "The HemoCu... 
Printer Friendly Version
02/20/13Quest Diagnostics to Provide Nationwide Access to Natera's New Non-Invasive Prenatal Test
MADISON, N.J. and SAN CARLOS, Calif., Feb. 20, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading diagnostic information services company, and Natera, a leading innovator in prenatal genetic testing, today announced that Quest Diagnostics will offer physicians access to Panorama™, a new non-invasive prenatal test developed by Natera. Panorama uses cell-free fetal DNA in circulating maternal blood to screen for chromosomal abnormalities associated with trisomy 21 (Dow... 
Printer Friendly Version
02/11/13Quest Diagnostics Names Tracy L. Cinco-Abela Vice President and Treasurer
MADISON, N.J., Feb. 11, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that Tracy L. Cinco-Abela has been named vice president and treasurer. Ms. Cinco-Abela has responsibility for all treasury activities, including capital planning, capital markets and funding, financial risk management and treasury operations. Most recently, she served as the company's assistant treasurer. She reports to Robert A. Hage... 
Printer Friendly Version
02/08/13Quest Diagnostics To Speak At The Leerink Swann Global Healthcare Conference 2013
MADISON, N.J., Feb. 8, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Leerink Swann Global Healthcare Conference in New York City. The presentation is scheduled for Thursday, February 14, 2013 at 11:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site: http://leerin... 
Printer Friendly Version
01/23/13Quest Diagnostics Reports Fourth Quarter And Full Year 2012 Financial Results; Announces 2013 Guidance
-- Full year record cash from operations of $1.2 billion and expanded operating margins -- Fourth quarter adjusted diluted EPS from continuing operations of $1.01, vs. $1.20 in 2011 -- Fourth quarter reported diluted EPS from continuing operations of $0.87 vs. $1.16 in 2011 -- Fourth quarter revenues from continuing operations of $1.8 billion, 4% below prior year -- 2013 guidance before special items: Diluted EPS between $4.35 - $4.55; revenues to grow between 0% and 1% MADISON,... 
Printer Friendly Version
01/16/13Quest Diagnostics Plans to Sell HemoCue Diagnostic Products Business as Part of its Strategy to Refocus on Diagnostic Information Services
-- Fourth Quarter Charge to be Recorded in Discontinued Operations -- -- Company Finalizes Estimated Impact from Hurricane Sandy -- MADISON, N.J., Jan. 16, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it plans to sell its HemoCue diagnostic products business, as part of the company's strategy to refocus on diagnostic information services. HemoCue develops, produces and markets point-... 
Printer Friendly Version
01/08/13Quest Diagnostics To Speak At The 31st Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 8, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco.  The presentation is scheduled for Wednesday, January 9, 2013 at 2:30 p.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site:  http://jpm... 
Printer Friendly Version
01/07/13Quest Diagnostics To Release Fourth Quarter And Full Year 2012 Financial Results On January 23
MADISON, N.J., Jan. 7, 2013 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2012 results and provide financial guidance for 2013 on Wednesday, January 23, 2013 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can also be accessed i... 
Printer Friendly Version
01/02/13Quest Diagnostics Acquires UMass Memorial Medical Center's Clinical and Anatomic Pathology Outreach Laboratory Businesses
Finalizes Lease to Build 200,000 Square Foot "Lab of the Future" in Marlborough, Massachusetts MADISON, N.J. and WORCESTER, Mass., Jan. 2, 2013 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the Worcester-based clinical outreach laboratory business of UMass Memorial Medical Center, a member of UMass Memorial Health Care, the largest health care system in ... 
Printer Friendly Version
12/31/12Quest Diagnostics Sells OralDNA Labs to Access Genetics
MADISON, N.J., Dec. 31, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has sold substantially all of the assets of its OralDNA® Labs salivary-diagnostics business to Access Genetics, a leading clinical laboratory with advanced molecular diagnostics test development and information technology capabilities. Terms of the transaction were not disclosed. The divestiture of OralDNA represents a step i... 
Printer Friendly Version
12/04/12Quest Diagnostics Clinical Trials' Biorepository Accredited by the College of American Pathologists
Signifies achievement of highest quality standards for management of biological specimens and molecular material used in new drug development MADISON, N.J., Dec. 4, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that the specimen biorepository of its Quest Diagnostics Clinical Trials business, a leader in laboratory testing services to advance drug discovery and development, has been accredit... 
Printer Friendly Version
11/16/12Quest Diagnostics Details Strategy at 2012 Investor Day
-- Increases Invigorate Cost Reduction Goal by $100 Million to $600 Million -- -- Announces 76% Increase in Dividend to $1.20 per Share Annually -- MADISON, N.J., Nov. 16, 2012 /PRNewswire/ -- As previously announced, Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, will host its Investor Day today, November 16, 2012 in New York City.  During the event, Quest Diagnostics executives will share their views of the industry and ... 
Printer Friendly Version
11/09/12Quest Diagnostics Confirms Investor Day on November 16
MADISON, N.J., Nov. 9, 2012 /PRNewswire/ -- As previously announced, Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, will host an Investor Day on Friday, November 16, 2012 at The Hudson Theatre at the Millennium Broadway Times Square, 145 West 44th Street, New York, NY.  During the event, Quest Diagnostics' new executive leadership team will discuss the company's strategy, performance and plans to drive shareholder... 
Printer Friendly Version
10/19/12Quest Diagnostics Announces First EHRs Certified Under Laboratory-based Health IT Quality Solutions™ Program
Program designed to help facilitate rigorous industry-wide standards for quality and interoperability of physician-practice electronic health records with the company's laboratory data system MADISON, N.J., Oct. 19, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the first electronic health record (EHR) solutions to be certified under its Health IT Quality Solutions™ Program. The program is des... 
Printer Friendly Version
10/17/12Quest Diagnostics Reports Third Quarter 2012 Financial Results
-- Adjusted diluted EPS of $1.18, unchanged from prior year -- Reported diluted EPS of $1.01, 6% below prior year -- Revenues of $1.9 billion, 2.9% below prior year -- Full year adjusted EPS guidance of $4.45 - $4.55; revenue growth outlook of approximately 0.5% MADISON, N.J., Oct. 17, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the third quarter ended... 
Printer Friendly Version
10/16/12Quest Diagnostics to Acquire Clinical Outreach Laboratory from UMass Memorial Medical Center; Plan to Build 'Lab of the Future' to Serve Massachusetts Health Care Community
--Relationship will provide innovation, resources, and expanded access and connectivity for patients and doctors' offices, all at reduced costs-- MADISON, N.J. and WORCESTER, Mass., Oct. 16, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world leader in diagnostic testing, information and services, signed a definitive agreement today to purchase the clinical outreach laboratory business of UMass Memorial Medical Center, a member of UMass Memorial Health Care and the largest ... 
Printer Friendly Version
10/11/12Quest Diagnostics Launches New Organizational Structure To Drive Operational Excellence and Restore Growth; Appoints New Senior Leaders
MADISON, N.J., Oct. 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, launched a major management restructuring aimed at driving operational excellence and restoring growth. In addition, the company appointed senior leaders to head its new Commercial, Operations and Human Resources functions. The key element of the organization change will be to eliminate existing business structures and repl... 
Printer Friendly Version
10/09/12Focus Diagnostics and 3M Launch FDA-Cleared Simplexa™ Test on 3M™ Cycler for Molecular Influenza and Respiratory Virus Testing by Moderate Complexity Healthcare Facilities
First moderate-complexity Simplexa™ assay developed through funding by U.S. Department of Health and Human Services' BARDA BAA program for public health preparedness CYPRESS, Calif. and SAINT PAUL, Minn., Oct. 9, 2012 /PRNewswire/ -- Focus Diagnostics, a business of Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and 3M, a global diversified technology company (NYSE: MMM), today announced that the U.S. Food and Drug Administration... 
Printer Friendly Version
10/04/12Quest Diagnostics To Release Third Quarter 2012 Financial Results On October 17
MADISON, N.J., Oct. 4, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report third quarter 2012 results on Wednesday, October 17, 2012 before the stock market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcast availabl... 
Printer Friendly Version
10/02/12PLOS ONE Study Finds HIV Genotypic Sequencing Test Performs Comparably to Standard Phenotypic Test in Predicting Potential Response to CCR5 Antagonist
Genotypic HIV tropism laboratory-developed testing service now available nationally for HIV-infected patients MADISON, N.J., Oct. 2, 2012 /PRNewswire/ -- A laboratory-developed blood test that uses deep-sequencing technology performed comparably to the industry's standard phenotypic test in helping to predict potential clinical response to HIV-1 antiretroviral CCR5-antagonist therapy, according to a new study from researchers at Quest Diagnostics (NYSE: DGX) and Pfizer. The findings undersc... 
Printer Friendly Version
09/28/12Quest Diagnostics To Host Investor Day On November 16, 2012
MADISON, N.J., Sept. 28, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the  world's leading provider of diagnostic testing, information and services, will host an investor day with institutional investors and sell-side financial analysts in New York City on Friday, November 16, 2012. During the event, Quest Diagnostics executives will discuss the company's strategy, performance and plans to drive shareholder value.   Advanced registration is required for ... 
Printer Friendly Version
09/14/12Quest Diagnostics Marks Ninth Year on Dow Jones Sustainability Index
MADISON, N.J., Sept. 14, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has again been named to the Dow Jones Sustainability World Index and North America Index. Quest Diagnostics is in its ninth year on the World Index (since 2004) and in its eighth on the North America Index (since 2005). "All of us at Quest Diagnostics are proud to have again earned a place on the Dow Jones Sustainability I... 
Printer Friendly Version
08/30/12Quest Diagnostics Launches Molecular Cervical Cancer Test Based on National Institutes of Health's TERC Gene Marker
May enhance evaluation of cancer risk in the up to 1.5 million women who receive an indeterminate Pap test result each year MADISON, N.J., Aug. 30, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory test that identifies molecular changes to cervical cells that increase the likelihood a woman may develop cervical cancer. The test is designed to help physicians i... 
Printer Friendly Version
08/24/12Quest Diagnostics Gazelle® Mobile Health App Earns 2012 CIO 100 Award
MADISON, N.J., Aug. 24, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, accepted a 2012 CIO 100 award from International Data Group's (IDG) CIO magazine for its Gazelle® mobile health application. The 25th annual award program recognizes organizations around the world that exemplify the highest level of operational and strategic excellence in information technology. The Gazelle mobile application for Blackberry... 
Printer Friendly Version
08/21/12Quest Diagnostics Blueprint for Wellness® Earns URAC's Comprehensive Wellness Accreditation
Endorsement recognizes wellness program for commitment to excellence MADISON, N.J., Aug. 21, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its Blueprint for Wellness® health risk assessment service earned Comprehensive Wellness Accreditation by meeting the highest standards for education, care and service delivery from URAC, a Washington, DC-based organization that establishes quality ... 
Printer Friendly Version
08/09/12Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 9, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on October 16, 2012, to shareholders of record of Quest Diagnostics common stock on October 1, 2012. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and se... 
Printer Friendly Version
07/27/12Harvard and MIT Students Rally Boston to Join Global Guinness World Record Attempt on World Hepatitis Day
Team HBV Chapters in Boston and Quest Diagnostics Urge City Residents and Visitors to Come Out and Be Counted at 'See No Evil, Hear No Evil, Speak No Evil' Viral Hepatitis Awareness Event, Boston Common, Noon Tomorrow BOSTON, July 27, 2012 /PRNewswire/ -- Students at Harvard and Massachusetts Institute of Technology aren't the type to take the summer off. Those who comprise a group called Team HBV, while working well-earned and prized internships, are also dedicating their off... 
Printer Friendly Version
07/19/12Quest Diagnostics Reports Second Quarter 2012 Financial Results
-- Adjusted diluted EPS of $1.17, up 4.5% -- Reported diluted EPS of $1.11, up 8.8% -- Revenues of $1.9 billion, essentially unchanged from prior year -- Full year adjusted earnings guidance unchanged; revenue growth outlook lowered to 1.0% - 2.0% MADISON, N.J., July 19, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the second quarter ended June 30, 2012, adjust... 
Printer Friendly Version
07/17/12Vitamin D Supplementation May Not Reduce Cholesterol-Related Heart Disease Risk, New Study Finds
Analysis published in Circulation by researchers at Quest Diagnostics and Rockefeller University contradicts prior research suggesting optimal vitamin D levels may have a beneficial impact on heart health MADISON, N.J., July 17, 2012 /PRNewswire/ -- Raising vitamin D to optimal from deficient blood levels may not improve total cholesterol and other blood lipids, key markers of cardiovascular disease risk, according to a study published today in Circulation, a publication of the American Hea... 
Printer Friendly Version
06/28/12National Business Group on Health Honors Quest Diagnostics as Platinum-Level Best Employer for Healthy Lifestyles
HealthyQuest Program Recognized for Eighth Straight Year MADISON, N.J., June 28, 2012 /PRNewswire/ -- The National Business Group on Health (NBGH) has honored Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, with its 2012 Best Employer for Healthy Lifestyles Award. This is the fourth consecutive year Quest Diagnostics has earned Platinum distinction, the highest level award, for its commitment to improving the health of employees a... 
Printer Friendly Version
06/27/12Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
MADISON, N.J., June 27, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report second quarter 2012 results on Thursday, July 19, 2012 before the stock market opens. It will hold its quarterly conference call to discuss the results beginning at 8:00 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcast availab... 
Printer Friendly Version
06/15/12Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
MADISON, N.J., June 15, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Wells Fargo Securities 2012 Healthcare Conference in Boston.  The presentation is scheduled for Tuesday, June 19, 2012 at 9:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site: http... 
Printer Friendly Version
06/01/12Quest Diagnostics Launches New Molecular Test Panel for Enhanced Thyroid Cancer Detection
Results of a study of the test panel to be unveiled at the 2012 ASCO Annual Meeting on June 4; new test may reduce risk of surgical removal of healthy thyroids for some patients MADISON, N.J., June 1, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new molecular test panel designed to help physicians determine if a thyroid gland is cancerous and requires surgical removal. The test is believed... 
Printer Friendly Version
05/23/12Many Pregnant Women Not Screened For Chlamydia and Gonorrhea
Study by Quest Diagnostics of 1.3 million pregnant women also found that 16% of pregnant 16-year olds tested positive for chlamydia, higher than any other age group MADISON,  N.J., May 23, 2012 /PRNewswire/ -- Many women are not screened for chlamydia and gonorrhea infection during their pregnancy, and follow-up testing is not always performed as medically recommended for those who test positive for chlamydia, according to a study published online in the American Jou... 
Printer Friendly Version
05/17/12Quest Diagnostics Extends Endocrine Diagnostic Menu with New Congenital Adrenal Hyperplasia (CAH) Steroid Screening Panels
Features newborn screening panel that measures all 13 CAH-associated steroids by tandem mass spectrometry in a single analysis MADISON, N.J., May 17, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has extended its endocrine diagnostics menu with the introduction of four new tests panels for congenital adrenal hyperplasia (CAH), an endocrine disorder found in newborns, children and women. The p... 
Printer Friendly Version
05/16/12Quest Diagnostics Reminds Women to Make Their Health a Priority During National Women's Health Week
Company Distributes 10,000 Vouchers for Free Wellness Screenings in May in Support of American Cancer Society Choose You® Women's Health Movement MADISON, N.J., May 16, 2012 /PRNewswire/ -- This week, National Women's Health Week, Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, joins the American Cancer Society Choose You® movement and the U.S. Department of Health and Human Services' (HHS) Office on Women's Health (OWH) in remind... 
Printer Friendly Version
05/11/12Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on July 18, 2012, to shareholders of record of Quest Diagnostics common stock on July 3, 2012. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and services... 
Printer Friendly Version
05/01/12Quest Diagnostics Sponsors American Cancer Society Choose You® Women's Health Movement
Company Offers 10,000 Vouchers for Free Wellness Screenings as National Presenting Sponsor NEW YORK, May 1, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced its national presenting sponsorship of the American Cancer Society Choose You® movement, which encourages women nationwide to live well today and stay well tomorrow. In support of the Choose You movement and in recognition of National Women'... 
Printer Friendly Version
04/27/12Three in Five Americans Misuse Their Prescription Drugs, Finds National Study of Prescription Medication Lab Testing
Quest Diagnostics Health Trends(TM) analysis finds many women and men of all ages, income levels and health plan coverage use pain and other prescription medications contrary to clinician orders, potentially putting their health at risk MADISON, N.J., April 27, 2012 /PRNewswire via COMTEX/ --Results of a national study of nearly 76,000 laboratory tests for monitoring prescription drug use indicate that the majority of Americans tested misused their prescription drugs, including potentially ad... 
Printer Friendly Version
04/27/12Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
MADISON, N.J., April 27, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced it has begun an effort to assign a unique Patient Identifier - a secure 16 digit identification number - to every Quest Diagnostics patient. In what is believed to be the largest effort of its kind in the area of assigning health IDs, the company has assigned unique identifiers to approximately 80 million Quest Diagnostics... 
Printer Friendly Version
04/25/12Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrig's Disease)
The company's Athena Diagnostics business unit to unveil the new test at the American Academy of Neurology Annual Meeting this week in New Orleans MADISON, N.J. and WORCESTER, Mass., April 25, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new genetic testing service from its Athena Diagnostics business unit, a leader in neurology diagnostics, for amyotrophic lateral sclerosis (ALS),... 
Printer Friendly Version
04/18/12Quest Diagnostics Reports First Quarter 2012 Financial Results
-- Revenues of $1.9 billion, up 6.3% -- Adjusted diluted EPS of $1.07, up 7.0% -- Reported diluted EPS of $0.99 in 2012 compared to a loss of $0.33 per diluted share in 2011 -- Full year adjusted earnings outlook increased to $4.45 - $4.60 per diluted share MADISON, N.J., April 18, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the first quarter ended March 3... 
Printer Friendly Version
04/11/12Quest Diagnostics Names Steve Rusckowski as President and CEO
-- Daniel C. Stanzione, Ph.D. is appointed Non-Executive Chairman of the Board of Directors -- MADISON, N.J., April 11, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that Stephen H. Rusckowski will succeed Surya N. Mohapatra, Ph.D. as President and Chief Executive Officer, effective May 1, 2012. Dr. Mohapatra will remain in his role through April 30 to ensure a smooth leadership transition. Mr. Rusckowski will also become a member of the Board of Directors.... 
Printer Friendly Version
04/11/12FDA Clears the Quest Diagnostics Simplexa® C. difficile Molecular Test
Test eliminates nucleic-acid sample extraction, for faster results MADISON, N.J. and CYPRESS, Calif., April 11, 2012 /PRNewswire/ -- Quest Diagnostics  (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to its Simplexa C. difficile Universal Direct Test on the 3M™ Integrated Cycler.  The test, from the company's Focus Diagnostics business, is intended to ... 
Printer Friendly Version
04/09/12Institute for Health and Productivity Management Honors Quest Diagnostics
Company receives Level 1 Corporate Health and Productivity Award for its Commitment to Employee Health MADISON, N.J., April 9, 2012 /PRNewswire/ -- The Institute for Health and Productivity Management (IHPM) honored Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, with the Level 1 Corporate Health and Productivity Award earlier this month at its 12th annual conference in Orlando, Florida. "With its HealthyQuest employee wellnes... 
Printer Friendly Version
04/03/12Quest Diagnostics to Release First Quarter 2012 Financial Results
MADISON, N.J., April 3, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report first quarter 2012 results on Wednesday, April 18, 2012 before the stock market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcast available on Quest Diag... 
Printer Friendly Version
03/27/12Quest Diagnostics Supports 'Diabetes Alert Day'
Americans Encouraged to Use American Diabetes Association Diabetes Risk Test, and Take Action for Their Health MADISON, N.J., March 27, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today joins the American Diabetes Association (ADA) in recognizing the 24th annual Diabetes Alert Day. This one-day "wake-up call" encourages the public to take the Diabetes Risk Test to learn if they are at risk for developing T... 
Printer Friendly Version
03/22/12Redesigned Quest Diagnostics Website Features New Tools to Educate and Engage Healthcare Providers and Patients
MADISON, N.J., March 22, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has unveiled its redesigned corporate website at www.QuestDiagnostics.com. The site provides several new features, technologies and resources to help healthcare professionals and patients interact with the company online and access a broad span of information on diagnostic testing and health issues. The site features a new Test Center t... 
Printer Friendly Version
03/15/12Quest Diagnostics Launches First Molecular Test for Kidney Organ Transplant Rejection
Based on exclusive biomarker licenses with Beth Israel Deaconess Medical Center and Weill Cornell Medical College MADISON, N.J., March 15, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of the industry's first molecular blood test for identifying renal (kidney) organ-transplant rejection. The Renal Transplant Monitoring laboratory-developed test is designed to help physicians ... 
Printer Friendly Version
03/13/12Cocaine Positives Spike 33% After New Government Rule for Safety-Sensitive Workers
Amphetamines Positives Jump Nearly 26% After New Rule, Continuing Upward Trend, Shows Quest Diagnostics Drug Testing Index™ MADISON, N.J., March 13, 2012 /PRNewswire/ -- Safety-sensitive workers have been subject to more stringent government drug testing rules over the past year, and the crackdown may be paying off, according to annual Drug Testing Index™ data released today by Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. New d... 
Printer Friendly Version
03/07/12Quest Diagnostics to Speak at the 2012 Barclays Capital Global Healthcare Conference
MADISON, N.J., March 7, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 2012 Barclays Capital Global Healthcare Conference in Miami.  The presentation is scheduled for Wednesday, March 14, 2012 at 4:15 p.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site: h... 
Printer Friendly Version
02/28/12Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb. 28, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.17 per share, payable on April 17, 2012, to shareholders of record of Quest Diagnostics common stock on April 3, 2012. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and servic... 
Printer Friendly Version
02/28/12Quest Diagnostics to Speak at the 2012 RBC Capital Markets Healthcare Conference
MADISON, N.J., Feb. 28, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 2012 RBC Capital Markets Healthcare Conference in New York City.  The presentation is scheduled for Wednesday, February 29, 2012 at 10:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following... 
Printer Friendly Version
02/23/12Care360® EHR From Quest Diagnostics Honored by Black Book's 2012 Rankings and Capterra's Top 20 List
EHR is Ideal Solution for Small to Medium-Sized Physician Practices Across the Nation LAS VEGAS, Feb. 23, 2012 /PRNewswire/ -- The highly-acclaimed Care360® Electronic Health Record (EHR) solution from Quest Diagnostics (NYSE: DGX) has been honored by receiving the top spot in the Single Physician Practice and ePrescribing categories in Black Book's 2012 Rankings of Top EHR and Electronic Medical Record (EMR) Vendors. In addition, Care360 EHR was ranked eighth on Capterra's To... 
Printer Friendly Version
02/22/12Trinity Health to Improve Revenue Cycle Through ChartMaxx® Implementation
Enterprise-Wide Content Management Helps Organization to Realize Greater Efficiencies Throughout the Continuum of Care LAS VEGAS, Feb. 22, 2012 /PRNewswire/ -- Trinity Health of Novi, Michigan, the fourth-largest Catholic healthcare system in the country, operating 49 acute-care hospitals, 379 outpatient facilities and 26 long-term care facilities throughout seven states, has selected Quest Diagnostics' (NYSE: DGX) ChartMaxx® Enterprise Content Management (ECM) solution to provide its staff... 
Printer Friendly Version
02/21/12Quest Diagnostics Offers Industry-First 30-Day Ambulatory EHR Implementation Guarantee for Hospitals and IDNs
Care360® EHR Streamlines the Development of Hospital Physician Referral Networks LAS VEGAS, Feb. 21, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, launched today at HIMSS the industry's first 30-day electronic health record (EHR) implementation guarantee for hospitals looking to quickly enable bi-directional data exchange with their ambulatory physicians through its award winning Care360® EHR we... 
Printer Friendly Version
01/24/12Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
-- Revenues of $1.9 billion, up 3% -- Adjusted diluted EPS of $1.23, up 19%; reported diluted EPS of $1.19, up 23% -- Cash flow from operations of $338 million compared to $340 million in 2010 -- 2012 guidance before special items: Diluted EPS between $4.40 and $4.55; revenues to grow between 2% and 2.5% -- Board approves $1 billion share repurchase authorization MADISON, N.J., Jan. 24, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), ... 
Printer Friendly Version
01/24/12Quest Diagnostics Increases Share Repurchase Authority by $1 Billion
-- Increase brings current authorization to $1.1 billion -- MADISON, N.J., Jan. 24, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $1 billion. This action increases the current share repurchase authorization to $1.1 billion. During 2011, the company repurchased approximately 17  million shares of co... 
Printer Friendly Version
01/20/12Quest Diagnostics STRATIFY JCV(TM) First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Based on exclusive collaboration with Biogen Idec, the test is only available in the U.S. through Quest Diagnostics' Focus Diagnostics lab MADISON, N.J., Jan. 20, 2012 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV(TM) Antibody ELISA testing service. STRATIFY JCV is the first b... 
Printer Friendly Version
01/20/12Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
Based on exclusive collaboration with Biogen Idec, the test is only available in the U.S. through Quest Diagnostics' Focus Diagnostics lab MADISON, N.J., Jan. 20, 2012 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV™ Antibody ELISA testing service. STRATIFY JCV is the first blood test t... 
Printer Friendly Version
01/18/12Quest Diagnostics Launches National EHR Grant Program for Physicians
Program Offers Subsidies Equivalent to an 85 Percent Discount on Care360® EHR Physicians can receive a certified EHR solution for less than $100 per month MADISON, N.J., Jan. 18, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that, beginning January 23rd and throughout 2012, it is offering to eligible physician practices subsidies of 85 percent off the re... 
Printer Friendly Version
01/09/12ChartMaxx® Earns 2011 'Best in KLAS' for Healthcare Document Management and Imaging Software
Healthcare Professionals Honor MedPlus Enterprise-wide Electronic Patient Record System with Top Ranking for Eight of Last 10 Years CINCINNATI, Jan. 9, 2012 /PRNewswire/ -- MedPlus, the healthcare IT subsidiary of Quest Diagnostics (NYSE: DGX), announced today that its ChartMaxx® enterprise-wide electronic patient record system has been ranked the top healthcare Document Management and Imaging (DMI) software product, according to the 2011 Best in KLAS Awards: Software ... 
Printer Friendly Version
01/06/12Quest Diagnostics Completes Acquisition of S.E.D. Medical Laboratories
MADISON, N.J., Jan. 6, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the successful completion of its previously announced agreement with Lovelace Health System to acquire S.E.D. Medical Laboratories. Under the terms of the transaction, Quest Diagnostics has acquired the assets of S.E.D. Medical Laboratories and will manage in-patient labs for the four Lovelace ho... 
Printer Friendly Version
01/05/12Quest Diagnostics to Release Fourth Quarter and Full Year 2011 Financial Results
MADISON, N.J., Jan. 5, 2012 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it will report fourth quarter and full year 2011 results and provide financial guidance for 2012 on Tuesday, January 24, 2012 before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the confere... 
Printer Friendly Version
01/04/12One in Six Pregnant Women Tested Are Positive for Hypothyroidism
Study of half a million pregnant women in the United States finds 15.5% of those tested were positive for gestational hypothyroidism, much higher than prior estimates MADISON, N.J., Jan. 4, 2012 /PRNewswire/ -- As many as one in six pregnant women tested were positive for gestational hypothyroidism, or underactive thyroid during pregnancy, under new clinical guidelines for detecting the disorder, according to a study published in The Journal of Clinical Endocrinology & M... 
Printer Friendly Version
01/03/12S.E.D. Labs to be Acquired by Quest Diagnostics
--Transaction will provide innovation, resources and expanded access and connectivity for patients-- --Synergistic lab purchase to enable Quest Diagnostics to significantly increase its presence in New Mexico-- ALBUQUERQUE, N.M. and MADISON, N.J., Jan. 3, 2012 /PRNewswire/ -- S.E.D. Medical Laboratories will soon become part of Quest Diagnostics Incorporated (NYSE: DGX), the world leader in diagnostic testing, information and services, through a definitive ag... 
Printer Friendly Version
12/09/11Quest Diagnostics Care360™ Named Top e-Prescribing Platform by Black Book Rankings
- Care360™ Ranked #1 in Customer Experience and Satisfaction - More than 92 Percent of Care360™ Clients Are On Track for Meaningful Use MADISON, N.J., Dec. 9, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that Care360™, the company's electronic health platform, has been named the leading stand-alone e-Prescribing software system by Black Book Rankings, a leading sou... 
Printer Friendly Version
12/08/11One in Three First-Time Participants in Laboratory-Based Wellness Program Learn of High Risk for Chronic Disease, Quest Diagnostics Study Shows
Eighty-Nine Percent of Those at High Risk for Chronic Kidney Disease, 59 Percent of Those at High Risk for High Cholesterol, and 28 Percent of Those at High Risk for Diabetes First Learned of Health Condition through Lab-Based Wellness Program MADISON, N.J., Dec. 8, 2011 /PRNewswire/ -- One in three first-time participants in a company-sponsored, lab-based wellness program were not aware they were at high risk for a serious medical condition, according to an article publis... 
Printer Friendly Version
12/07/11Quest Diagnostics Adds Timothy M. Ring to Board of Directors
MADISON, N.J., Dec. 7, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors has elected Timothy M. Ring to serve as a director, effective immediately. Including Mr. Ring, the Board has nine members. Mr. Ring is Chairman and Chief Executive Officer of C. R. Bard, Inc., a leading multinational developer, manufacturer and marketer of innovative, life-e... 
Printer Friendly Version
12/06/11Quest Diagnostics Launches Simplexa™ Dengue Test in Brazil, First Commercial Molecular Test Approved for Nation's Public and Private Health Testing
Country's public health labs now evaluating the test's potential for aiding clinical management of the country's nearly one million Dengue fever cases MADISON, N.J. and CYPRESS, Calif., Dec. 6, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa™ Dengue molecular test kit developed by its Focus Diagnostics products business has been registered for distribution in Braz... 
Printer Friendly Version
11/15/11Quest Diagnostics CE Marks Simplexa(TM) Test for Cytomegalovirus for Sale in Europe
With the new Focus Diagnostics' Simplexa molecular test on the 3M(TM) Integrated Cycler, the company now offers one of the most comprehensive molecular transplant-testing menus in Europe MADISON, N.J. and CYPRESS, Calif., Nov. 15, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics business has CE marked its new Simplexa Cytomegalovirus (CMV) molecular test k... 
Printer Friendly Version
11/11/11Quest Diagnostics to Speak at the Lazard Capital Markets 8th Annual Healthcare Conference
MADISON, N.J., Nov. 11, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lazard Capital Markets 8th Annual Healthcare Conference in New York City.  The presentation is scheduled for Tuesday, November 15, 2011 at 11:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 outlook before future special items. The company expects re... 
Printer Friendly Version
11/08/11Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th
Company Applauds American Cancer Society for Working to Inform the Fight Against Cancer for Future Generations DENVER, Nov. 8, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics joined the American Cancer Society today to encourage Denver-area residents to participate in the American Cancer Society's historic Cancer Prevention Study - 3 (CPS-3). The Denver enrollment period for this national, longitudinal study is between November 8 and 19, 2011. The CPS-3 Study focuses on uncovering the lifes... 
Printer Friendly Version
11/01/11Quest Diagnostics Announces Launch of Simplexa(TM) Direct Test for Influenza and Respiratory Viruses in Europe
Focus Diagnostics product eliminates nucleic-acid sample extraction with proprietary technology, for faster testing CYPRESS, Calif. and MADISON, N.J., Nov. 1, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the CE mark and European availability of the Simplexa Flu A/B & RSV Direct test on the 3M(TM) Integrated Cycler. The new test, from the company's Focus Diagnostics ... 
Printer Friendly Version
10/25/11Quest Diagnostics Reports Third Quarter 2011 Financial Results
-- Revenues of $1.9 billion, up 2.2% -- Adjusted diluted EPS of $1.18, up 4%; reported diluted EPS of $1.08, down 4% -- Cash flow from operations of $338 million, up $8 million -- Quarterly dividend increased by 70% to $0.17 per share MADISON, N.J., Oct. 25, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that for the third quarter ended September 30, 2011, adjusted income from co... 
Printer Friendly Version
10/25/11Quest Diagnostics Increases Quarterly Cash Dividend
MADISON, N.J., Oct. 25, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors has increased the quarterly cash dividend to $0.17 per share, payable on January 24, 2012, to shareholders of record of Quest Diagnostics common stock on January 9, 2012. The dividend represents a 70% increase from the current $0.10 per share level. "This increase in our di... 
Printer Friendly Version
10/25/11Quest Diagnostics Initiates CEO Succession Process
Surya Mohapatra to Remain Chairman and CEO to Ensure Smooth Transition -- MADISON, N.J., Oct. 25, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced that its Board of Directors has begun the process of identifying a successor to Surya N. Mohapatra, Ph.D., President, Chairman and Chief Executive Officer. The Board of Directors has formed a search committee, engaged a leading executive recruitment firm and will consider both external and internal candida... 
Printer Friendly Version
10/13/11Quest Diagnostics to Release Third Quarter 2011 Financial Results
MADISON, N.J., Oct. 13, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report third quarter 2011 results on Tuesday, October 25, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Qu... 
Printer Friendly Version
10/11/11Hydrocodone and Oxycodones Lead U.S. General Workforce Positives, Outranked Only by Marijuana, According to Quest Diagnostics Drug Testing Index(TM)
Hydrocodone and oxycodones remain most detected prescription opiates in U.S. general workforce Random drug tests for hydrocodone and oxycodones find nearly double the positives than pre-employment screening MADISON, N.J., Oct. 11, 2011 /PRNewswire via COMTEX/ --American workers continue to use prescription opiates at relatively high levels, according to Drug Testing Index(TM) (DTI) data released today by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic t... 
Printer Friendly Version
09/27/11Quest Diagnostics Named Healthiest Employer in Philadelphia, Baltimore and Washington, D.C. Regions
Regional honors follow company's Platinum-Level 'Best Employer for Healthy Lifestyles' distinction from National Business Group on Health MADISON, N.J., Sept. 27, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services has been ranked as top healthy employer in the Philadelphia, Baltimore and Washington, D.C. regions. These honors follow the company's selection in May as a Platinum-level 'Best Employer for Heal... 
Printer Friendly Version
09/13/11New Rules Opening Access to Lab Test Results Will Empower Patients to Understand Their Health Better
MADISON, N.J., Sept. 13, 2011 /PRNewswire via COMTEX/ --New rules proposed by the U.S. Department of Health and Human Services (HHS) to expand the rights of Americans to access their personal health information will empower patients to understand their health condition better, according to Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostics testing, information and services. "Patient engagement in healthcare decision making is vital to promoting better health outcomes... 
Printer Friendly Version
09/09/11Quest Diagnostics Selected as Member of Dow Jones® Sustainability Index
Company Again Named to Both World and North American Indexes MADISON, N.J., Sept. 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it has again been selected to be part of the Dow Jones® Sustainability World Indexes and North America Indexes (DJSI World and DJSI North America). "Quest Diagnostics is proud to be included in the Dow Jones Sustainability Index," sa... 
Printer Friendly Version
09/08/11Quest Diagnostics to Speak at the Morgan Stanley Global Healthcare Conference
MADISON, N.J., Sept. 8, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York City. The presentation is scheduled for Tuesday, September 13, 2011 at 10:55 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the follow... 
Printer Friendly Version
09/02/11Hawaii, Arkansas and Oklahoma Lead the Nation for Methamphetamine Use in the Workforce, Reveals Quest Diagnostics Drug Testing Index(TM)
Five-year data suggest methamphetamine's national decline has halted and that the drug's stronghold may be moving eastward MADISON, N.J., Sept. 2, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today issued its annual report on U.S. worker drug use, the Quest Diagnostics Drug Testing Index(TM). The study includes its first state-by-state analysis of methamphetamine positives, based on mor... 
Printer Friendly Version
08/12/11Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 12, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on October 24, 2011, to shareholders of record of Quest Diagnostics common stock on October 7, 2011. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information ... 
Printer Friendly Version
07/25/11Quest Diagnostics to Unveil Extensions to its Women's Health and Personalized Medicine Test Offerings at the 2011 AACC Annual Meeting and Clinical Lab Expo
Athena Diagnostics' spinal muscular atrophy (SMA) testing menu is broadly available nationally to Quest Diagnostics' clients for the first time Quest Diagnostics will also present novel scientific research and host the "What's New in Laboratory Medicine?" scientific speaker series in booth 3130 MADISON, N.J., July 25, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced it will... 
Printer Friendly Version
07/20/11Quest Diagnostics Reports Second Quarter 2011 Financial Results
-- Revenues of $1.9 billion, up 1.5% -- Adjusted diluted EPS of $1.12, up 5%; reported diluted EPS of $1.02, down 5% -- Updated 2011 adjusted guidance before special items: Diluted EPS between $4.25 and $4.35; revenues to grow 1.5% -- New initiative to reduce cost structure by $500 million and position company for the future MADISON, N.J., July 20, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and ... 
Printer Friendly Version
07/14/11Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests
Genomic Vision's Molecular Combing genomic-analysis technique to provide basis for developing new clinical testing services for cancer, neurology and other diseases MADISON, N.J. and PARIS, July 14, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Genomic Vision, a biotechnology company dedicated to the development of molecular diagnostics, today announced a multi-year exclusive collaboration involv... 
Printer Friendly Version
07/06/11Quest Diagnostics to Release Second Quarter 2011 Financial Results
MADISON, N.J., July 6, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report second-quarter 2011 results on Wednesday, July 20, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Que... 
Printer Friendly Version
06/27/11Poll: One in Three Adults 60-70 Years of Age Screened for Colon Cancer Have Only Done So Once, Suggesting Failure to Follow Periodic Testing Guidelines
Poll also finds while most screened opt for colonoscopy, those who do not cite unpleasant bowel preparation and side effects as the chief reasons they prefer a different colon cancer test WASHINGTON, June 27, 2011 /PRNewswire via COMTEX/ -- Results from a nationwide research poll released today by the Colon Cancer Alliance and Quest Diagnostics (NYSE: DGX) suggest that one in three of men and women age 60-70 who have been screened for colon cancer have done so only once, suggesting a failure t... 
Printer Friendly Version
06/22/11Quest Diagnostics Gazelle® Mobile Health Platform Now Available for Android Smartphones
MADISON, N.J., June 22, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced a new version of Gazelle, the company's mobile health platform, which now features compatibility with the fast-growing Google Android® smartphone operating system. (Photo: http://photos.prnewswire.com/prnh/20110622/NY24398) Gazelle for Android is now available for download free of charge at Gazelleapp.com and in... 
Printer Friendly Version
06/16/11Nearly One in Three Men and Women Age 50 and Over Have Not Been Screened for Colon Cancer; One in Four Say their Healthcare Provider Didn't Recommend Screening
Poll respondents also report "too busy" and "fear" as reasons they haven't been screened, but most claim they would be screened if a blood test were available WASHINGTON, June 16, 2011 /PRNewswire via COMTEX/ --Results from a nationwide research poll released today by the Colon Cancer Alliance and Quest Diagnostics (NYSE: DGX) show that 31 percent of men and women age 50 years and over have never been screened for colon cancer by standard screening methods such as a colonoscopy, fecal occult ... 
Printer Friendly Version
06/09/11Quest Diagnostics Wins Gold Medical Design Excellence Award (MDEA) for Diagnostic Innovation
Focus Diagnostics Simplexa(TM) molecular test on the 3M(TM) Integrated Cycler Wins Highest MDEA Award for in vitro diagnostics MADISON, N.J., June 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Simplexa(TM) molecular diagnostic test on the 3M(TM) Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards ceremony yesterday i... 
Printer Friendly Version
06/03/11Quest Diagnostics to Speak at the Jefferies 2011 Global Healthcare Conference
MADISON, N.J., June 3, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies 2011 Global Healthcare Conference in New York City. The presentation is scheduled for Monday, June 6, 2011 at 8:30 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site:... 
Printer Friendly Version
05/25/11Men May Have Greater Allergy Risk Than Women, Suggests Largest Ever National Allergy Study
Quest Diagnostics Health Trends analysis raises possibility that men are underdiagnosed for allergies MADISON, N.J., May 25, 2011 /PRNewswire via COMTEX/ -- A study of nearly 14 million blood tests for aiding allergy diagnosis shows that men exhibited higher sensitivity to 11 common allergens than women when tested, contradicting other research suggesting women experience allergies more frequently than men. The study's findings raise the possibility that men have a higher risk for allergies t... 
Printer Friendly Version
05/24/11OVA1 Improves Ovarian Cancer Detection Over CA 125 Blood Test and Clinical Assessment
Second study in Obstetrics & Gynecology showcases OVA1's role in evaluating women with an ovarian mass MADISON, N.J. and AUSTIN, Texas, May 24, 2011 /PRNewswire via COMTEX/ -- A paper published in the June issue of Obstetrics & Gynecology demonstrated that adding OVA1 to a physician's preoperative assessment of a woman's ovarian mass would identify more ovarian cancers than a physician's preoperative assessment alone. The study is the second published online this month in the journal, ... 
Printer Friendly Version
05/24/11Quest Diagnostics Earns Platinum Honor as "Best Employer for Healthy Lifestyles" for Third Consecutive Year
National Business Group on Health Recognizes HealthyQuest Program for Seventh Straight Year WASHINGTON, and MADISON, N.J., May 24, 2011 /PRNewswire/ -- The National Business Group on Health (NBGH) has awarded its 2011 Best Employers for Healthy Lifestyles Platinum Award to Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. The 2011 award, in recognition of the company's HealthyQuest employee wellness initiative, marks the ... 
Printer Friendly Version
05/23/11Ragweed and Mold Lead Overall Upswing in Allergy Prevalence; Climate Change Suspected
Quest Diagnostics Health Trends analysis of nearly 14 million allergy tests ranks "30 Worst Big Cities for Ragweed" (Click here for ranking) MADISON, N.J., May 23, 2011 /PRNewswire via COMTEX/ -- Early results from the largest cross-sectional national allergy study ever conducted, to be released later this week, suggest that allergies have increased in America, but that most of the increase was due to two environmental allergens, ragweed and mold. The study, based on nearly 14 million test res... 
Printer Friendly Version
05/19/11Quest Diagnostics Finalizes Agreement to Settle California Lawsuit Related to Medi-Cal Billing
MADISON, N.J., May 19, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced it has finalized an agreement to settle a previously disclosed civil lawsuit, brought by a California competitor against a number of California clinical laboratories, in which the State of California intervened, for a payment of $241 million. The company had announced an agreement in principle to resolve the lawsuit on May 9, 2011. In the lawsuit, the plaintiffs alleged, among other t... 
Printer Friendly Version
05/17/11Quest Diagnostics Successfully Completes Acquisition of Celera
MADISON, N.J., May 17, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the successful completion of its acquisition of Celera Corporation (NASDAQ: CRA). The acquisition was completed by means of a short-form merger under Delaware law, under which a wholly owned subsidiary of Quest Diagnostics was merged with and into Celera, with Celera surviving the merger as a wholly owned ... 
Printer Friendly Version
05/17/11Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 17, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on July 19, 2011, to shareholders of record of Quest Diagnostics common stock on July 5, 2011. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and ser... 
Printer Friendly Version
05/17/11Food Allergies Common among Children and Linked to Environmental Allergies and Asthma Later in Life, Suggests Largest-Ever National Allergy Study
Quest Diagnostics Health Trends(TM) Report also finds economically disadvantaged children tested for allergies at later ages MADISON, N.J., May 17, 2011 /PRNewswire via COMTEX/ -- Early results from the largest cross-sectional national allergy study ever conducted, to be released later this month, demonstrate that food allergies commonly occur in infants and toddlers, while environmental allergies, such as to dust, ragweed and mold, are more common in older children and adults. The study, bas... 
Printer Friendly Version
05/12/11OVA1 Blood Test Detects Ovarian Cancer More Accurately Than Medically Accepted CA 125 Method for Evaluating Women with Ovarian Mass
Obstetrics & Gynecology study also considers OVA1's place in future surgical referral guidelines MADISON, N.J. and AUSTIN, Texas, May 12, 2011 /PRNewswire via COMTEX/ -- A study published online ahead of print in the June 2011 edition of Obstetrics & Gynecology demonstrated that American College of Obstetrics and Gynecology (ACOG) guidelines for determining the likelihood that an ovarian mass is cancerous prior to surgery would accurately identify more women with ovarian cancer if the... 
Printer Friendly Version
05/11/11Quest Diagnostics Announces Completion of Final Extension of the Subsequent Offering Period and Intent to Exercise Top-Up Option and Complete Merger
MADISON, N.J., May 11, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), announced today the completion of the final extension of the subsequent offering period with respect to Spark's cash tender offer for all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA). The final extension of the subsequent o... 
Printer Friendly Version
05/11/11Quest Diagnostics to Speak at the Bank of America Merrill Lynch 2011 Healthcare Conference
MADISON, N.J., May 11, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America Merrill Lynch 2011 Healthcare Conference in Las Vegas. The presentation is scheduled for Thursday, May 12, 2011 at 12:50 p.m. Eastern Time. During the conference, the company will reaffirm its adjusted 2011 outlook before future special items. The company ... 
Printer Friendly Version
05/09/11Quest Diagnostics Sponsors American Cancer Society's Choose You® Movement
National Sponsor of Society Initiative to Prevent Cancer-Related Deaths MADISON, N.J., May 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics, the world's leading provider of diagnostic testing, information and services (NYSE: DGX), today announced its national sponsorship of Choose You®, the American Cancer Society's movement that inspires women to stay well by putting their health first and making healthy lifestyle choices to help prevent cancer. According to the American Cancer Society, 1... 
Printer Friendly Version
05/09/11Quest Diagnostics Announces Final Extension of Subsequent Offering Period for Shares of Celera
Offer Concludes at 5 p.m. Tomorrow, Tuesday, May 10th MADISON, N.J., May 9, 2011 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), has extended the cash tender offer for all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA).  The expiration date of the subsequent offering period has been ext... 
Printer Friendly Version
05/09/11Quest Diagnostics Reaches Agreement in Principle to Settle California Lawsuit Related to Medi-Cal Billing
MADISON, N.J., May 9, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced it has reached an agreement in principle to settle a previously disclosed civil lawsuit, brought by a California competitor, in which the State of California intervened. In the lawsuit, the plaintiffs alleged, among other things, that the company did not comply with California's "comparable charge" regulations, resulting in overpayments for laboratory testing services by Medi-Cal, Cal... 
Printer Friendly Version
05/06/11Quest Diagnostics Care360 EHR Customer Successfully Completes Meaningful Use Attestation to Receive the Medicare EHR Incentive
MADISON, N.J., May 6, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics® (NYSE: DGX) today announced that Care360 user Paulo Andre, M.D., a neurologist in Framingham, MA, was the first Care360 EHR customer to successfully complete the attestation process for demonstrating Meaningful Use of an electronic health record with an ONC-ATCB certified complete EHR* in accordance with the Centers for Medicare and Medicaid Services (CMS) EHR incentive program. Dr. Andre was the 25th physician in the U... 
Printer Friendly Version
05/05/11Quest Diagnostics Launches Simplexa(TM) C. Difficile Universal Direct Test in Europe
First test from the Focus Diagnostics' Simplexa product line for the hospital-acquired infection (HAI) market MADISON, N.J. and CYPRESS, Calif., May 5, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability in Europe of the Simplexa C. difficile Universal Direct test on the 3M(TM) Integrated Cycler. The new CE marked in vitro diagnostic (IVD) Simplexa test enable... 
Printer Friendly Version
05/04/11Quest Diagnostics Announces Successful Tender Offer and Commencement of a Subsequent Offering Period for Shares of Celera
MADISON, N.J., May 4, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), successfully completed the cash tender offer for all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA), which expired at 5:00 p.m., New York City time, on Tuesday, May 3, 2011. Computershare Trust Company, N.A.,... 
Printer Friendly Version
05/03/11Quest Diagnostics Announces One Day Extension of Offer to Acquire Celera to 5pm Today
Over 52% of Fully-Diluted Shares Tendered to Date, Including Guaranteed Shares MADISON, N.J., May 3, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that Spark Acquisition Corporation, its wholly owned subsidiary ("Spark"), has extended the expiration of its tender offer to acquire all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA) for $8.00 per shar... 
Printer Friendly Version
05/03/11Quest Diagnostics to Speak at the Deutsche Bank 36th Annual Healthcare Conference
MADISON, N.J., May 3, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Deutsche Bank 36th Annual Healthcare Conference in Boston. The presentation is scheduled for Wednesday, May 4, 2011 at 10:40 a.m. Eastern Time. During the conference, the company will reaffirm its adjusted 2011 outlook before future special items. The company expects reven... 
Printer Friendly Version
04/28/11Quest Diagnostics CE Marks Simplexa(TM) Tests for Epstein Barr and BK Viruses for Sale in Europe
Focus Diagnostics' Simplexa molecular tests on the 3M(TM) Integrated Cycler aid in detecting infectious disease viruses for organ transplant and other immunocompromised patients MADISON, N.J., and CYPRESS, Calif., April 28, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that two new Simplexa-branded molecular test kits developed by its Focus Diagnostics business have been ... 
Printer Friendly Version
04/20/11Quest Diagnostics Reports First Quarter 2011 Financial Results
- Total revenues of $1.8 billion, up 1% - Adjusted diluted earnings per share of $1.00 - Reported diluted earnings per share of $0.86 MADISON, N.J., April 20, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2011, adjusted income from continuing operations was $164 million, or $1.00 per diluted share, compared to $182 million, or $0.99 ... 
Printer Friendly Version
04/18/11Quest Diagnostics Launches Hepatitis C Virus Therapy Test Based on IL28B Gene Variants
AccuType(R) IL28B test now available to physicians and for clinical trials research MADISON, N.J., April 18, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType(R) IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection. Quest Diagnostics is now offering the test to p... 
Printer Friendly Version
04/18/11Quest Diagnostics Extends Tender Offer for all Outstanding Shares of Celera Corporation to May 2, 2011
Enters into Memorandum of Understanding Providing for the Settlement of Merger Agreement Litigation MADISON, N.J., April 18, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostics testing, information and services, announced today that, in connection with the entry by it and Celera Corporation (NASDAQ: CRA) into a memorandum of understanding (the "MOU") providing for the settlement of previously consolidated purported class actio... 
Printer Friendly Version
04/13/11Quest Diagnostics Announces HSR Clearance for the Acquisition of Celera
MADISON, N.J., April 13, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, has expired in connection with the $8 per share all cash tender offer by its wholly-owned subsidiary, Spark Acquisition Corporation, to purchase all outstanding shares of common stock of Celera Corporation (NASDAQ: CRA). Expiration of the waiting period under the HSR Act satisfi... 
Printer Friendly Version
04/12/11Quest Diagnostics to Release First Quarter 2011 Financial Results
MADISON, N.J., April 12, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report first-quarter 2011 results on Wednesday, April 20, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Q... 
Printer Friendly Version
04/06/11Quest Diagnostics Honored for Diagnostic Innovation at 2011 Edison Awards
Simplexa(TM) molecular diagnostic test on the 3M(TM) Integrated Cycler wins bronze for best new product, science and medical diagnostic MADISON, N.J., April 6, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa(TM) molecular test on the 3M(TM) Integrated Cycler was honored with a bronze award for best new science and medical diagnostic product during the 2011... 
Printer Friendly Version
04/04/11Quest Diagnostics Completes Acquisition of Athena Diagnostics
Solidifies leadership in growing market for neurology diagnostics MADISON, N.J., April 4, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced it has completed its previously announced acquisition of Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurological disorders, from Thermo Fisher Scientific (NYSE: TMO). Athena Diagnostics will contin... 
Printer Friendly Version
03/28/11Quest Diagnostics Commences Tender Offer for Acquisition of Celera
MADISON, N.J., March 28, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today it has commenced a tender offer through its wholly owned subsidiary, Spark Acquisition Corporation, for all of the outstanding shares of common stock (the "Shares") of Celera Corporation (Nasdaq: CRA), one of the world's pioneers in genetic diagnostics discovery and development for $8.00 per share in cash... 
Printer Friendly Version
03/22/11Quest Diagnostics Launches National Electronic Health Records Awareness Tour Showcasing Care360 EHR
Small Practice Physicians Can Learn About the Benefits of EHR Adoption During 12-Week Care360 EHR Road Test Tour MADISON, N.J., March 22, 2011 /PRNewswire via COMTEX/ -- Later this month, Quest Diagnostics (NYSE: DGX) will demonstrate how physicians can benefit from $39 billion in federal incentives by utilizing Care360(TM) EHR. The 12-week, 10-city Care360 EHR Road Test tour was developed to help hospitals and physician practices across the nation experience first-hand the operational and fi... 
Printer Friendly Version
03/21/11Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., March 21, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $1,250,000,000 in aggregate principal amount of four series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and uncon... 
Printer Friendly Version
03/18/11Quest Diagnostics to Acquire Celera, Strengthening Position as World's Leading Innovator in Molecular Diagnostics and Development
-- Provides Immediate Access to Proprietary Genetic Tests and Pipeline of Biomarkers to Drive Sustainable Growth -- -- Berkeley HeartLab Brings Unique Esoteric Cardiovascular Test Offering and Specialized Sales Force -- -- Adds Leading Genetic IVD Products and Development Capability -- -- Transaction Valued at Approximately $344 Million, Net of Acquired Cash and Short-Term Investments -- MADISON, N.J. and ALAMEDA, Calif., March 18, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorpor... 
Printer Friendly Version
03/17/11New York State Approves the Quest Diagnostics ColoVantage(TM) Colorectal Cancer Blood Test
Test designed to promote colorectal cancer evaluation of the nearly 53 million patients in the U.S. who resist recommended screening MADISON, N.J., March 17, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company, today announced that its ColoVantage test has been approved by New York State's Department of Health for testing onsamples of patients in the state. It is believed to be the first molecular colorectal cancer detectio... 
Printer Friendly Version
03/14/11Quest Diagnostics to Speak at the Barclays Capital 2011 Global Healthcare Conference
MADISON, N.J., March 14, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Barclays Capital 2011 Global Healthcare Conference in Miami. The presentation is scheduled for Tuesday, March 15, 2011 at 9:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 guidance. Excluding the impact of the acquisition of Athena Diagno... 
Printer Friendly Version
03/04/11Quest Diagnostics Ranked Among FORTUNE Magazine's 'World's Most Admired Companies' for Fourth Consecutive Year
MADISON, N.J., March 4, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it has been included on FORTUNE magazine's "World's Most Admired Companies" list. Quest Diagnostics moved to second in the "Health Care" industry category of "Pharmacy and Other Services." The 2011 ranking is the fourth consecutive year that the company has been included on FORTUNE magazine's we... 
Printer Friendly Version
02/28/11Quest Diagnostics to Speak at the Citi 2011 Global Healthcare Conference
MADISON, N.J., Feb. 28, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Citi 2011 Global Healthcare Conference in New York City. The presentation is scheduled for Wednesday, March 2, 2011 at 11:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 guidance. The company expects revenues to grow approximately 1%, oper... 
Printer Friendly Version
02/24/11Quest Diagnostics to Acquire Athena Diagnostics, Establishing Leading Position in Rapidly Growing Neurology Testing Market
Addition of Premier Provider of Neurology Testing to Complement Quest Diagnostics' Leadership in Testing for Cancer, Infectious Disease and Cardiovascular Disease -- MADISON, N.J., Feb. 24, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has signed a definitive agreement to acquire Athena Diagnostics, an esoteric laboratory specializing in genetic testing for neurol... 
Printer Friendly Version
02/22/11Quest Diagnostics Care360(TM) Becomes First Certified, Commercially Available EHR to Include Direct Project Specifications
Enhancements to Care360(TM) EHR Provide Physicians with the Ability to Securely Share Patient Information Across Disparate Systems ORLANDO, Fla., Feb. 22, 2011 /PRNewswire via COMTEX/ -- HIMSS 2011 -- At HIMSS 2011 in Orlando, Florida, Quest Diagnostics (NYSE: DGX) announcedthe availability of the next release of its Care360(TM) Electronic Health Record (EHR) solution, which is the first certified, commercially available EHR to include the Direct Project specifications established under the c... 
Printer Friendly Version
02/16/11Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb. 16, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on April 19, 2011, to shareholders of record of Quest Diagnostics common stock on April 5, 2011. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and ... 
Printer Friendly Version
02/10/11Quest Diagnostics and Withings Announce Availability of Integrated WiFi Weight Tracking for the Gazelle Mobile Health Platform
MADISON, N.J., Feb. 10, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics and Withings announced that the Withings WiFi Body Scale, the world's first WiFi connected personal weight scale, can now automatically import body weight data directly into Gazelle(TM), the secure mobile health platform from Quest Diagnostics. With Gazelle, users can electronically receive their Quest Diagnostics laboratory results and manage their personal health information directly from their Apple(R) iPhone, BlackBer... 
Printer Friendly Version
02/02/11Quest Diagnostics to Speak at the UBS Global Healthcare Services Conference 2011
MADISON, N.J., Feb. 2, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the UBS Global Healthcare Services Conference 2011 in New York City. The presentation is scheduled for Tuesday, February 8, 2011 at 8:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2011 guidance. The company expects revenues to grow approximately 1... 
Printer Friendly Version
02/01/11Quest Diagnostics Announces Pricing in Offering of Common Stock by the Company's Largest Shareholder
MADISON, N.J., Feb. 1, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced the pricing of the previously announced secondary public offering of 15,377,600 shares of Quest Diagnostics common stock held by its largest stockholder, SB Holdings Capital Inc., an affiliate of GlaxoSmithKline plc ("GSK") at a price to the public of $56.25. Quest Diagnostics has not sold any shares of common stock in the offering and will not receive any of the proceeds from th... 
Printer Friendly Version
01/31/11/C O R R E C T I O N -- Quest Diagnostics Incorporated/
MADISON, N.J., Jan. 31, 2011 /PRNewswire via COMTEX/ --In the news release, Quest Diagnostics Announces Offering of Common Stock by the Company's Largest Stockholder, issued 31-Jan-2011 by Quest Diagnostics Incorporated over PR Newswire, we are advised by the company that the third paragraph should read, "Deutsche Bank Securities Inc. and J.P. Morgan Securities LLC are joint bookrunners for the offering" rather than, "Deutsche Bank Securities Inc. will act as lead manager for the offering, and J... 
Printer Friendly Version
01/31/11Quest Diagnostics Agrees to Repurchase 15.4 Million Shares From Largest Shareholder
MADISON, N.J., Jan. 31, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced that it had agreed to repurchase at a negotiated price 15.4 million shares of its common stock from its largest shareholder, an affiliate of GlaxoSmithKline plc (GSK). Subsequent to the transaction, GSK will no longer hold any shares of common stock of Quest Diagnostics. "Through this transaction, we are taking advantage of a unique opportunity to enhance shareholder value and d... 
Printer Friendly Version
01/31/11Quest Diagnostics Announces Offering of Common Stock by the Company's Largest Stockholder
MADISON, N.J., Jan. 31, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX) today announced the underwritten public offering of 15,377,600 shares of Quest Diagnostics common stock held by its largest stockholder, SB Holdings Capital Inc., an affiliate of GlaxoSmithKline plc ("GSK"). After giving effect tothe proposed offering andthe company's repurchase from GSK of15,377,551 shares of Quest Diagnostics common stock also announced today, it isexpected that GSK will no longer... 
Printer Friendly Version
01/25/11Quest Diagnostics Reports Fourth Quarter 2010 Financial Results; Provides Guidance for 2011
- Diluted EPS of $0.97, unchanged from 2009 - Revenues of $1.8 billion, 1.3% below 2009 - Cash flow from operations of $340 million - 2011 guidance before special items: Diluted EPS between $4.10 and $4.30; revenues to grow approximately 1% - Board approves $750 million share repurchase authorization, bringing total available to $1 billion MADISON, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing,... 
Printer Friendly Version
01/25/11Quest Diagnostics Increases Share Repurchase Authority by $750 Million
Increase brings current authorization to $1 billion -- MADISON, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $750 million. This action increases the current share repurchase authorization to $1 billion. During 2010, the company repurchased approximately 15 million shares of... 
Printer Friendly Version
01/25/11Oral Fluid Reveals More Heroin Use Than Previously Believed, According to Quest Diagnostics Drug Testing Index
MADISON, N.J., Jan. 25, 2011 /PRNewswire via COMTEX/ --Oral fluid has revealed approximately five times more heroin use in the general U.S. workforce than previously believed, according to new data today released by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. In the company's first special report on oral fluid testing with more than 320,000 oral-fluid samples from the general U.S. workforce from January to June 2010, d... 
Printer Friendly Version
01/13/11Quest Diagnostics to Release Fourth Quarter and Full Year 2010 Financial Results
MADISON, N.J., Jan. 13, 2011 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report fourth quarter and full year 2010 results and provide financial guidance for 2011 on Tuesday, January 25, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the confe... 
Printer Friendly Version
12/20/10Pregnant Women Are Not Screened Adequately for Gestational Diabetes, Obstetrics and Gynecology Study Finds
Study also finds nearly one in five women with gestational diabetesare not screened for diabetes postpartum MADISON, N.J., Dec. 20, 2010 /PRNewswire via COMTEX/ --Nearly one third of pregnant women are not being screened by a simple laboratory test for gestational diabetes mellitus (gestational diabetes), according to a study of more than 900,000 American women published online today in Obstetrics and Gynecology. The study, conducted by scientists at Quest Diagnostics (NYSE: DGX), suggests th... 
Printer Friendly Version
12/16/10Quest Diagnostics(R) Care360(TM) EHR Receives ONC-ATCB 2011/2012 Certification
MADISON, N.J., Dec. 16, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Care360(TM) Electronic Health Record (EHR), Version 2010.2, is 2011/2012 compliant and was certified as a Complete EHR on Wednesday, December 15, 2010, by the Certification Commission for eligible Health Information Technology (CCHIT(R)), an ONC-ATCB, in accordance with the applicable eligible provider certifi... 
Printer Friendly Version
12/02/10Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec. 2, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on January 25, 2011, to shareholders of record of Quest Diagnostics common stock on January 10, 2011. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, informatio... 
Printer Friendly Version
12/01/10FDA Clears Influenza and Respiratory Virus Test Kit from Quest Diagnostics' Focus Diagnostics Business
Simplexa(TM) is first molecular test kit that does not require additional testing to confirm flu A, flu B or respiratory syncytial virus (RSV) infection MADISON, N.J., and CYPRESS, Calif., Dec. 1, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Focus Diagnostics Simplexa Flu A/B & RSV te... 
Printer Friendly Version
11/23/10New Study Questions Value of Expanded Genetic Testing for Cystic Fibrosis
Eight-year study in Genetics in Medicine shows core mutation panel reliably detects carriers MADISON, N.J., Nov. 23, 2010 /PRNewswire via COMTEX/ --Testing for genetic mutations beyond those medically recommended is unlikely to prevent the birth of children with classic cystic fibrosis and may detect mutations causing only mild disease, according to a study published online in Genetics in Medicine, the official publication of the American College of Medical Genetics (ACMG).The findings raise ... 
Printer Friendly Version
11/16/10Quest Diagnostics to Speak at the Lazard Capital Markets 7th Annual Healthcare Conference
MADISON, N.J., Nov. 16, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lazard Capital Markets 7th Annual Healthcare Conference in New York City. The presentation is scheduled for Wednesday, November 17, 2010 at 8:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2010 guidance. The company expects revenues to be appr... 
Printer Friendly Version
10/28/10Quest Diagnostics Introduces Gazelle(TM) Secure Mobile Health Platform
- First Mobile Health Platform From A Diagnostic Testing Company - Empowers Patients To Actively Manage And Take Personal Accountability For Their Health - Direct Patient Access To Quest Diagnostics Lab Results In 33 States - A Gateway That Welcomes Third Party Application Developers MADISON, N.J., Oct 28, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today introduced Gazelle, a secure mobile heal... 
Printer Friendly Version
10/20/10Quest Diagnostics Reports Third Quarter 2010 Financial Results; Updates Guidance for 2010
- Diluted EPS of $1.13, 11% above 2009 - Revenues of $1.9 billion, 1.7% below 2009 - Cash flow from operations of $330 million - Full year guidance before special items: Diluted EPS between $3.95 and $4.00; revenues approximately 1.5% below prior year - Board authorizes new $250 million share repurchase program MADISON, N.J., Oct 20, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, anno... 
Printer Friendly Version
10/20/10Quest Diagnostics Increases Share Repurchase Authority By $250 Million
MADISON, N.J., Oct 20, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $250 million. During the first three quarters of 2010, the company repurchased approximately 15 million shares of common stock for $750 million, fully utilizing its previous authorization, which was granted in January, 2010. ... 
Printer Friendly Version
10/15/10American Medical Association To Offer Quest Diagnostics Care360(TM) EHR On Its New Online Physician Platform
Care360 EHR Offers Physicians Affordable Health Information Technology to Meet Clinical and Practice Needs and Help Demonstrate Meaningful Use MADISON, N.J., Oct 15, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics' (NYSE: DGX) healthcare information (IT) technology subsidiary MedPlus and the American Medical Association (AMA), the nation's largest physician organization, today announced they are partnering to expand the adoption of health information technology by offering Care360(TM) EHR, a... 
Printer Friendly Version
10/05/10Quest Diagnostics and HP Simplify Electronic Health Records for Physician Practices
Companies Offer Comprehensive EHR Solutions to Accelerate Adoption Including a Nationwide Tour to Educate Small Physician Practices MADISON, N.J., Oct 05, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics' (NYSE: DGX) health information technology subsidiary MedPlus and HP today announced they are partnering to facilitate and simplify electronic health record (EHR) adoption for physician practices nationwide. Quest Diagnostics' web-based Care360(TM) EHR software and services coupled with ... 
Printer Friendly Version
09/28/10Quest Diagnostics to Release Third Quarter 2010 Financial Results
MADISON, N.J., Sept 28, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report third quarter 2010 results on Wednesday, October 20, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on ... 
Printer Friendly Version
09/16/10U.S. Worker Use of Prescription Opiates Climbing, Shows Quest Diagnostics Drug Testing Index(TM)
Post-accident tests find opiates up to four times more than pre-employment tests MADISON, N.J., Sept 16, 2010 /PRNewswire via COMTEX/ --More American workers and job applicants are testing positive for prescription opiates, according to U.S. general workforce data in the 2009 annual Drug Testing Index(TM) (DTI) released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services.Results from more than 5.5 million urine dru... 
Printer Friendly Version
09/10/10Quest Diagnostics Marks Seventh Year on Dow Jones Sustainability Index
Company Named to Both World and North American Indexes MADISON, N.J., Sept 10, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it has again been selected to be part of the Dow Jones Sustainability World Indexes and North America Indexes (DJSI World and DJSI North America). The company is in its seventh year on the World Index (since 2004) and in its sixth on the North ... 
Printer Friendly Version
08/23/10Quest Diagnostics' Care360(TM) EHR Module Receives Preliminary ARRA IFR Stage 1 Certification
MADISON, N.J., Aug 23, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Care360(TM) Electronic Health Record (EHR), Version 2010.1, has been inspected by the Certification Commission for Health Information Technology (CCHIT(R)) and is a certified EHR Module, IFR Stage 1, achieving all 14 of the requirements applied for of the 24 requirements for Eligible Providers published by the ... 
Printer Friendly Version
08/11/10Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug 11, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on October 19, 2010, to shareholders of record of Quest Diagnostics common stock on October 4, 2010. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information ... 
Printer Friendly Version
07/28/10New York State Approves Quest Diagnostics' Fragile X Syndrome Test
XSense(R) is the first laboratory test that may be suitable for population-based screening for Fragile X Syndrome, the leading inherited cause of mental retardation MADISON, N.J., July 28, 2010 /PRNewswire via COMTEX/ --An accurate, faster testing option to identify female carriers and other patients with genetic abnormalities that cause Fragile X Syndrome is now available to physicians in all fifty states with the recent approval in New York. Fragile X is the leading cause of inherited menta... 
Printer Friendly Version
07/21/10Quest Diagnostics Reports Second Quarter 2010 Financial Results; Updates Guidance for 2010
- Diluted earnings per share of $1.07, 7% above 2009 - Revenues of $1.9 billion, 1.4% below 2009 - Full year EPS expected to be between $3.90 and $4.00; full year revenues expected to be approximately 1% below prior year MADISON, N.J., July 21, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2010, income from continuing operations incr... 
Printer Friendly Version
07/14/10Quest Diagnostics To Release Second Quarter 2010 Financial Results
MADISON, N.J., July 14, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report second quarter 2010 results on Wednesday, July 21, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Qu... 
Printer Friendly Version
06/14/10Quest Diagnostics Again Earns Platinum Honor As 'Best Employer For Healthy Lifestyles'
National Business Group on Health Recognizes HealthyQuest Program for Sixth Straight Year WASHINGTON, and MADISON, N.J., June 14, 2010 /PRNewswire via COMTEX/ --The National Business Group on Health (NBGH) has awarded its 2010 Best Employers for Healthy Lifestyles Platinum Award to Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. The 2010 award, in recognition of the company's HealthyQuest employee wellness initiative, m... 
Printer Friendly Version
06/09/10Quest Diagnostics to Speak at the William Blair & Company 30th Annual Growth Stock Conference
MADISON, N.J., June 9, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the William Blair & Company 30th Annual Growth Stock Conference in Chicago. The presentation is scheduled for Tuesday, June 15, 2010 at 10:10 a.m. Central Time. The presentation will be webcast live during the conference and will be available to registered investors on the... 
Printer Friendly Version
05/24/10First FDA Clearance of a 2009 H1N1 Test Given to Quest Diagnostics' Focus Diagnostics Business
Simplexa(TM) molecular RT-PCR test runs on the 3M Integrated Cycler MADISON, N.J., and CYPRESS, Calif., May 24, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has issued 510(k) clearance to the Simplexa(TM) Influenza A H1N1 (2009) test on the 3M(TM) Integrated Cycler. The Simplexa test, developed and manufactured by Quest Di... 
Printer Friendly Version
05/21/10ONC Recognizes New Mexico as First State to Successfully Obtain HIE Implementation Funds
Federal Funds and MedPlus Centergy Solution Accelerate New Mexico Health Information Collaborative's (NMHIC) Plan to Serve Two Million Patients Statewide ALBUQUERQUE, N.M., May 21, 2010 /PRNewswire via COMTEX/ --New Mexico is the first state to meet all requirements for strategic and operational planning as part of the American Recovery and Reinvestment Act (ARRA) state health information exchange (HIE) cooperative agreement program, according to the United States Office of the National Coord... 
Printer Friendly Version
05/06/10Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 6, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on July 20, 2010, to shareholders of record of Quest Diagnostics common stock on July 6, 2010. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and servic... 
Printer Friendly Version
04/29/10H1N1 Crowds Out Other Flu Viruses, Higher Positive Trends in Children Tested
The Quest Diagnostics Health Trends(TM) Report analyzes 195,000 H1N1 test results performed nationally since May 2009 MADISON, N.J., April 29, 2010 /PRNewswire via COMTEX/ --More than 99 percent of specimens tested for influenza were positive for H1N1 over approximately the past 11 months, according to a report released today from Quest Diagnostics Incorporated (NYSE: DGX). The Quest Diagnostics Health Trends(TM) Report suggests that H1N1 "crowded out" other influenza viruses to be the domina... 
Printer Friendly Version
04/21/10Quest Diagnostics Reports First Quarter 2010 Financial Results; Updates Guidance for 2010
- Diluted earnings per share of $0.89, and revenues of $1.8 billion, unchanged from 2009 - 2010 adjusted EPS guidance unchanged at between $4.10 and $4.30 - On a reported basis, 2010 EPS guidance is expected to be between $4.00 and $4.20 MADISON, N.J., April 21, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2010, income from continu... 
Printer Friendly Version
04/12/10Quest Diagnostics Moves Start of April 21 Financial Conference Call to 8 am ET
MADISON, N.J., April 12, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has moved the start of its quarterly conference call scheduled for Wednesday, April 21, to 8 a.m. ET. The company had previously scheduled the call to begin at 8:30 a.m. ET on that day. The company plans to report first-quarter 2010 financial results earlier that morning. The public may access... 
Printer Friendly Version
04/06/10Quest Diagnostics To Release First Quarter 2010 Financial Results
MADISON, N.J., April 6, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report first-quarter 2010 results on Wednesday, April 21, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Ques... 
Printer Friendly Version
04/01/10Quest Diagnostics Honored by CEO Roundtable on Cancer
Company Granted CEO Gold Standard(TM) Accreditation for Its Commitment to Employee Health and the Fight Against Cancer MADISON, N.J., April 1, 2010 /PRNewswire via COMTEX/ --Quest Diagnostics Incorporated (NYSE: DGX), the world's leader in cancer diagnostics, announced today that the company has received CEO Cancer Gold Standard accreditation(TM) from The CEO Roundtable on Cancer. This prestigious designation recognizes Quest Diagnostics for taking important actions to reduce the cancer risk ... 
Printer Friendly Version
03/17/10Health Discovery Corporation and Smart Personalized Medicine Form Agreement for Developing Laboratory Tests for Breast Cancer Therapy Selection with Quest Diagnostics
SAVANNAH, Ga. & MILFORD, Del., Mar 17, 2010 (BUSINESS WIRE) -- Health Discovery Corporation (OTCBB: HDVY) (HDC) and Smart Personalized Medicine, LLC (SPM) announced today that they have entered into development and related licensing agreements with Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. Under the agreements, Quest Diagnostics will develop new laboratory tests for aiding in the selection of breast cancer therapies.... 
Printer Friendly Version
03/16/10Quest Diagnostics To Speak at the Barclays Capital Global Healthcare Conference
MADISON, N.J., March 16, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Barclays Capital Global Healthcare Conference in Miami. The presentation is scheduled for Wednesday, March 24, 2010 at 9:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following site: ... 
Printer Friendly Version
03/09/10OVA1 Blood Test Now Available to Aid Pre-surgical Evaluation of Women for Ovarian Cancer
FDA-cleared test helps direct women to the most appropriate surgeon, promoting better outcomesMADISON, N.J. and FREMONT, Calif., March 9, 2010 /PRNewswire via COMTEX/ -- OVA1(TM), the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer, is now available nationally through Quest Diagnostics, Inc. (NYSE: DGX), the world's leading cancer diagnostics provider. With the availability of OVA1, physicians ... 
Printer Friendly Version
03/05/10Quest Diagnostics Ranked Among FORTUNE Magazine's 'World's Most Admired Companies' For Third Consecutive Year
Company also ranked among top 100 Best Corporate Citizens by Corporate Responsibility MagazineMADISON, N.J., March 5, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has been included on FORTUNE magazine's 2010 "World's Most Admired Companies" list. Quest Diagnostics ranked third in the "Health Care" industry category of "Pharmacy and Other Services." The 2010 ranking... 
Printer Friendly Version
03/04/10Quest Diagnostics and Surescripts to Pioneer Integrated Service Combining Lab and Prescription Information to Improve Patient Safety and Clinical Outcomes
ATLANTA, March 4, 2010 /PRNewswire via COMTEX/ -- Two of the nation's largest healthcare information networks, Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, and Surescripts(R), The Nation's E-Prescription Network(TM), today announced an agreement to pioneer the formation of an integrated service to make laboratory and prescription information broadly and easily accessible to physicians. The collaboration is designed to improve patien... 
Printer Friendly Version
03/01/10Quest Diagnostics to Speak at the RBC Capital Markets 2010 Healthcare Conference
MADISON, N.J., March 1, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the RBC Capital Markets 2010 Healthcare Conference in New York City. The presentation is scheduled for Wednesday, March 3, 2010 at 9:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2010 guidance for revenue growth of 3% to 4%, operating income to app... 
Printer Friendly Version
03/01/10Quest Diagnostics Unveils Care360(TM) EHR
--Company Empowers Physicians to Embrace Digital Healthcare, Connect with Peers, and Work Toward Meaningful Use One Step at a Time --90-Day Free Trial for Web-based Care360 EHR and Care360 ePrescribing Introduced at HIMSS10MADISON, N.J., March 1, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today introduced Care360(TM) EHR (Electronic Health Record), the next evolution of its innovative C... 
Printer Friendly Version
02/11/10Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb 11, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on April 20, 2010, to shareholders of record of Quest Diagnostics common stock on April 6, 2010. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information and ser... 
Printer Friendly Version
02/05/10Quest Diagnostics to Speak at the UBS Global Healthcare Services Conference
MADISON, N.J., Feb 05, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the UBS 2010 Global Healthcare Services Conference in New York City. The presentation is scheduled for Wednesday, February 10, 2010 at 9:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2010 guidance for revenue growth of 3% to 4%, operating income to... 
Printer Friendly Version
01/25/10Quest Diagnostics Reports Strong Performance for Fourth Quarter and Full Year 2009; Provides Guidance for 2010
- Fourth quarter diluted EPS grew 11% on revenue growth of 2.7%; cash from operations totaled $360 million - Full year diluted EPS grew 20% on revenue growth of 2.8%; cash from operations totaled $1 billion - 2010 EPS expected to be between $4.10 and $4.30 per diluted shareMADISON, N.J., Jan 25, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended Dece... 
Printer Friendly Version
01/25/10Quest Diagnostics Increases Share Repurchase Authority By $750 Million
MADISON, N.J., Jan 25, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $750 million. "The expansion of our share repurchase program reflects the company's financial strength and our ability to continue generating strong cash flows, and, in addition to continuing to invest in the growth of our bu... 
Printer Friendly Version
01/19/10Quest Diagnostics To Speak at the Jefferies 2010 Global Healthcare Services Conference
MADISON, N.J., Jan 19, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies 2010 Global Healthcare Services Conference in New York City. The presentation is scheduled for Tuesday, January 26, 2010 at 9:30 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the fol... 
Printer Friendly Version
01/11/10Quest Diagnostics Introduces Molecular Blood Test for Aiding Colorectal Cancer Detection
MADISON, N.J., Jan 11, 2010 /PRNewswire via COMTEX/ -- A new blood test that identifies changes in DNA associated with colorectal cancer is now available in the U.S. through Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company. The test is designed to aid the detection of colorectal cancer, the third leading cause of cancer-related deaths. The new test is based on DNA methylation of the Septin9 gene, a proprietary biomarker associated with colorectal cance... 
Printer Friendly Version
01/08/10Quest Diagnostics To Release Fourth Quarter and Full Year 2009 Financial Results
MADISON, N.J., Jan 08, 2010 /PRNewswire via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report fourth-quarter and full year 2009 results and provide financial guidance for 2010 on Monday, January 25, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conferenc... 
Printer Friendly Version
12/18/09End of H1N1 'Second Wave' in Sight in the U.S., According to Quest Diagnostics
Quest Diagnostics Health Trends(TM) Report shows 75 percent decline in rates of 2009 H1N1 influenza virus testing, but H1N1 is still the predominant influenza strain infecting AmericansMADISON, N.J., Dec 18, 2009 /PRNewswire-FirstCall via COMTEX/ -- Rates of 2009 H1N1 influenza virus testing in the U.S. have declined more than 75 percent since their peak in late October, suggesting that the "second wave" of virus infection that sickened tens of millions of Americans since it began four months ag... 
Printer Friendly Version
12/09/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec 09, 2009 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend of $0.10 per share, payable on January 22, 2010, to shareholders of record of Quest Diagnostics common stock on January 7, 2010. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, inform... 
Printer Friendly Version
12/03/09Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition
Research to expand Leumeta(TM) line of blood plasma diagnostics; Scientists also describe technique for predicting response to Heparin surrogate MADISON, N.J., Dec. 3 /PRNewswire-FirstCall/ -- A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics (NYSE: DGX) will present duri... 
Printer Friendly Version
11/24/09Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference
MADISON, N.J., Nov. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 21st Annual Piper Jaffray Healthcare Conference in New York City. The presentation is scheduled for Wednesday, December 2, 2009 at 9:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operating inco... 
Printer Friendly Version
11/20/09Quest Diagnostics Announces Final Tender Offer Results
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 and any and all of its 7.50% Senior Notes due 2011 (collectively, the "Notes"). Additional terms and conditions of the Tender Offer are set forth in... 
Printer Friendly Version
11/20/09New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services, reveal that drug testing of hair specimens from employees and job applicants in the general U.S. workforce has tracked sharp downward trends in cocaine and methamphetamine use from 2005 to the first half of 2009 that mirror similar drops shown by urine testing. Data in the Quest Diagnostics D... 
Printer Friendly Version
11/20/09H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics
MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Rates of infection by the 2009 H1N1 influenza virus may have peaked in late October, but the pandemic flu virus continues to be a potential source of illness in all age groups, including the elderly, according to a new report by Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services. In its most recent Quest Diagnostics Health Trends(TM) Report "Testing for H1N1 in America," ... 
Printer Friendly Version
11/18/092009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name
Simplexa(TM) molecular RT-PCR test runs on the 3M Integrated Cycler; employs RT-PCR technologies comparable to 2009 H1N1 flu test used by World Health Organization MADISON, N.J., Nov. 18 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the Simplexa Influenza A H1N1 (2009) test developed by its Focus Diagnostics business has been CE marked and is now available as a test k... 
Printer Friendly Version
11/17/09Quest Diagnostics Announces Pricing of Tender Offer for Any and All of Certain of its Outstanding Notes
MADISON, N.J., Nov. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the determination of the pricing for its previously announced cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 (the "2010 Notes") and any and all of its 7.50% Senior Notes due 2011 (the "2011 Notes" and, together with the 2010 Notes, the "Note... 
Printer Friendly Version
11/13/09Quest Diagnostics to Speak at the Lazard Capital Markets 6th Annual Healthcare Conference
MADISON, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lazard Capital Markets 6th Annual Healthcare Conference in New York City. The presentation is scheduled for Tuesday, November 17, 2009 at 10:55 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operatin... 
Printer Friendly Version
11/12/09Quest Diagnostics Commences Cash Tender Offer for Any and All of Certain of its Outstanding Notes
MADISON, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has commenced a cash tender offer (the "Tender Offer") to purchase any and all of its 5.125% Senior Notes due 2010 (the "2010 Notes") and any and all of its 7.50% Senior Notes due 2011 (the "2011 Notes" and, together with the 2010 Notes, the "Notes"). Additional terms and conditions of ... 
Printer Friendly Version
11/12/09Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
MADISON, N.J., Nov. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (the "Company") (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it intends to offer $750,000,000 in aggregate principal amount in two series of senior notes in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and unconditionall... 
Printer Friendly Version
11/02/09Quest Diagnostics To Speak At The Oppenheimer 20th Annual Healthcare Conference
MADISON, N.J., Nov. 2 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Oppenheimer 20th Annual Healthcare Conference in New York City. The presentation is scheduled for Wednesday, November 4, 2009 at 11:25 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth to approximate 3%, operatin... 
Printer Friendly Version
11/02/09New ChartMaxx(R) V5.5 with Recovery Audit Contractor (RAC) Manager Helps Hospitals Handle RAC Audit Requests
CINCINNATI, Nov. 2 /PRNewswire-FirstCall/ -- MedPlus®, the healthcare information technology subsidiary of Quest Diagnostics® Incorporated (NYSE: DGX), today announced the release of ChartMaxx® V5.5, an upgrade to its industry-leading ChartMaxx document management and imaging solution. With the new optional RAC Manager, ChartMaxx V5.5 helps health care providers tie together electronic forms, discrete data, color coded timers and e-mail alerts, dashboard reports, and release of infor... 
Printer Friendly Version
10/27/09New Mexico Health Information Collaborative (NMHIC) Appointed as State's Official Health Information Exchange (HIE)
ALBUQUERQUE, N.M., Oct. 27 /PRNewswire-FirstCall/ -- Maggie Gunter, PhD, president of the New Mexico Health Information Collaborative (NMHIC), announced today that the organization has been appointed as the state's official health information exchange (HIE) by New Mexico Governor Bill Richardson. NMHIC will create the health information exchange infrastructure to connect New Mexico's health care providers through a contract with its technology partner, MedPlus, the healthcare info... 
Printer Friendly Version
10/26/09MedPlus Maintains Top Ranking in KLAS Industry Report
MADISON, N.J., Oct. 26 /PRNewswire-FirstCall/ -- MedPlus, the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), announced today that it has been recognized as the health care industry's number one Document Management & Imaging (DMI) vendor for its ChartMaxx® enterprise-wide electronic patient record system in the KLAS (1) Enterprise DMI: Finding the Right Stepping-Stone to Full EMR report issued on October 2, 2009 (www.KLASresearch.com). Char... 
Printer Friendly Version
10/22/09Quest Diagnostics Health Trends (TM) Report on 2009 H1N1 Influenza
Click here for the full report, including charts and tables - In 2009, the H1N1 influenza A virus emerged as the first influenza pandemic in forty years. As the leading diagnostic testing company in the U.S. - and the only provider of two commercial tests authorized by the FDA for emergency use* - Quest Diagnostics is uniquely positioned to provide insights into the behavior of this new pandemic virus and its impact on Americans. In our latest Quest Diagnostics Health TrendsTM Report, we ... 
Printer Friendly Version
10/20/09Quest Diagnostics Reports Strong Performance in Third Quarter 2009
- Total revenues of $1.9 billion, up 3.9% - Diluted earnings of $1.02 per share, up 26% - Cash flow from operations of $374 million, up 14% - 2009 EPS outlook increased to a range of $3.80 to $3.85 MADISON, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2009, income from continuing operations rose to $192 million, or $... 
Printer Friendly Version
10/16/09FDA Issues Another Emergency Use Authorization for Commercial H1N1 Flu Test to Quest Diagnostics' Focus Diagnostics
MADISON, N.J., Oct. 16 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today issued a second emergency use authorization (EUA) to Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics Incorporated (NYSE: DGX), for its 2009 H1N1 influenza virus test. With the EUA, Focus Diagnostics is the only company in the U.S. to offer test kits for detecting the pandemic 2009 H1N1 virus that the FDA has authorized for emergency use by CLIA h... 
Printer Friendly Version
10/07/09Quest Diagnostics Brings Genetic Testing for Plavix(R) Response to Coronary Stent Patients at Scripps Health
First saliva-based cardiovascular disease test from Quest Diagnostics identifies gene variants implicated in potentially lethal reaction to popular anti-clotting drug MADISON, N.J., Oct. 7 /PRNewswire/ -- DNA testing for gene variants that can increase the risk of major coronary events in certain patients taking the anti-clotting drug Plavix® (clopidogrel bisulfate) is now being performed by Quest Diagnostics (NYSE: DGX) for Scripps Health patients electing to undergo coronary stent pro... 
Printer Friendly Version
10/06/09Quest Diagnostics to Release Third Quarter Financial Results on October 20, 2009
MADISON, N.J., Oct. 6 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its third quarter results will be made public on Tuesday, October 20, before the market opens. The company will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio w... 
Printer Friendly Version
10/05/09Methodist Hospital Adopts New Technology Solutions to Improve Care for California Patients and Reduce Operating Costs
MedPlus Centergy(R) Clinical Portal and ChartMaxx(R) Enable Streamlined Chart Completion Online MADISON, N.J., Oct. 5 /PRNewswire-FirstCall/ -- Methodist Hospital of Arcadia, California, has launched an integrated deployment of innovative health care information technology (HIT) solutions designed to help improve the quality of patient care and deliver operational efficiencies. MedPlus®, the health care information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), pro... 
Printer Friendly Version
09/23/09Quest Diagnostics Empowers the Nation's Physicians to Immediately Embrace ePrescribing
Company to Enable All Care360(TM) Labs & Meds Users to Use ePrescribing Feature; Invites All U.S. Physicians to Use Care360 ePrescribing Risk Free for Six Months MADISON, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX) today announced plans to make it easy for every physician in the United States to quickly embrace digital healthcare technology with a six-month, risk-free trial of its Care360(TM) ePrescribing service. For physicians currently using its Care360 Labs & ... 
Printer Friendly Version
09/11/09U.S. Food and Drug Administration Clears Vermillion's OVA1(TM) Test to Determine Likelihood of Ovarian Cancer in Women with Pelvic Mass
MADISON, N.J. and FREMONT, Calif., Sept. 11 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malig... 
Printer Friendly Version
09/11/09Quest Diagnostics To Speak at the Bank of America Merrill Lynch Global Healthcare Conference
MADISON, N.J., Sept. 11 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America Merrill Lynch Global Healthcare Conference in London, United Kingdom. The presentation is scheduled for Tuesday, September 15, 2009 at 9:50 a.m. Greenwich Mean Time, 5:50 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance fo... 
Printer Friendly Version
09/04/09Quest Diagnostics Marks Sixth Year on Dow Jones Sustainability Index
MADISON, N.J., Sept. 4 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it was again selected to be part of the Dow Jones Sustainability World Indexes and North America Indexes (DJSI World and DJSI North America). The company is in its sixth year on the World Index (since 2004) and in its fifth on the North American Index (since 2005). According to Sustainabl... 
Printer Friendly Version
08/20/09Focus Diagnostics Launches 2009 H1N1 Flu Test Kit to Commercial Laboratories in the U.S.
First test for detecting the new virus to be authorized by FDA for use by CLIA high-complexity labs during pandemic emergency CYPRESS, Calif., Aug. 20 /PRNewswire-FirstCall/ -- Focus Diagnostics, the infectious disease diagnostics business of Quest Diagnostics Incorporated (NYSE: DGX), today announced that its Influenza A H1N1 (2009) Real Time RT-PCR test is now available as a test kit for use by "high complexity" clinical laboratories in the U.S. The test quali... 
Printer Friendly Version
08/12/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on October 19, 2009, to shareholders of record on October 2, 2009. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, info... 
Printer Friendly Version
07/24/09FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business
MADISON, N.J., July 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that the U.S. Food and Drug Administration (FDA) has granted an emergency use authorization to the company's Focus Diagnostics business for its test for detecting the 2009 H1N1 influenza virus (the "pandemic flu virus"), a strain of influenza A virus initially referred to as the swine flu virus. T... 
Printer Friendly Version
07/21/09Quest Diagnostics Reports Strong Performance in Second Quarter 2009
Total revenues of $1.9 billion, up 3.5%; Diluted earnings of $1.00 per share, up 20%; 2009 EPS outlook increased to between $3.70 and $3.80 MADISON, N.J., July 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2009, income from continuing operations rose to $188 million, or $1.00 pe... 
Printer Friendly Version
07/20/09Quest Diagnostics MedPlus Subsidiary Enables New York Clinical Information Exchange (NYCLIX) to Share Meaningful Data and Enhance Patient Care
Patient-Based Record Improves Quality, Safety and Efficiency MADISON, N.J., July 20 /PRNewswire-FirstCall/ -- MedPlus, the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that NYCLIX is now sharing key patient data electronically among ten unaffiliated healthcare organizations across New York City using the company's Centergy(TM) suite of integrated health information exchange (HIE) solutions. NYCLIX partner hospital... 
Printer Friendly Version
07/09/09Quest Diagnostics To Release Second Quarter Financial Results
MADISON, N.J., July 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its second quarter results will be made public on Tuesday, July 21, before the market opens. The company will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio... 
Printer Friendly Version
06/24/09Quest Diagnostics Earns Platinum Honor As 'Best Employer For Healthy Lifestyles'
National Business Group on Health Recognizes HealthyQuest Program for Fifth Consecutive Year MADISON, N.J., June 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that the National Business Group on Health (NBGH) has awarded its 2009 Best Employers for Healthy Lifestyles Platinum Award to the company for its HealthyQuest employee wellness program. The Platinum Award... 
Printer Friendly Version
06/22/09Quest Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems
Agreement with Medical Automation Systems, Inc. Will Add RALS(R)-Plus Module to Company's Hemoglobin and Glucose Handheld Devices MADISON, N.J., June 22 /PRNewswire-FirstCall/ -- HemoCue Inc., the U.S. point-of-care testing distribution subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has signed an agreement with Medical Automation Systems, Inc. (MAS) for the development of a RALS(R)-Plus module for the HemoCue 201 DM analyzer whole blood systems fo... 
Printer Friendly Version
06/17/09Quest Diagnostics Announces Final Tender Offer Results
MADISON, N.J., June 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the final results for its previously announced cash tender offer to purchase up to $200 million total aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender offer are describe... 
Printer Friendly Version
06/15/09Quest Diagnostics to Speak at the Jefferies 3rd Annual Healthcare Conference
MADISON, N.J., June 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies 3rd Annual Healthcare Conference in New York City on Thursday, June 18, 2009. The Quest Diagnostics presentation is scheduled to begin at 11:45 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registere... 
Printer Friendly Version
06/12/09New Test from Quest Diagnostics Helps Physicians Choose HIV Antiretroviral Therapy in Patients with History of Drug Resistance
Faster reporting aids physicians in identifying HIV mutations that can inhibit effectiveness of newest class of antiretroviral therapy MADISON, N.J., June 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced the availability of a new laboratory developed test designed to help physicians determine whether a patient with a history of HIV drug resistance will respond to th... 
Printer Friendly Version
06/12/09Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., June 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today the determination of the pricing for its previously announced cash tender offer to purchase up to $200 million total aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender off... 
Printer Friendly Version
06/08/09Study Finds Noninvasive Blood Test for Liver Fibrosis May Alleviate Need for Liver Biopsies for Some Patients with Chronic Hepatitis C
MADISON, N.J., June 8, 2009 /PRNewswire-FirstCall via COMTEX/ -- A study in the June issue of Clinical Gastroenterology and Hepatology, published by Elsevier, demonstrates that the Hepascore(TM) liver fibrosis blood-serum test panel may help physicians more accurately diagnose and stage liver fibrosis in patients with chronic hepatitis C (HCV), potentially alleviating the need for liver biopsy, the standard of care for staging fibrosis, in a particular subset of patients. The Hepascore test pane... 
Printer Friendly Version
06/08/09Quest Diagnostics to Speak at the William Blair & Company 29th Annual Growth Stock Conference
MADISON, N.J., June 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the William Blair & Company 29th Annual Growth Stock Conference in Chicago on Tuesday, June 9, 2009. The Quest Diagnostics presentation is scheduled to begin at 8:10 a.m. Central Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth ... 
Printer Friendly Version
06/04/09Health Care Finance to Implement District's First Medicaid 'Patient Data Hub' Using MedPlus Technology
Health Information Exchange for Medicaid Beneficiaries, Powered by MedPlus Centergy(TM) Solutions, will Connect Physicians, Hospitals and Clinics to Accelerate Access to Patient Information and Better Health Outcomes WASHINGTON, and MADISON, N.J., June 4 /PRNewswire-FirstCall/ -- The Department of Health Care Finance, DHCF, the District's Medicaid agency, announced the selection of MedPlus, the health information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), ... 
Printer Friendly Version
06/03/09Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., June 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that, as of 5:00 p.m., New York City time, on June 2, 2009 (the "Early Tender Date"), the following principal amounts of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes") have been validly tendered and not validly withdrawn in connection with its previously ann... 
Printer Friendly Version
06/03/09Quest Diagnostics India Recognized as Laureate by the Computerworld Honors Program
Quest4Health.com Lauded in Healthcare Category for 'Visionary Application of Information Technology to Promote Positive Social and Economic Progress' MADISON, N.J., June 3 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its subsidiary Quest Diagnostics India Pvt. Ltd. has been recognized as a Laureate by the International Data Group's (IDG) Computerworld Honors Program. The a... 
Printer Friendly Version
06/02/09Quest Diagnostics HemoCue AB Subsidiary to Add Avie(TM) Hemoglobin A1c to Diabetes Point-of-Care Test Suite
Agreement to Distribute MEC HbA1c Test To Provide Physicians in U.S. and Europe With Fast, Accurate Near-Patient Test for Diabetes Monitoring MADISON, N.J., June 2 /PRNewswire-FirstCall/ -- HemoCue AB, an international company in the field of point-of-care testing and a subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has signed an agreement with MEC Dynamics Corp (MEC) for the exclusive distribution of the Avie(TM) A1c point-of-care test in the Uni... 
Printer Friendly Version
06/01/09Quest Diagnostics Introduces First Comprehensive Laboratory Test To Analyze KRAS, NRAS, and BRAF Gene Mutations in Reflex Testing Service
EGFR Pathway Test analyzes in sequential reflex fashion more mutations potentially inhibiting anti-EGFR therapy response in metastatic colorectal cancer patients MADISON, N.J., June 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading cancer diagnostics company, today launched the EGFR Pathway test (KRAS with reflex to NRAS, BRAF), the first laboratory-developed test from a national commercial reference laboratory for comprehensively identify... 
Printer Friendly Version
05/28/09Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 29 through June 2 in Orlando, FL. Quest Diagnostics Incorporated (NYSE: DGX) is the world's leading provider of diagnostic testing, informatio... 
Printer Friendly Version
05/19/09Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., May 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it has commenced a cash tender offer to purchase up to $200 million aggregate principal amount (the "Tender Cap") of its 5.125% Senior Notes due 2010 and 7.50% Senior Notes due 2011 (collectively, the "Notes"). The terms and conditions of the tender offer are described in the Offer to Purchase date... 
Printer Friendly Version
05/15/09Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online
MADISON, N.J., May 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX) announced today that it will enable patients and their physicians to share diagnostic laboratory test results, using Microsoft HealthVault(TM). The connection will enable physicians who use Quest Diagnostics' Care360(TM) patient-centric physician portal to securely transfer, at a patient's request, diagnostic laboratory test results in a HIPAA-compliant format into the patient's protected account... 
Printer Friendly Version
05/15/09Quest Diagnostics to Speak at the Deutsche Bank 34th Annual Healthcare Conference
MADISON, N.J., May 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Deutsche Bank 34th Annual Healthcare Conference in Boston on Tuesday, May 19, 2009. The Quest Diagnostics presentation is scheduled to begin at 11:30 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth of approxima... 
Printer Friendly Version
05/14/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on July 20, 2009, to shareholders of record on July 6, 2009. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, information ... 
Printer Friendly Version
05/11/09Quest Diagnostics Introduces First Commercial Laboratory Test for Identifying the H1N1 Swine Flu Virus
Real-time PCR test validated using clinical specimens confirmed positive for Influenza A H1N1 Swine-origin flu virus MADISON, N.J., May 11 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Focus Diagnostics infectious disease reference laboratory has introduced a laboratory-developed real-time polymerase chain reaction (PCR) test to aid in identifying Influe... 
Printer Friendly Version
05/08/09Quest Diagnostics Announces Annual Shareholders Meeting Webcast
MADISON, N.J., May 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, will conduct its annual meeting of shareholders on Thursday, May 14th at 10:30 am ET. An audio webcast will be accessible through the Investor Relations section of the company Web site at www.QuestDiagnostics.com/investor. For those unable to listen to the live broadcast, a replay will be available on the Web site... 
Printer Friendly Version
05/07/09Quest Diagnostics to Speak at the Bank of America and Merrill Lynch 2009 Healthcare Conference
MADISON, N.J., May 7 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America and Merrill Lynch 2009 Healthcare Conference in New York City on Tuesday, May 12, 2009. The Quest Diagnostics presentation is scheduled to begin at 1:20 p.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue... 
Printer Friendly Version
05/06/09Cocaine Use Among U.S. Workers Declines Sharply in 2008, According to Quest Diagnostics Drug Testing Index(TM)
Methamphetamine Use Drops While Amphetamine Use Continues to Rise Random Drug Testing Programs May Deter Use, Data Show MADISON, N.J., May 6 /PRNewswire/ -- Cocaine use among U.S. employees and job applicants in the general U.S. workforce declined sharply in 2008, according to the annual Quest Diagnostics Drug Testing Index(TM) (DTI), based on 5.7 million urine drug tests performed last year by Quest Diagnostics (NYSE: DGX), the nation's leading provider of drug testing se... 
Printer Friendly Version
04/27/09Quest Diagnostics Discovers New Genetic Mutations Affecting Cystic Fibrosis Screening
Company's Scientists also Enhance Industry Standards for Quality Screening in Three Articles Published in The Journal of Molecular Diagnostics MADISON, N.J., April 27 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists provide new insights into genetic factors affecting the accuracy and quality of Cystic Fibrosis (CF) carrier and newborn screening in three separate articles published in the May 2009 issue of The Journal of Molecular Diagnostics. Quest Diagnostics Incorporated (N... 
Printer Friendly Version
04/21/09Quest Diagnostics Reports Strong Earnings Growth In First Quarter 2009
Diluted earnings per share of $0.89, up 24% Total revenues of $1.8 billion, up 1.3% Cash flow from operations of $273 million, up 73% 2009 EPS outlook increased to between $3.65 and $3.75 MADISON, N.J., April 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2009, income from continuing operations was $169 mi... 
Printer Friendly Version
04/15/09Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
MADISON, N.J., April 15, 2009 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced it finalized resolution of the previously disclosed federal government investigation related to certain test kits manufactured by NID, a test kit manufacturing subsidiary closed voluntarily in 2006. Quest Diagnostics cooperated with the government since its investigation began in 2004. Quest Diagnostics will pay $262 million to settle the civil investigation. While... 
Printer Friendly Version
04/13/09Quest Diagnostics to Release First Quarter Financial Results
MADISON, N.J., April 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its first-quarter results will be made public on Tuesday, April 21, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The public may access the conference call through a live audio webcas... 
Printer Friendly Version
04/03/09MedPlus Centergy(TM) Suite for Hospitals and HIEs Paves a New, Faster Path to Healthcare Information Technology Benefits
The Choice of Leading Nationwide Health Information Network Contractors and Health Information Exchanges Connects Physicians to the Nation's Largest Provider Network Visit MedPlus at HIMSS Booth 2362 in Chicago, April 5-9 CINCINNATI, April 3 /PRNewswire-FirstCall/ -- MedPlus, the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today introduced a suite of clinical portal and data exchange services for hospitals and health information ... 
Printer Friendly Version
03/31/09Quest Diagnostics to Support Walgreens and Take Care Health Systems' Offer of Free Health Services by Providing Certain Free Laboratory Testing
MADISON, N.J., March 31 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, will provide strep and urine cultures and other select laboratory testing services for free to qualified patients served through the Take Care Recovery Plan, which is an offer, announced by Walgreens (NYSE, Nasdaq: WAG) and Take Care Health Systems, to provide free health care services at Take Care Clinics. The offer... 
Printer Friendly Version
03/17/09Quest Diagnostics ClariSure(TM) Postnatal Molecular Test Receives Clinical Laboratory Approval from New York State
Test aiding diagnosis of mental retardation, birth defects, and autism spectrum and developmental disorders now approved for use on patients in New York MADISON, N.J., March 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its ClariSure(TM) microarray-based comparative genomic hybridization (aCGH) postnatal test is now available for testing on patients in th... 
Printer Friendly Version
03/12/09Jon R. Cohen, M.D., Named Senior Vice President and Chief Medical Officer at Quest Diagnostics
Former Chief Policy Advisor to New York Governor David A. Paterson is distinguished vascular surgeon and healthcare policy expert MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that Jon R. Cohen, M.D., Senior Advisor to New York Governor David A. Paterson, will join the company as Senior Vice President and Chief Medical Officer on March 30, 20... 
Printer Friendly Version
03/09/09Quest Diagnostics to Speak at Barclays Capital Global Healthcare Conference
MADISON, N.J., March 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Barclays Capital Healthcare Conference in Miami on Tuesday, March 10, 2009. The Quest Diagnostics presentation is scheduled to begin at 9:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2009 guidance for revenue growth of approximately 3%, ... 
Printer Friendly Version
03/03/09Quest Diagnostics Again Named to FORTUNE Magazine's 'World's Most Admired Companies' List
Ranks second overall and first for long-term investment and social responsibility in industry category MADISON, N.J., March 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, has again been named to FORTUNE magazine's list of the World's Most Admired Companies. Quest Diagnostics ranked second in the "Health Care" category of "Pharmacy and Other Services." The 2009 ranking is the seco... 
Printer Friendly Version
02/20/09Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
Study published in New England Journal of Medicine employs Quest Diagnostics' blood-based leukemia testing MADISON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Testing of blood specimens may detect abnormal white blood cells in patients years before the chronic form of lymphocytic leukemia (CLL) develops, according to research published in the current issue of the New England Journal of Medicine. The finding may lead to a better understanding of cellular changes that characterize the ... 
Printer Friendly Version
02/11/09Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb 11, 2009 /PRNewswire-FirstCall via COMTEX/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share payable on April 20, 2009, to shareholders of record on April 6, 2009. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, informati... 
Printer Friendly Version
01/26/09Quest Diagnostics Reports Growth in Revenue and Earnings for Fourth Quarter 2008 and Provides 2009 Guidance
MADISON, N.J., Jan 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- - Diluted earnings per share of $0.87, up 10% - Total revenues of $1.8 billion, up 1.7% - Cash flow from operations improved to $363 million - 2009 EPS expected to be between $3.50 to $3.70 per diluted share Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2008, income from continu... 
Printer Friendly Version
01/26/09Quest Diagnostics' Board Authorizes $500 Million in Share Repurchases
MADISON, N.J., Jan. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors has authorized $500 million in share repurchases. The company had approximately 190 million common shares outstanding as of December 31, 2008. "This repurchase program demonstrates confidence in our performance and commitment to increasing shareholder value," said Surya N. M... 
Printer Friendly Version
01/12/09Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results
MADISON, N.J., Jan. 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that it will report fourth-quarter and full year 2008 results and provide financial guidance for 2009 on Monday, January 26, before the market opens. It will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the co... 
Printer Friendly Version
12/19/08MedPlus® ChartMaxx® Receives 2008 ‘Best in KLAS’ Ranking for Healthcare Document Management and Imaging Software
Healthcare Professionals Rank ChartMaxx Number One DMI Solution for Fifth Time Cincinnati, OH – December 19, 2008 – Healthcare professionals have chosen MedPlus’ ChartMaxx® enterprise-wide electronic patient record system as the top healthcare Document Management and Imaging (DMI) software product, according to the 2008 Top 20 Best in KLAS Awards: Software & Professional Services report, an independent ranking based on customer feedback of top healthcare information technology (HIT) vendor... 
Printer Friendly Version
12/18/08Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec. 18 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on January 26, 2009, to shareholders of record on January 9, 2009. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, info... 
Printer Friendly Version
12/02/08Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference
MADISON, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Piper Jaffray Healthcare Conference in New York City today, December 2, 2008. The Quest Diagnostics presentation is scheduled to begin at 4:00 p.m. Eastern Time. During the conference, the company will reaffirm its 2008 guidance for revenue growth of greater than 8%,... 
Printer Friendly Version
11/17/08Quest Diagnostics' Laboratory in India Accredited by Two Leading Laboratory Accrediting Organizations
- Less than one tenth of one percent of labs in India are CAP and NABL accredited - Quest Diagnostics' laboratory also becomes one of only five labs in India to achieve NGSP certification for Hemoglobin A1c testing for diabetes MADISON, N.J. and GURGAON, India, Nov. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it... 
Printer Friendly Version
11/10/08Quest Diagnostics to Speak at the 2008 Credit Suisse Healthcare Conference
MADISON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Credit Suisse Healthcare Conference on Wednesday, November 12, 2008. The Quest Diagnostics presentation is scheduled to begin at 10:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2008 guidance for revenue growth of greater than 8%, operat... 
Printer Friendly Version
10/25/08Rotavirus Infections Decline More than 70 Percent in Children in U.S.
Quest Diagnostics Health Trends(TM) Report shows declines vary widely by state MADISON, N.J., Oct. 25 /PRNewswire-FirstCall/ -- The largest study of rotavirus laboratory data developed since an oral rotavirus vaccine was introduced in the U.S. in early 2006 shows that cases of rotavirus infection have decreased significantly, suggesting the vaccine is preventing infection in infants and young children. The latest Quest Diagnostics Health Trends(TM) Report also provides evidence fo... 
Printer Friendly Version
10/21/08Quest Diagnostics Reports Growth in Revenue and Earnings for Third Quarter 2008
Total revenues of $1.8 billion, up 3.4% Adjusted diluted earnings per share of $0.86, up 12% Cash flow from operations improved to $329 million 2008 adjusted EPS guidance increased to $3.17 - $3.22 per diluted share Agreement in principle reached regarding previously disclosed NID-related matter MADISON, N.J., Oct. 21 /PRNewswire-FirstCall/ -- , 2008-- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, informa... 
Printer Friendly Version
10/08/08Quest Diagnostics to Release Third Quarter 2008 Financial Results
MADISON, N.J., Oct. 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its third-quarter 2008 results will be made public on Tuesday, October 21, before the market opens, and that it will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast availa... 
Printer Friendly Version
09/23/08Quest Diagnostics to Speak at the 2008 UBS Global Life Sciences Conference
MADISON, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 2008 UBS Global Life Sciences Conference on Wednesday, September 24, 2008. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors ... 
Printer Friendly Version
09/10/08Quest Diagnostics Again Named to Dow Jones Sustainability World and North American Indexes
2008 marks fifth year on World Index MADISON, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that it was again selected to be part of the Dow Jones Sustainability (DJSI) World and North American Indexes. The company is in its fifth year on the World Index, first added in 2004, and has appeared on the North American Index since 2005. ... 
Printer Friendly Version
08/05/08Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on October 20, 2008, to shareholders of record on October 3, 2008. About Quest Diagnostics Quest Diagnostics is the world's leading provider of diagnostic testing, infor... 
Printer Friendly Version
07/22/08Quest Diagnostics Reports Strong Revenue and Earnings Growth in Second Quarter 2008
- Total revenues of $1.8 billion, up 12%; - Diluted earnings of $0.83 per share, up 14%; - Cash flow improved to $213 million; - 2008 EPS guidance midpoint increased, new range $3.10 to $3.20 per diluted share. MADISON, N.J., July 22 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2008, income from con... 
Printer Friendly Version
07/10/08Quest Diagnostics to Release Second Quarter 2008 Financial Results
MADISON, N.J., July 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic testing, information and services, announced today that its second-quarter 2008 results will be made public on Tuesday, July 22, before the market opens, and that it will hold its quarterly conference call with investors to discuss the results beginning at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webc... 
Printer Friendly Version
06/23/08Quest Diagnostics to Speak at the Jefferies 2nd Annual Healthcare Conference
MADISON, N.J., June 23 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies Healthcare Conference on Tuesday, June 24, 2008. The Quest Diagnostics presentation is scheduled to begin at 9:00a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following si... 
Printer Friendly Version
06/20/08Quest Diagnostics to Provide Diagnostic Testing Services for the Women of Ireland through Ireland's First Nationwide Cervical-Cancer Screening Program
MADISON, N.J., June 20 /PRNewswire-FirstCall/ -- Women in Ireland will soon be able to take advantage of diagnostic testing services provided by Quest Diagnostics Incorporated (NYSE: DGX), the world's leader in cervical-cancer screening services. Through a contract with the Irish National Cancer Screening Service (NCSS), Quest Diagnostics will provide quality-assured screening services intended to improve medical outcomes and reduce anxiety wait time for women ages 25 to 60 who partici... 
Printer Friendly Version
06/18/08HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker
MADISON, N.J., June 18 /PRNewswire-FirstCall/ -- HemoCue(R) AB, a global point-of-care diagnostic test manufacturer and wholly owned subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that its HemoCue Albumin 201 System is the first quantitative point-of-care test for screening for, diagnosing and monitoring microalbuminuria to be granted a CLIA waiver by the U.S. Food and Drug Administration (FDA). With the FDA CLIA waiver, non-laboratory trained physicians and... 
Printer Friendly Version
06/03/08Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
MADISON, N.J., June 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced results of a study that demonstrates that a novel diagnostic testing technique it has developed is the first to provide direct, accurate and reproducible physical measurement of both the size and concentration of a broad range of lipoproteins in blood plasma. Results of the study were published in the May 29, 2008, online edition of Clinical Chemistry. "Our data suggest that ... 
Printer Friendly Version
05/21/08Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., May 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on July 18, 2008, to shareholders of record on July 3, 2008. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information and ser... 
Printer Friendly Version
05/20/08Annual FIT Testing Detects Colorectal Cancer Two Years Earlier Than Colonoscopy Alone, Study of High-Risk Population Finds
SAN DIEGO, May 20 /PRNewswire-FirstCall/ -- An interim analysis of a study presented today at the 39th Annual Digestive Disease Week (DDW) Conference found that, among patients at increased risk for colorectal cancer who completed an annual fecal immunochemical (FIT) test, detection of cancerous lesions occurred an average of 26.5 months earlier than would have occurred during the three- or five-year study-required colonoscopy. Detection of precancerous lesions in this group occurred 1... 
Printer Friendly Version
05/19/08Quest Diagnostics and Google Empower Patients and Physicians to Share Diagnostic Test Results Online With Launch of Google Health
MADISON, N.J., May 19 /PRNewswire-FirstCall/ -- Patients and physicians have a new way to share diagnostic laboratory data online, thanks to Quest Diagnostics and Google Health, a product launched today by Google. More than 100,000 physicians in the U.S. who use Quest Diagnostics' family of Care360(TM) connectivity products will be able to securely provide diagnostic data with a brief explanation of test results to a patient's Google Health Account, where a patient can maintain medica... 
Printer Friendly Version
05/13/08Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles'
Company's "Biggest Loser" Bill Germanakos to Deliver NBGH Keynote Address MADISON, N.J., May 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today that the National Business Group on Health (NBGH), an association of more than 300 large U.S. employers, has presented its 2008 Best Employers for Healthy Lifestyles Gold Award to the company for its HealthyQuest employee wellness progr... 
Printer Friendly Version
05/12/08Quest Diagnostics Announces Annual Shareholder's Meeting Webcast
MADISON, N.J., May 12 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, will conduct its annual meeting of shareholders on Friday, May 16th at 10:30 am ET. An audio webcast will be accessible through the Investor Relations section of the company Web site at www.questdiagnostics.com/investor . For those unable to listen to the live broadcast, a replay will be available on the Web site beginni... 
Printer Friendly Version
05/08/08Enterix Inc. Launches Its Point-of-Care Test for Colorectal Cancer Screening
- New test provides laboratory-quality results in physician's office - MADISON, N.J., May 8 /PRNewswire-FirstCall/ -- Enterix Inc., a wholly-owned subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced the availability of the InSure(R) Quik F I T(TM) fecal immunochemical test, a point-of-care version of the company's lab-based InSure(R) FIT(TM) test, that provides physicians with the sensitivity and specificity of the laboratory-based InSure FIT test. The av... 
Printer Friendly Version
04/21/08Quest Diagnostics Reports Strong Revenue and Earnings Growth in First Quarter 2008
- 2008 Outlook Reaffirmed - MADISON, N.J., April 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2008, income from continuing operations was $141 million, or $0.72 per diluted share, compared to $108 million, or $0.55 per diluted share, in the first quarter of 2007. Included in the results for the first qu... 
Printer Friendly Version
04/07/08Quest Diagnostics to Release First Quarter 2008 Financial Results and Conduct Quarterly Investor Conference Call
MADISON, N.J., April 7, 2008 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it will make public its first-quarter 2008 results on Monday, April 21, before the market opens, and that it will conduct it's first quarter investor conference call at 8:30 a.m. ET on that day. The public may access the conference call through a live audio webcast available on Quest Diagnostics... 
Printer Friendly Version
03/31/08Quest Diagnostics Campaign Challenges Colorectal Cancer Screening Status Quo
'Do You Have the Guts?' aims to reach five million in five yearsMADISON, N.J., March 31, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing information and services, today announced the launch of a novel campaign designed to help increase compliance with take-home colorectal screening tests. Titled "It's Time to Challenge Colon Cancer: Do You Have the Guts?," the campaign aims to break down ... 
Printer Friendly Version
03/14/08Quest Diagnostics to Speak at Lehman Brothers 11th Annual Global Healthcare Conference
MADISON, N.J., March 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lehman Brothers Eleventh Annual Global Healthcare Conference on Wednesday, March 19, 2008, at The Loews Miami Beach Hotel, Miami, Florida. The Quest Diagnostics presentation is scheduled to begin at 9:00 a.m. Eastern Time. The presentation will be webcast live duri... 
Printer Friendly Version
03/14/08Quest Diagnostics to Speak at Cowen and Company 28th Annual Health Care Conference
MADISON, N.J., March 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Cowen and Company Twenty Eighth Annual Health Care Conference on Tuesday, March 18, 2008, at the Marriott Copley Place, Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 8:45 a.m. Eastern Time. The presentation will be webcast live ... 
Printer Friendly Version
03/12/08Use of Methamphetamine Among U.S. Workers and Job Applicants Drops 22 Percent in 2007 and Cocaine Use Slows Dramatically, Reports Quest Diagnostics
MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- The percentage of positive tests for methamphetamine among U.S. job applicants and workers in the general U.S. workforce dropped more than 22 percent between 2006 and 2007. These findings, from the Quest Diagnostics Drug Testing Index(R), reflect the reversal of an upward trend in use of the drug by more than 73 percent from 2002 to 2004. These data were released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading... 
Printer Friendly Version
03/12/08Large Disparities in Kidney Testing Based on Disease, Gender and State, Quest Diagnostics Health Trends(TM) Report Finds
MADISON, N.J., March 12 /PRNewswire-FirstCall/ -- Diabetes and hypertension are the two leading risk factors for chronic kidney disease (CKD), responsible for up to two-thirds of cases. Yet a new study that will be presented at a National Kidney Foundation Spring Clinical Meeting next month indicates there is wide discrepancy in diagnostic testing for kidney disease among patients with these conditions, with patients with high blood pressure (hypertension) tested at half the rate as th... 
Printer Friendly Version
03/05/08Quest Diagnostics Named to FORTUNE Magazine's America's Most Admired Companies List
Only diagnostic testing company in rankingMADISON, N.J., March 5, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that it has been selected by FORTUNE magazine to the 2008 list of America's Most Admired Companies. Quest Diagnostics was ranked third among four companies in the "Health Care" category of "pharmacy and other services." 2008 marks the first year the company has been named to the list. "Our ranking as one of the m... 
Printer Friendly Version
02/28/08Quest Diagnostics to Collaborate with Google on New Health Offering
Partnership will provide patients electronic access to their diagnostic laboratory data MADISON, N.J., Feb. 28 /PRNewswire-FirstCall/ -- Patients nationwide may soon have easy and secure access to their own medical diagnostic laboratory records as a result of a new collaboration between Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, and Google, the world's leading Internet sear... 
Printer Friendly Version
02/25/08MedPlus Technology Driving Three New York Health Information Exchanges
Clinical Portal & Data Exchange Engine Implementations Begin for HEAL 1 Grant Recipients CINCINNATI, Feb. 25 /PRNewswire/ -- MedPlus(R), the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), announced today that it has begun installations of its Clinical Portal & Data Exchange Engine for three health information exchanges (HIE) qualified for HEAL NY (Healthcare Efficiency and Affordability Law for New Yorkers) ... 
Printer Friendly Version
02/21/08Quest Diagnostics Reports Fourth Quarter and Full Year Results
Company Provides 2008 Guidance MADISON, N.J., Feb. 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2007, income from continuing operations was $154 million, or $0.79 per diluted share, compared to $151 million, or $0.77 per diluted share, in the fourth quarter of 2006. The fourth quarter of 2007 include... 
Printer Friendly Version
02/20/08Birla Sun Life Insurance Names Quest Diagnostics its Exclusive Provider of Health Assessment Services in India
MADISON, N.J., Feb. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE:DGX), the leading provider of diagnostic testing, information and services, today announced that its wholly-owned subsidiary Quest Diagnostics India Pvt. Ltd. has entered into a long-term agreement to provide health assessment services, including diagnostic laboratory testing, for Birla Sun Life Insurance Company Limited (Birla Sun Life), a joint venture between The Aditya Birla Group, one of the larg... 
Printer Friendly Version
02/19/08Quest Diagnostics to Develop Blood Test to Aid in the Detection of Colorectal Cancer
Company Licenses Septin-9 DNA Methylation Biomarker from Epigenomics MADISON, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, today announced that it has licensed rights to uses of the Septin 9 DNA methylation biomarker from Epigenomics AG (Frankfurt, Prime Standard: ECX), a cancer molecular diagnostics company, to develop a molecular-based laboratory test that can help physic... 
Printer Friendly Version
02/15/08Focus Diagnostics Launches Laboratory Test for Chikungunya Virus
First Laboratory Developed Test in the U.S. for Detecting the Mosquito-Borne Infectious Disease CYPRESS, Calif., Feb 15, 2008 /PRNewswire via COMTEX News Network/ -- Focus Diagnostics, Inc., the infectious disease diagnostics company of Quest Diagnostics (NYSE: DGX), today announced the first laboratory developed test in the U.S. for detecting the mosquito-borne chikungunya virus. Commercial availability of the molecular polymerase chain reaction (PCR) test will enable physicians in the U... 
Printer Friendly Version
02/14/08Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on April 18, 2008, to shareholders of record on April 4, 2008. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information and ... 
Printer Friendly Version
01/29/08Quest Diagnostics to Speak at Wachovia Securities 2008 Healthcare Conference
MADISON, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Wachovia Securities 2008 Healthcare Conference on Wednesday, January 30, 2008, at the Langham Hotel, Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time. During the conference, the company will reaffirm its 2007 ... 
Printer Friendly Version
01/17/08Quest Diagnostics Sets New Date to Report Fourth Quarter and Full Year 2007 Results
Reaffirms Previous Guidance for 2007 MADISON, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it will report results for the fourth quarter and year ended December 31, 2007 and provide financial guidance for 2008 on February 21, 2008, instead of the previously scheduled date of January 29. The company is rescheduling its report of f... 
Printer Friendly Version
01/11/08MedPlus to Implement Clinical Portal and Information Exchange for the Brooklyn Health Information Exchange
MADISON, N.J., Jan. 11 /PRNewswire/ -- MedPlus, the healthcare information technology subsidiary of Quest Diagnostics Incorporated (NYSE: DGX), today announced that it has been awarded a contract to implement a clinical portal and information exchange for the Brooklyn Health Information Exchange (BHIX). Organized by Maimonides Medical Center and other healthcare organizations in New York, the BHIX is a not-for-profit corporation that will offer health information exchange services in B... 
Printer Friendly Version
01/07/08Quest Diagnostics to Speak at the 26th Annual JPMorgan Healthcare Conference
MADISON, N.J., Jan 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 26th Annual JPMorgan Healthcare Conference on Tuesday, January 8, 2008, at the Westin St. Francis in San Francisco, California. The Quest Diagnostics presentation is scheduled to begin at 11:00 a.m. Eastern Time. The presentation will be webcast ... 
Printer Friendly Version
12/18/07Quest Diagnostics Declares Quarterly Cash Dividend
MADISON, N.J., Dec 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on January 23, 2008, to shareholders of record on January 9, 2008. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic te... 
Printer Friendly Version
11/26/07Quest Diagnostics to Speak at the Merrill Lynch Health Services Investor Conference
MADISON, N.J., Nov. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Merrill Lynch Health Services Investor Conference at the Merrill Lynch Headquarters in New York City on Tuesday, November 27, 2007. The Quest Diagnostics presentation is scheduled to begin at 10:15 a.m. Eastern Time. During the conference, the company will reiterate ... 
Printer Friendly Version
11/06/07Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
MADISON, N.J., Nov. 6 /PRNewswire-FirstCall/ -- The majority of people with diabetes and/or high blood pressure -- the two leading causes of chronic kidney disease (CKD) -- are not receiving recommended tests to identify this disease early, when medical treatment can slow or halt disease progression, according to the latest Quest Diagnostics Health Trends(TM) Report. In addition, the report's findings suggest that patients with early-stage CKD are not being well managed for contributin... 
Printer Friendly Version
11/01/07Two Point of Care Tests From Quest Diagnostics Receive FDA 510(k) Clearance
First step for performing important diagnostics in physician offices MADISON, N.J., Nov. 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its HemoCue and Focus Diagnostics subsidiaries have received FDA 510(k) clearance for two new point of care tests. The HemoCue(R) White Blood Cell (WBC) Analyzer is a whole-blood test performed on finger-stick samples that a... 
Printer Friendly Version
10/26/07Quest Diagnostics Licenses Technology Underlying SensiTrop(TM) HIV Co-Receptor Tropism Test from Pathway Diagnostics
-First national diagnostic testing company to license proprietary technology- MADISON, N.J., Oct. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it has entered into a non- exclusive license agreement for the heteroduplex tracking technology underlying Pathway Diagnostics' SensiTrop(TM) HIV co-receptor tropism test. Tropism refers to the way a virus targets host ... 
Printer Friendly Version
10/24/07Quest Diagnostics Reports Third Quarter Results
- Operating performance improvement continues - MADISON, N.J., Oct. 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2007, income from continuing operations was $150 million, or $0.77 per diluted share, compared to $164 million, or $0.82 per diluted share in the third quarter of 2006. The third quarter of 2007 inc... 
Printer Friendly Version
10/09/07Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
Collaboration Expected to Drive Physician Adoption of Patient-Safety Technology eRx NOW(TM) Functionality Expanded to Include Quest Diagnostics Care360(TM) Physician Portal Lab Order and Results Capabilities LYNDHURST, N.J. and CHICAGO, Oct. 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services and a leading developer of healthcare IT... 
Printer Friendly Version
09/21/07Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
LYNDHURST, N.J., Sept. 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 2007 UBS Global Life Sciences Conference in New York City on Monday, September 24, 2007. The Quest Diagnostics presentation is scheduled to begin at 4:30 p.m. Eastern Time. The presentation will be webcast live during the conference and will be available to regis... 
Printer Friendly Version
09/10/07Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
LYNDHURST, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bear Stearns Healthcare Conference in New York City on Tuesday, September 11, 2007. The Quest Diagnostics presentation is scheduled to begin at 9:30 a.m. Eastern Time. During the conference, the company will reiterate its 2007 guidance for revenues of between $... 
Printer Friendly Version
09/10/07Quest Diagnostics Again Selected as Part of Dow Jones Sustainability World and North American Indexes
LYNDHURST, N.J., Sept. 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that it was again selected to be part of the Dow Jones Sustainability (DJSI) World and North American Indexes. The company was first added to the World Index in 2004 and the North American Index in 2005. According to DJSI, companies were identified as "sustainability leaders" and ranked accord... 
Printer Friendly Version
08/30/07Quest Diagnostics Introduces ClariSure(TM) Test for Identifying Chromosome Abnormalities Associated With 85 Developmental Disorders in Children
First commercial test available nationally LYNDHURST, N.J., Aug. 30 /PRNewswire-FirstCall/ -- A molecular diagnostic test that detects chromosome abnormalities associated with 85 developmental disorders affecting children now is commercially available from a national diagnostic testing company, affording testing and reimbursement by leading health plans across the U.S. Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, inf... 
Printer Friendly Version
08/17/07Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., Aug. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on October 17, 2007, to shareholders of record on October 3, 2007. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, informati... 
Printer Friendly Version
08/09/07Quest Diagnostics Drug Testing Index(R) Finds Cocaine Use at 10-Year Low Among U.S. Workers
Double-digit declines reported across the U.S.LYNDHURST, N.J., Aug 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- An unprecedented decline in cocaine use by American workers drove use of the illicit drug to a new low during the first half of 2007, according to the "Quest Diagnostics Drug Testing Index: Cocaine Use Among America's Workers -- A Special 2007 Mid-Year Report." Released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic ... 
Printer Friendly Version
07/24/07Quest Diagnostics Reports Second Quarter 2007 Results
LYNDHURST, N.J., July 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2007, income from continuing operations was $142 million, or $0.73 per diluted share, compared to $156 million, or $0.78 per diluted share, in the second quarter of 2006. The second quarter of 2007 includes the results of AmeriPath, Inc., which was acquired on Ma... 
Printer Friendly Version
07/19/07Quest Diagnostics Announces New Testing Technique for Improved Diagnosis of Metabolic And Nutritional Disorders
LYNDHURST, N.J., July 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced a new, proprietary diagnostic testing technique to help physicians diagnose genetic metabolic disorders, such as phenylketonuria (PKU) and homocystinuria. Genetic metabolic disorders can impair a child's mental and physical development. The new technique measures amino acids in blood plasma, urine ... 
Printer Friendly Version
07/17/07Quest Diagnostics Launches National Patient Appointment Scheduling
Industry's first national scheduling system provides convenient scheduling options and reduced wait times for patients LYNDHURST, N.J., July 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced the first national patient appointment-scheduling system in the diagnostic testing service industry. The new system gives patients the option to schedule appointm... 
Printer Friendly Version
06/23/07Diabetes Patients Make Significant Gains in Disease Control; Still, Nearly Half Fail to Reach ADA Treatment Goals
Gains come soon after diagnosis then plateau; young male adults fare worse than females Test results found to worsen in winter Six-year data released from nation's largest laboratory testing database CHICAGO, June 23 /PRNewswire/ -- Over the last six years, Americans being treated for diabetes improved control of their disease by a significant 44.4 percent. As of December, 2006, more than half (54.6 percent) had reached ... 
Printer Friendly Version
06/22/07Quest Diagnostics to Speak at the Jefferies Healthcare Conference
LYNDHURST, N.J., June 22 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Jefferies Healthcare Conference on Tuesday, June 26, 2007. The Quest Diagnostics presentation is scheduled to begin at 9:50 a.m. Eastern Time. The presentation will be webcast live during the conference and will be available to registered investors on the following... 
Printer Friendly Version
06/20/07Quest Diagnostics Announces Pricing of Senior Notes
LYNDHURST, N.J., June 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information, and services, announced today that it priced $800 million in aggregate principal amount of senior notes in a public offering. The notes were sold in two tranches, as follows: $375 million of 6.40% senior notes due 2017 and $425 million of 6.95% senior notes due 2037. The offering is expected to close on June 22, 2007. The net p... 
Printer Friendly Version
06/19/07Quest Diagnostics Incorporated Announces Proposed Senior Notes Offering
LYNDHURST, N.J., June 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information, and services, announced today that it intends to offer $800,000,000 in aggregate principal amount in two series of senior notes, in a public offering made under a shelf registration statement filed with the Securities and Exchange Commission, subject to market and other conditions. The notes will be fully and unconditionally gu... 
Printer Friendly Version
06/19/07Quest Diagnostics Incorporated Announces Completion of Tender Offer for the 10 1/2% Senior Subordinated Notes Due 2013 of AmeriPath, Inc.
LYNDHURST, N.J., June 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostics testing, information and services, announced today that it has completed its cash tender offer for the outstanding $350 million, 10 1/2% Senior Subordinated Notes due 2013 (the "Notes") (CUSIP Nos. 03071D AC 3 and 03071D AA 7) of AmeriPath, Inc. ("AmeriPath"). The cash tender offer expired, as scheduled, on June 18, 2007, at 12:00 midnight, ET, (t... 
Printer Friendly Version
06/07/07Quest Diagnostics Extends Agreement With CIGNA Healthcare
LYNDHURST, N.J., June 7 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it has signed a multi-year contract extension with CIGNA HealthCare and will remain a participating provider in all markets for all products. Quest Diagnostics is the largest provider of laboratory services to CIGNA HealthCare, providing its members and providers with the nation's broadest acces... 
Printer Friendly Version
06/05/07Quest Diagnostics Incorporated Announces Pricing and Receipt of Requisite Consents for Cash Tender Offer and Consent Solicitation for the 10 1/2% Senior Subordinated Notes Due 2013 of AmeriPath, Inc.
LYNDHURST, N.J., June 5 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostics testing, information and services, announced today the determination of pricing in connection with its cash tender offer and consent solicitation for any and all of the outstanding $350,000,000 principal amount 10 1/2% Senior Subordinated Notes due 2013 (the "Notes") (CUSIP Nos. 03071D AC 3 and 03071D AA 7) of AmeriPath, Inc. ("AmeriPath"). The... 
Printer Friendly Version
05/31/07Quest Diagnostics Completes Acquisition of AmeriPath
LYNDHURST, N.J., MAY 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced that today it completed its previously announced acquisition of AmeriPath, Inc., a national diagnostic testing company. "This acquisition creates the world's premier cancer diagnostics company focused on dermatopathology, anatomic pathology and molecular diagnostics," said Surya N. Mohapa... 
Printer Friendly Version
05/30/07Quest Diagnostics Plans to Complete Acquisition of AmeriPath on May 31
LYNDHURST, N.J., May 30 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today that it plans to complete its previously announced acquisition of AmeriPath, Inc. on May 31, 2007. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act expired on May 29, 2007. About AmeriPath AmeriPath, a leading national provider of physician-based anatomic pathology, derm... 
Printer Friendly Version
05/29/07Quest Diagnostics to Speak at the Bank of America Healthcare Conference 2007
LYNDHURST, N.J., May 29 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America Healthcare Conference on Thursday, May 31, 2007, at the Four Seasons Hotel in Las Vegas, Nevada. The Quest Diagnostics presentation is scheduled to begin at 5:40 p.m. Eastern Time. During the conference, the company will reiterate its 2007 guidance f... 
Printer Friendly Version
05/21/07Study Reports Point-of-Care Test to be as Accurate as Conventional Laboratory Analysis in Detecting Kidney Disease in Patients with Diabetes and Cardiovascular Disease
CHICAGO, May 21 /PRNewswire-FirstCall/ -- A study presented today at the American Society of Hypertension, Inc. (ASH) Twenty-Second Annual Scientific Meeting and Exposition (ASH 2007) in Chicago reports that the HemoCue Albumin 201 system, a point-of-care diagnostic test developed by HemoCue AB, can detect microalbuminuria, a biological marker for kidney and cardiovascular disease as accurately as conventional laboratory tests. HemoCue, a Quest Diagnostics (NYSE: DGX) company, is the d... 
Printer Friendly Version
05/21/07Quest Diagnostics Commences Cash Tender Offer for AmeriPath 10 1/2% Senior Subordinated Notes Due 2013
LYNDHURST, N.J., May 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostics testing, information and services, announced today that it has commenced a cash tender offer for all of the outstanding $350,000,000 principal amount 10 1/2% Senior Subordinated Notes due 2013 (CUSIP Nos. 03071D AC 3 and 03071D AA 7) of AmeriPath, Inc. (AmeriPath). The tender offer is being made by Quest Diagnostics in connection with its previousl... 
Printer Friendly Version
05/10/07Award for 'Best Employer for Healthy Lifestyles' Given to Quest Diagnostics
HealthyQuest Employee Wellness Program Features Unique Combination of Diagnostic Screening, Lifestyle Assessment and Health Education LYNDHURST, N.J., May 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today that the National Business Group on Health, an association of 266 large U.S. employers, has awarded its 2007 Best Employers for Healthy Lifestyles Gold Award to the... 
Printer Friendly Version
05/08/07Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., May 8 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on July 18, 2007, to shareholders of record on July 5, 2007. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information and se... 
Printer Friendly Version
04/19/07Quest Diagnostics Reports First Quarter 2007 Results
LYNDHURST, N.J., April 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2007, income from continuing operations was $108 million, or $0.55 per diluted share compared to $155 million, or $0.77 per diluted share in the first quarter of 2006. Earnings in the first quarter were reduced by an estimated $0.17 per share as a result of... 
Printer Friendly Version
04/17/07Quest Diagnostics' MedPlus(R) Subsidiary Selected To Develop The Lab Information System For The Province of British Columbia's Electronic Health Record System
One of North America's largest electronic health networks will deliver better care at lower costLYNDHURST, N.J., April 17, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX) today announced that its healthcare information technology subsidiary MedPlus, Inc., has been selected as a subcontractor by Sun Microsystems (B.C.) Inc., a subsidiary of Sun Microsystems of Canada Inc., and subcontractors to develop and implement a comprehensive electronic ... 
Printer Friendly Version
04/16/07Quest Diagnostics to Acquire AmeriPath in a Transaction Valued at $2 Billion
-- Establishes Leading Position in Cancer Diagnostics with a Focus on Dermatopathology, Anatomic Pathology and Molecular Diagnostics -- -- Strengthens Leadership in Hospital and Esoteric Testing -- -- Enhances Position as World's Premier Diagnostic Testing Company -- LYNDHURST, N.J. and PALM BEACH GARDENS, Fla., April 16 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and service... 
Printer Friendly Version
03/22/07Quest Diagnostics Selected as Sole Laboratory Service Provider to National Health Service Hospital and Primary Care Trust
Agreement strengthens company's U.K. presence LYNDHURST, N.J., March 22 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading U.S. provider of diagnostic testing, information and services, announced today that it has been awarded a new, five-year contract with the U.K.'s National Health Service West Middlesex University Hospital Trust and the Hounslow Primary Care Trust of London to provide end-to-end diagnostic testing and related support se... 
Printer Friendly Version
03/15/07Quest Diagnostics to Speak at the Lehman Brothers Tenth Annual Healthcare Conference
LYNDHURST, N.J., March 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lehman Brothers Tenth Annual Healthcare Conference on Monday, March 19, 2007, at the Loews Miami Beach Hotel in Miami, Florida. The Quest Diagnostics presentation is scheduled to begin at 4:15 p.m. Eastern Time. The presentation will be webcast live during the con... 
Printer Friendly Version
03/07/07Drug Use Hits New Low Among U.S. Workers in 2006, According to Quest Diagnostics' Drug Testing Index(R)
-- Lowest levels since 1988 -- -- Significant decline in use of amphetamines and marijuana continues trend from previous year -- LYNDHURST, N.J., March 7 /PRNewswire-FirstCall/ -- A continued decline in drug positivity for the amphetamine class of drugs among safety-sensitive workers, coupled with a decrease in positive marijuana drug test results among the general U.S. workforce, drove workplace drug use to a new low in 2006. The... 
Printer Friendly Version
03/05/07Focus Diagnostics Receives FDA Clearance to Market Plexus HerpeSelect
Focus Diagnostics Receives FDA Clearance to Market Plexus HerpeSelect Monday March 5, 6:30 pm ET CYPRESS, Calif., March 5 /PRNewswire-FirstCall/ -- Focus Diagnostics, Inc., a wholly owned subsidiary of Quest Diagnostics Incorporated, (NYSE: DGX - News), today announced it has received FDA 510k clearance to market its new Plexus(TM) HerpeSelect® 1 and 2 IgG test kit, the first multiplex type- specific HSV serology panel using xMAP® technology from Luminex Corporation. Focus Diagnostics... 
Printer Friendly Version
02/22/07MedPlus' ChartMaxx(R) Earns Top Ranking in the '2006 Top 20 Year-End Best in KLAS' Report for Third Consecutive Year
LYNDHURST, N.J., Feb. 22 /PRNewswire-FirstCall/ -- MedPlus' ChartMaxx(R), an enterprise-wide electronic health record solution for hospitals, Integrated Delivery Networks and healthcare communities, placed first in Document Management and Imaging (DMI) in the "2006 Top 20: Year-End Best in KLAS" report issued by KLAS Enterprises. ((C) 2006 KLAS Enterprises, LLC. All rights reserved). This marks the third consecutive year and fourth time in five years that ChartMaxx has placed first in... 
Printer Friendly Version
02/14/07National Survey Shows Physicians Have Clear Preference Between the Two Largest Diagnostic Laboratories
- Results show overwhelming preference for Quest Diagnostics - LYNDHURST, N.J., Feb. 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of diagnostic testing, information and services, announced today results of a national physician study on preference and performance of medical laboratory services. When physicians were asked which of the two largest national laboratories they preferred, the majority of physicians expressed a preferenc... 
Printer Friendly Version
02/13/07Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on April 18, 2007, to shareholders of record on April 4, 2007. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information an... 
Printer Friendly Version
02/01/07Quest Diagnostics Acquires HemoCue for Approximately $420 Million, Entering Market for Near Patient Testing
LYNDHURST, N.J., Feb. 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the leading U.S. provider of diagnostic testing, information and services, announced today that it has acquired HemoCue, a Swedish company specializing in near patient testing, also known as point-of- care testing, from the private equity firm EQT II B.V. in a cash transaction valued at approximately $420 million. The acquisition will allow Quest Diagnostics to enter the growing near patient t... 
Printer Friendly Version
01/29/07Quest Diagnostics to Speak at Wachovia Securities 2007 Healthcare Conference
LYNDHURST, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Wachovia Securities 2007 Healthcare Conference on Tuesday, January 30, 2007, at the Langham Hotel, Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 8:30 a.m. Eastern Time. The presentation will be webcast live during the conferenc... 
Printer Friendly Version
01/25/07Quest Diagnostics Reports Strong Results for Fourth Quarter and Full Year 2006
- Company provides 2007 guidance - LYNDHURST, N.J., Jan. 25 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2006, income from continuing operations was $151 million, or $0.77 per diluted share compared to $149 million, or $0.73 per diluted share for the prior year. Fourth quarter revenues from continuing... 
Printer Friendly Version
01/19/07Quest Diagnostics Announces Licensing Agreement for Genetic Testing Technology to Screen for Most Common Inherited Mental Impairment, Fragile X Syndrome
New Technology Will Allow for Widespread Population-Based Carrier Screenings LYNDHURST, N.J., Jan. 19 /PRNewswire-FirstCall/ -- In a move that promises to advance physicians' ability to widely screen for Fragile X Syndrome (FXS), the most common form of inherited mental retardation,(1) Quest Diagnostics Incorporated (NYSE: DGX) today announced the signing of a worldwide license agreement with U.S. Genomics. The terms grant Quest Diagnostics rights to develop an advanced screening meth... 
Printer Friendly Version
01/09/07Quest Diagnostics to Speak at the 25th Annual JPMorgan Healthcare Conference
LYNDHURST, N.J., Jan 09, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 25th Annual JPMorgan Healthcare Conference on Wednesday, January 10, 2007, at the Westin St. Francis in San Francisco, California. The Quest Diagnostics presentation is scheduled to begin at 12:30 p.m. Eastern Time. The presentation will be web... 
Printer Friendly Version
12/14/06Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., Dec. 14 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on January 24, 2007, to shareholders of record on January 10, 2007. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, informat... 
Printer Friendly Version
12/14/06Quest Diagnostics Launches Test to Help Oncologists Predict Risk of Breast Cancer Recurrence in Women with Estrogen Receptor (ER)-Positive, Lymph Node- Negative Cancers
SAN ANTONIO, Dec. 14 /PRNewswire-FirstCall/ -- Clinicians will have a new prognostic tool in the battle against breast cancer, as Quest Diagnostics Incorporated (NYSE: DGX) announced today that it has introduced its newly developed test, the Breast Cancer Gene Expression Ratio (HOXB13:IL17BR), to help physicians predict the risk of disease recurrence in women with estrogen receptor (ER)-positive, lymph node-negative breast cancer. Quest Diagnostics is the first company to develop a bre... 
Printer Friendly Version
11/14/06Ronald D. Luff, M.D., Recognized By the American Society of Cytopathology for Groundbreaking Work in Diagnosis of Cervical Disease
- Quest Diagnostics Physician Receives 2006 Papanicolaou Award for Achievements in Cellular Pathology and Disease - LYNDHURST, N.J., Nov. 14 /PRNewswire-FirstCall/ -- A pioneer in the science and standardization of cervical disease diagnosis, Ronald D. Luff, M.D., M.P.H, and Director of Anatomic Clinical Trials at Quest Diagnostics (NYSE: DGX), recently received a lifetime achievement honor -- the 2006 Papanicolaou Award -- from the American Society of Cytopatholog... 
Printer Friendly Version
11/02/06New Study Shows InSure(R) Colorectal Cancer Screening Test Significantly Better at Detecting Early Stage Colorectal Cancers Compared to Traditional Test
The InSure Test Should Help Reduce Colorectal Cancer Mortality and Incidence LYNDHURST, N.J., Nov. 2 /PRNewswire-FirstCall/ -- A study published in the journal CANCER found that InSure,(R) a Fecal Immunochemical Test (FIT) from Quest Diagnostics Incorporated (NYSE: DGX) detected three times as many early- stage colorectal cancers and nearly two times as many significant (pre- cancerous) adenomas compared to Hemoccult II Sensa(R)(1), the traditional guaiac fecal occult blood test.(2) ... 
Printer Friendly Version
10/19/06Quest Diagnostics Reports Strong Performance in Third Quarter 2006 on 16% Revenue Growth
LYNDHURST, N.J., Oct 19, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2006, income from continuing operations was $164 million, or $0.82 per diluted share compared to $140 million, or $0.68 per diluted share for the prior year. Net income for 2006 was reduced by $13 million of pretax expenses, or $0.04... 
Printer Friendly Version
10/03/06Quest Diagnostics to No Longer Be a National Contracted Provider of Lab Services to UnitedHealthcare Effective 2007
- Quest Diagnostics expects to continue to service UnitedHealthcare members as a non-contracted provider of high quality convenient laboratory services - LYNDHURST, N.J., Oct. 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it will not be a national contracted provider of laboratory services to UnitedHealthcare beginning January 1, 2007. UnitedHealthcare accounts for ... 
Printer Friendly Version
09/22/06Quest Diagnostics to Speak at the UBS Global Life Sciences Conference
LYNDHURST, N.J., Sept. 22 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the UBS Global Life Sciences Conference on Monday, September 25, 2006, at the Grand Hyatt New York Hotel. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will be avail... 
Printer Friendly Version
09/19/06Quest Diagnostics Again Selected as Part of Dow Jones Sustainability World Index
- Company is also Selected for Inclusion in the DJSI North America Index - LYNDHURST, N.J., Sept. 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it was again selected to be part of the Dow Jones Sustainability (DJSI) World and North American Indexes. The company was first added to the World Index in 2004 and the North American Index in 2005. "We are delighted t... 
Printer Friendly Version
09/07/06Quest Diagnostics Acquires Maker of InSure(R) Colorectal Cancer Screening Test
LYNDHURST, N.J., Sept. 7 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it has completed the acquisition of Enterix, Inc., the privately held Australian-based company that developed and manufactures the InSure(R) Fecal Immunochemical Test (F.I.T.), an FDA-cleared test for use in screening for colorectal cancer and other sources of lower gastrointestinal bleeding, for app... 
Printer Friendly Version
09/06/06Quest Diagnostics to Speak at the Thomas Weisel Partners Healthcare Conference 2006
LYNDHURST, N.J., Sept. 6 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Thomas Weisel Partners Healthcare Conference on Thursday, September 7, 2006, at the Four Seasons Boston in Boston, Massachusetts. The Quest Diagnostics presentation is scheduled to begin at 2:05 p.m. Eastern Time. During the conference, the company will reiterate i... 
Printer Friendly Version
09/06/06Cincinnati Children's Hospital Medical Center Selects ChartMaxx(R) for its Health Information Management Department
LYNDHURST, N.J., Sept. 6 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that Cincinnati Children's Hospital Medical Center has selected MedPlus' ChartMaxx(R) electronic health record solution to support its Health Information Management department with document management and imaging. ChartMaxx was developed by MedPlus, Quest Diagnostics' healthcare information technol... 
Printer Friendly Version
08/21/06Quest Diagnostics' MedPlus(R) Subsidiary Earns Top Ranking in KLAS Mid-Year Report For Its ChartMaxx(R) Electronic Patient Record Solution
LYNDHURST, N.J., Aug. 21 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that its MedPlus healthcare information technology subsidiary has been recognized as the number one Document Management and Imaging (DMI) vendor in the 2006 "Top 20: KLAS Mid-Year Report Card." ((C)2006 KLAS Enterprises, LLC. All rights reserved.) This top ranking position marks the fourth time the... 
Printer Friendly Version
08/09/06Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., Aug. 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on October 18, 2006, to shareholders of record on October 4, 2006. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, informatio... 
Printer Friendly Version
08/02/06Quest Diagnostics Reopens Louisiana Laboratory Damaged by Hurricane Katrina
NEW ORLEANS, Aug. 2 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced it has reopened its laboratory in Metairie, Louisiana, after successfully completing reconstruction to the facility following substantial damage to the building and testing equipment caused by Hurricane Katrina. Quest Diagnostics' Metairie laboratory performs rapid-response testing as well as anatomic pat... 
Printer Friendly Version
07/24/06Quest Diagnostics Reports Strong Performance In Second Quarter 2006 On 15% Revenue Growth
LYNDHURST, N.J., July 24 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the second quarter ended June 30, 2006, net income was $156 million, or $0.78 per diluted share, excluding the performance of NID, the company's test kit manufacturing subsidiary, whose operations are being discontinued. NID's performance reduced pretax earnings by $35 million, or $0.12 per shar... 
Printer Friendly Version
07/05/06Quest Diagnostics Completes Acquisition of Focus Diagnostics, Inc., a World Leader in Infectious Disease Testing
LYNDHURST, N.J., July 5 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, has completed the previously announced acquisition of Focus Diagnostics, Inc., in a cash transaction valued at approximately $185 million. Focus Diagnostics is recognized worldwide for its leadership in infectious and immunologic diseases and has established a reputation for being first to introduce new assays ... 
Printer Friendly Version
06/19/06Amphetamines Use Declined Significantly Among U.S. Workers in 2005, According to Quest Diagnostics' Drug Testing Index
- Drug Use Among Workers Declines to 17-year Low in 2005 - LYNDHURST, N.J., June 19 /PRNewswire-FirstCall/ -- Amphetamines use, which includes amphetamine and methamphetamine, declined significantly among general U.S. workforce employees during 2005, according to the semi-annual Drug Testing Index, released today by Quest Diagnostics Incorporated (NYSE: DGX), the leading provider of employer drug testing services in the United States. The findings were based on the results of... 
Printer Friendly Version
05/19/06Quest Diagnostics to Acquire Focus Diagnostics, Inc., A World Leader in Infectious Disease Testing
LYNDHURST, N.J., and HERNDON, Va., May 19 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, has agreed to acquire Focus Diagnostics, Inc., the premier infectious disease testing provider, in a cash transaction valued at approximately $185 million. Focus Diagnostics is privately held and based in Herndon, Virginia. The acquisition will add annual revenues of approximately $65 million. ... 
Printer Friendly Version
05/15/06Quest Diagnostics to Speak at the Bank of America Healthcare Conference 2006
LYNDHURST, N.J., May 15 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Bank of America Healthcare Conference on Wednesday, May 17, 2006, at the Four Seasons Hotel in Las Vegas, Nevada. The Quest Diagnostics presentation is scheduled to begin at 11:40 a.m. Eastern Time. During the conference, the company will reiterate its 2006 guidance... 
Printer Friendly Version
05/10/06Quest Diagnostics Declares Quarterly Cash Dividend
LYNDHURST, N.J., May 10 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its Board of Directors declared a quarterly cash dividend on Quest Diagnostics common stock of $0.10 per share, payable on July 21, 2006, to shareholders of record on July 7, 2006. About Quest Diagnostics Quest Diagnostics is the leading provider of diagnostic testing, information and s... 
Printer Friendly Version
05/05/06A.O. Fox Hospital Physicians Now Armed with ChartMaxx(R), an Electronic Health Record Solution, to Deliver Optimum Patient Care
LYNDHURST, N.J., and ONEONTA, N.Y., May 5 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, and A.O. Fox Hospital, Oneonta's largest healthcare provider, today announced the successful implementation of ChartMaxx(R), an electronic health record solution at A.O. Fox's hospital and offsite care centers. ChartMaxx was developed by MedPlus(R), Quest Diagnostics' healthcare information techno... 
Printer Friendly Version
05/03/06Patients Improved Diabetes Control Over 5-Year Period, But Many Fail to Achieve Treatment Goal
Quest Diagnostics Health Trends(TM) Diabetes Report Is Based on 14.3 Million Test Results From 2001 - 2005 From the Nation's Largest Database of Clinical Lab Results LYNDHURST, N.J., May 3 /PRNewswire/ -- People with diabetes who visit health professionals are doing a better job of managing their disease, according to results from the Quest Diagnostics Health Trends (TM) Diabetes Report. However, the Report also found that nearly half of all test results in 2... 
Printer Friendly Version
05/01/06Quest Diagnostics' Healthcare Information Technology Subsidiary to Test ePrescribing Technology Standards in Two New Pilot Programs
LYNDHURST, N.J., May 1 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic laboratory testing, information and services, announced today that its healthcare information technology subsidiary, MedPlus, will test electronic prescribing standards in two new pilot programs starting in May. MedPlus will conduct testing in pilot programs in New Jersey and Florida that are designed to research the function and interoperability ... 
Printer Friendly Version
04/20/06Quest Diagnostics Reports Strong Performance in First Quarter 2006
- Revenues grew 18% and earnings per share grew 13% - LYNDHURST, N.J., April 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the first quarter ended March 31, 2006, net income increased to $145 million from $132 million in the first quarter of 2005. Earnings per diluted share increased 13% to $0.72 from $0.64 a year ago. Included in the 2006 results wer... 
Printer Friendly Version
03/28/06Quest Diagnostics Launches the First Tests to Help Doctors Assess Status of Leukemia and Lymphoma in Patients Using Blood Plasma Instead of Bone Marrow
- LEUMETA Cancer Tests Are Less Invasive Than Bone Marrow Biopsies, Providing Doctors With New Tools to More Frequently Assess Disease Progress and Help the Physician Tailor Cancer Therapy to Individual Needs - LYNDHURST, N.J., March 28 /PRNewswire-FirstCall/ -- Nearly 1 million Americans who are battling or recovering from leukemia and lymphoma have a powerful new diagnostic tool available as Quest Diagnostics Incorporated (NYSE: DGX) today launches the first of its LEUMETA(TM) cancer ... 
Printer Friendly Version
03/09/06Quest Diagnostics to Speak at The Lehman Brothers Ninth Annual Healthcare Conference
LYNDHURST, N.J., March 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Lehman Brothers Ninth Annual Healthcare Conference on Friday, March 10, 2006, at the Loews Miami Beach Hotel in Miami, Florida. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time. The presentation will be webcast live during the conf... 
Printer Friendly Version
02/13/06Quest Diagnostics' Enhanced Care360(TM) Physician Portal Combines Laboratory Test Results and Prescription Data to Help Doctors Evaluate Patients' Response to Medication Therapy
- See an introductory demonstration at MedPlus booth # 2527 at the HIMSS conference, February 13 - 16 in San Diego - LYNDHURST, N.J., Feb. 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic laboratory testing, information and services announced today that its enhanced Care360 Physician Portal now combines laboratory test results and prescription data to help doctors evaluate patients' response to medi... 
Printer Friendly Version
01/26/06Quest Diagnostics Reports Strong Financial Results in Fourth Quarter and Full Year 2005
- 2006 earnings per share expected to grow to $2.75 to $2.85, after $0.20 per share estimated cost of SFAS 123R - LYNDHURST, N.J., Jan. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the fourth quarter ended December 31, 2005, net income increased to $130 million, or $0.64 per diluted share, compared to $126 million, or $0.60 per share in 2004... 
Printer Friendly Version
01/26/06Quest Diagnostics Expands Share Repurchase Authorization by $600 Million and Increases Quarterly Dividend
LYNDHURST, N.J., Jan. 26 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that its Board of Directors expanded its share repurchase authorization by an additional $600 million, bringing the total amount authorized and available for repurchases to $722 million. During 2005 the company repurchased 7.8 million common shares for $390 million. The company had approximately 199 milli... 
Printer Friendly Version
01/13/06Quest Diagnostics' MedPlus® Subsidiary Earns Top Ranking in KLAS Industry Report for Its ChartMaxx® Solution
ChartMaxx Receives '2005 BEST IN KLAS' Award in the Document Management & Imaging CategoryLYNDHURST, N.J., Jan 13, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that its MedPlus healthcare information technology subsidiary was recognized among healthcare IT executives, as the number one Document Management and Imaging (DMI) vendor in the 2005 "T... 
Printer Friendly Version
01/09/06Quest Diagnostics to Speak at the 24th Annual JPMorgan Healthcare Conference
LYNDHURST, N.J., Jan. 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the 24th Annual JPMorgan Healthcare Conference on Tuesday, January 10, 2006, at the Westin St. Francis in San Francisco, California. The Quest Diagnostics presentation is scheduled to begin at 2:30 p.m. Eastern Time. The presentation will be webcast live during the conf... 
Printer Friendly Version
12/13/05Quest Diagnostics Declares Quarterly Dividend
LYNDHURST, N.J., Dec. 13 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that its Board of Directors has declared a quarterly cash dividend on Quest Diagnostics common stock of $0.09 per share, payable on January 25, 2006 to shareholders of record on January 11, 2006. Quest Diagnostics is the leading provider of diagnostic testing, information and services that patients an... 
Printer Friendly Version
12/09/05Quest Diagnostics Unveils New Data Confirming Benefits Of Leukemia Tests Using Blood Plasma, Compared With Conventional Tests Using Cells In Bone Marrow Or Blood, At American Society Of Hematology Meeting
23 Quest Diagnostics abstracts demonstrate scientific leadership with data highlighting effectiveness of newer, more sensitive, less invasive tests to diagnose and monitor hematologic disease LYNDHURST, N.J., Dec. 9 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it is presenting new data on a new series of laboratory-developed diagnostic assays for hematologic di... 
Printer Friendly Version
12/09/05Quest Diagnostics Announces the Availability of a New Gene-Based Assay To Help Physicians Identify the Primary Site of a Metastatic Cancer of Unknown Origin
LYNDHURST, N.J., Dec. 9 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic laboratory testing, information and services, announced today that it has developed a new gene- based assay to help physicians identify metastatic Cancers of Unknown Primary origin (CUP). This laboratory-developed assay is currently available to physicians through Quest Diagnostics Nichols Institute, the company's esoteric testing laboratory, in San Juan Capistra... 
Printer Friendly Version
12/01/05Amphetamines Drug-Test Positives Are Up Among Safety-Sensitive Workers in the First Half of 2005, According to Quest Diagnostics' Drug Testing Index(R)
- Overall Decline in Positive Drug Tests Linked to Decrease in Marijuana Positivity - LYNDHURST, N.J., Dec. 1 /PRNewswire-FirstCall/ -- The proportion of drug- test positives for amphetamines increased among workers subject to federal testing regulations, while overall drug-test positives decreased among all U.S. workers in the first half of 2005, according to the semi-annual Drug Testing Index(R) released today by Quest Diagnostics Incorporated (NYS... 
Printer Friendly Version
11/28/05Quest Diagnostics to Speak at the Merrill Lynch Health Services Investor Conference
LYNDHURST, N.J., Nov 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the Merrill Lynch Health Services Investor Conference on Tuesday, November 29, 2005, at The Waldorf Astoria Hotel in New York City. The Quest Diagnostics presentation is scheduled to begin at 8:45 a.m. Eastern Time. During the conference, the co... 
Printer Friendly Version
11/22/05Quest Diagnostics' Care360 Physician Portal Offers Electronic Prescribing Tools for Pennsylvania Physicians Participating in Highmark eHealth Collaborative
~ Foundation provides incentives for physicians to adopt electronic prescribing technology ~LYNDHURST, N.J., Nov 22, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic laboratory testing, information and services announced today that its Care360(TM) Physician Portal is one of the preferred electronic health tools for Pennsylvania physicians who receive funding from the Highmark eHealth Collaborative, a physician ... 
Printer Friendly Version
11/17/05Quest Diagnostics, in Cooperation with AARP, Opens Doors for Older Job Seekers
Featured Employers Program Brings Value to 50+ Workers and Quest Diagnostics LYNDHURST, N.J., Nov. 17 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that it has been named one of AARP's Featured Employers, a program designed to help Americans aged 50 and over remain in the workforce as desired. The new Featured Employers are committed to an aggressive program of recrui... 
Printer Friendly Version
11/04/05Quest Diagnostics to Speak at the CIBC World Markets Sixteenth Annual Healthcare Conference
LYNDHURST, N.J., Nov. 4 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the CIBC World Markets Sixteenth Annual Healthcare Conference on Tuesday, November 8, 2005, at The Waldorf Astoria Hotel in New York City. The Quest Diagnostics presentation is scheduled to begin at 10:00 a.m. Eastern Time. The presentation will be webcast live during t... 
Printer Friendly Version
11/03/05Quest Diagnostics Offers Test to Detect Avian Influenza Virus
LYNDHURST, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, today announced that it has developed a diagnostic test to detect the avian influenza virus and will participate in the government's preparedness efforts to provide rapid diagnosis and early surveillance of an outbreak, should the need arise. Quest Diagnostics has notified physicians and hospitals that it has be... 
Printer Friendly Version
11/01/05Quest Diagnostics Completes Acquisition of LabOne
LYNDHURST, N.J., Nov 01, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX) announced today that it had completed the all-cash acquisition of LabOne, Inc. (Nasdaq: LABS) in a transaction valued at $934 million. The acquisition was funded primarily with proceeds from the sale of $900 million of senior notes on October 31, 2005. Headquartered in Lenexa, Kansas, LabOne provides health screening and risk assessment services to life insurance com... 
Printer Friendly Version
10/27/05LabOne Shareholders Vote to Approve Acquisition by Quest Diagnostics
LYNDHURST, N.J., and LENEXA, Kan., Oct 27, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX) and LabOne, Inc. (Nasdaq: LABS) announced that LabOne shareholders approved the acquisition of LabOne by Quest Diagnostics in a vote held at a special meeting today. The shareholder vote followed regulatory clearance of the transaction in mid-October. The transaction is expected to be completed during the first week of November. "We are excited t... 
Printer Friendly Version
10/25/05Quest Diagnostics Announces Proposed Senior Notes Offering
LYNDHURST, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information, and services, announced today that it intends to offer $900,000,000 in aggregate principal amount of senior notes, in a private placement, subject to market and other conditions. The net proceeds of the offering are expected to be used to complete the previously announced acquisition of LabOne, Inc. (Nasdaq: LABS). The no... 
Printer Friendly Version
10/25/05Quest Diagnostics Announces Pricing Of Senior Notes
LYNDHURST, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information, and services, announced today that it priced $900 million in aggregate principal amount of senior notes in a private placement. The notes were sold in two tranches, as follows: $400 million of 5.125% senior notes due 2010 and $500 million of 5.45% senior notes due 2015. The offering is expected to close on October 31, 2005. ... 
Printer Friendly Version
10/20/05Quest Diagnostics Reports Strong Revenue Growth In Third Quarter 2005
- Earnings growth in third quarter and full year reduced by Gulf Coast hurricanes and performance of test kit manufacturing business - LYNDHURST, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that for the third quarter ended September 30, 2005, net income increased to $135 million or $0.66 per diluted share, compared to $130 million, or $0.62 per diluted sha... 
Printer Friendly Version
10/10/05Average LDL Cholesterol Levels Decreased Approximately 10 Percent Among People Under Doctors' Care from 2001 to 2004
- Quest Diagnostics launches Health Trends(R), a national source of patient health information that provides insights from the nation's largest private database of clinical test results - - Cholesterol levels decreased less in women than men - LYNDHURST, N.J., Oct. 10 /PRNewswire-FirstCall/ -- Quest Diagnostics (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that it identified a significant ... 
Printer Friendly Version
09/29/05Quest Diagnostics Again Selected as Part of Dow Jones Sustainability World Index
- Company Also Selected for Inclusion in First DJSI North America Index - LYNDHURST, N.J., Sept. 29 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it again was selected to be part of the Dow Jones Sustainability World Index (DJSI World). The company was first added to the index in 2004. In addition, Quest Diagnostics was selected... 
Printer Friendly Version
09/28/05Quest Diagnostics' MedPlus(R) Subsidiary Earns Top Ranking in KLAS Industry Report for Its ChartMaxx(R) Electronic Patient Record Solution
LYNDHURST, N.J., Sept 28, 2005 /PRNewswire-FirstCall via COMTEX News Network/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced today that its MedPlus healthcare information technology subsidiary has been recognized as the number one Document Management and Imaging (DMI) vendor for its ChartMaxx(R) electronic patient record solution in an industry report published by KLAS Enterprises, LLC. KLAS is a heal... 
Printer Friendly Version
09/23/05Quest Diagnostics to Speak at the UBS Global Life Sciences Conference
LYNDHURST, N.J., Sept. 23 /PRNewswire-FirstCall/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic testing, information and services, announced that it is scheduled to speak at the UBS Global Life Sciences Conferences on Monday, September 26, 2005, at The Grand Hyatt Hotel, in New York City. The Quest Diagnostics presentation is scheduled to begin at 8:00 a.m. Eastern Time. The presentation will be webcast live during the conference and will... 
Printer Friendly Version
09/08/05